var title_f34_8_34944="Pilocarpine: Pediatric drug information";
var content_f34_8_34944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/40/25219?source=see_link\">",
"       Pilocarpine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7876?source=see_link\">",
"       Pilocarpine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12705 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34944=[""].join("\n");
var outline_f34_8_34944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34945="Contents: Geriatric medicine";
var content_f34_8_34945=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Geriatric medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Geriatric medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/27/17850\">",
"           Elder mistreatment: Abuse, neglect, and financial exploitation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/17/13592\">",
"           Clinical evaluation of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/59/16314\">",
"           Coronary reperfusion for acute myocardial infarction in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/36/34377\">",
"           Valvular heart disease in elderly adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/55/1913\">",
"           Cholinesterase inhibitors in the treatment of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/55/1914\">",
"           Clinical features and diagnosis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/61/12249\">",
"           Dementia and delirium in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/41/34455\">",
"           Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/57/37786\">",
"           Etiology, clinical manifestations, and diagnosis of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28057\">",
"           Evaluation of cognitive impairment and dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12618\">",
"           Frontotemporal dementia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/25/408\">",
"           Frontotemporal dementia: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/36/15946\">",
"           Parkinson disease dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/25/41369\">",
"           Prevention of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/34/21031\">",
"           Prognosis and treatment of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/22/36202\">",
"           Risk factors for dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4552\">",
"           Safety and societal issues related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10104\">",
"           Treatment and prevention of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/48/27402\">",
"           Treatment of behavioral symptoms related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/4/33865\">",
"           Treatment of dementia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         End of life care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/13/41178\">",
"           Approach to symptom assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/60/38858\">",
"           Assessment and management of depression in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/12/24778\">",
"           Euthanasia and physician assisted suicide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/6/29801\">",
"           Palliative care: Benefits, services, and models of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28058\">",
"           Pediatric palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/4/29769\">",
"           Psychosocial issues at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41208\">",
"           Religion, spirituality, and end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4280\">",
"           Sexuality in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/23/36213\">",
"           Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/33/22040\">",
"           Denosumab for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/22/12650\">",
"           Endocrine changes with aging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/25/6553\">",
"           Epidemiology and etiology of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/35/42553\">",
"           Evaluation and treatment of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/19/37178\">",
"           Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/13/4314\">",
"           Overview of testosterone deficiency in elderly men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/60/14279\">",
"           Overview of the clinical manifestations of hyperthyroidism in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/26/15786\">",
"           Parathyroid hormone therapy for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/26/17831\">",
"           Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/21/33113\">",
"           Prevention of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/32/41481\">",
"           Selective estrogen receptor modulators for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/42/682\">",
"           Treatment of type 2 diabetes mellitus in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/34/15913\">",
"           Accidental hypothermia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/19/3385\">",
"           Approach to the evaluation of older drivers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2617\">",
"           Approach to the patient with weight loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/38/43624\">",
"           Comprehensive geriatric assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/0/30730\">",
"           Drug prescribing for older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/32/11786\">",
"           Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/26/34215\">",
"           Failure to thrive in elderly adults: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/29/42455\">",
"           Failure to thrive in elderly adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/4/22602\">",
"           Falls in older persons: Risk factors and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/7/28792\">",
"           Frailty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/12/9417\">",
"           Gait disorders of elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/18/38186\">",
"           Geriatric health maintenance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/12/31946\">",
"           Geriatric nutrition: Nutritional issues in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/61/15322\">",
"           Hospital management of older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/9/11417\">",
"           Managing multiple comorbidities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/9/42138\">",
"           Medical care of the nursing home patient in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/24/38282\">",
"           Normal aging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33130\">",
"           Overview of geriatric rehabilitation: Program components and settings for rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/60/9161\">",
"           Physical activity and exercise in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/12/8393\">",
"           Prevention of falls and complications of falls in community-dwelling older persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/59/31673\">",
"           Prevention of falls in nursing care facilities and the hospital setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/8/20618\">",
"           Differential diagnosis of vulvar lesions",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/0/22538\">",
"           Anemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/54/32618\">",
"           Evaluation of infection in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/34/26152\">",
"           Important sites and pathogens causing infections in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/489\">",
"           Principles of infection control in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/24/44422\">",
"           Urinary tract infection associated with urethral catheters",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/0/34826\">",
"           Adjuvant systemic therapy for older women with early stage breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41864\">",
"           Comprehensive geriatric assessment for patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15029\">",
"           Management of malignant gliomas in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24441\">",
"           Prostate cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/42/10922\">",
"           Systemic chemotherapy for cancer in elderly persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36455\">",
"           Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/31/41466\">",
"           Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40903\">",
"           Treatment of metastatic breast cancer in older women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/13/14554\">",
"           Clinical manifestations of Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40841\">",
"           Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17512\">",
"           Treatment of seizures and epilepsy in the elderly patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/52/6986\">",
"           Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/19/2362\">",
"           Cataract in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/37/39514\">",
"           Diagnosis and management of late-life depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39081\">",
"           Diagnosis of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/60/16330\">",
"           Geriatric bipolar disorder: Acute treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7545\">",
"           Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/4/22601\">",
"           Geriatric bipolar disorder: Maintenance treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/21/41305\">",
"           Overview of electroconvulsive therapy (ECT) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/33/28185\">",
"           Prevention and treatment of delirium and confusional states",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10377\">",
"           Suicidal ideation and behavior in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/28/41416\">",
"           Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/43/5818\">",
"           Diagnosis and management of asthma in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/48/11014\">",
"           Emergency airway management in the geriatric patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/31/7671\">",
"           Sleep apnea and other causes of impaired sleep in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease and hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/31/29174\">",
"           Hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/29/43480\">",
"           Renal transplantation and the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/32/13832\">",
"           Clinical manifestations and diagnosis of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/49/12056\">",
"           Clinical manifestations of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/32/33287\">",
"           Diagnosis and classification of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26630\">",
"           Glenohumeral osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9687\">",
"           Investigational approaches to the pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/30/2538\">",
"           Nonpharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/59/35769\">",
"           Overview of hyperkyphosis in older persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19114\">",
"           Pathogenesis of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/40994\">",
"           Patient guidelines for weight-resistance training in osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/23/14714\">",
"           Pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29370\">",
"           Risk factors for and possible causes of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/9/12440\">",
"           Surgical therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/26/34217\">",
"           Treatment of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/41/40598\">",
"           Treatment of polymyalgia rheumatica",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/28/7621\">",
"           Weight-resistance exercises in patients with osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/19/5427\">",
"           Weight-resistance training in patients with osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/4/10314\">",
"           Preoperative medical evaluation of the healthy patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7192\">",
"           Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/29/28122\">",
"           Nocturia: Clinical presentation, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/10/43177\">",
"           Stress urinary incontinence in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/43/16055\">",
"           Stress urinary incontinence in women: Choosing a type of midurethral sling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/23/44409\">",
"           Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17319\">",
"           Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/49/33562\">",
"           Stress urinary incontinence in women: Retropubic midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/4/32842\">",
"           Treatment of urinary incontinence",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-0FE4BD605E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_8_34945=[""].join("\n");
var outline_f34_8_34945=null;
var title_f34_8_34946="Appendicitis PI";
var content_f34_8_34946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Appendicitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 559px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIvAgwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGhqXdVeaQRuQajNyo71DkkWotlzdRmqP2pfWkN2PWl7RD9my/uFG4Vmm7HrSG8HrU+2iP2TNPcKTeKyzeD1pDee9L28R+xZq7xSeYKyjd+9Ibv3qfrCH7Fmt5go8wetY5u/ek+1+9L6wh+wZs+YKXePWscXfvTvtfvT+sIXsWa24UbxWT9s96Q3nvT+sRD2LNfeKN4rGN570hvfel9ZiHsGbW8eopPMHrWN9s461G19jvR9ZQ/YM3fMX1pd49a51NQy3WrUd0WoWITB0GjY3ijeKyjc47037Z70/boXsWbG4UbhWSLz3p32z3p+3iL2LNPcKN4rN+1e9Na696HXQeyZqbxRvFZBu/ej7X71P1hD9izX3ijeKyftnvSi696ft0L2LNXeKN4rNF170faven7ZB7JmlvFG4Vm/avelF170e2QvZM0two3Cs4XPvThcj1p+2QvZsv7hS5FZxuvek+1gdTT9qg9mzRzRurPF4p704XIPemqiYezZeBzS0yE5TPrT60RmwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMDxXM1rDFOuduSp/pXNLq5b+Ku21uxGo6ZPbcBmX5Sezdq8ijd45WRwQynBB7GvMxkpQldbM9XAxjUg090damok96kW9Y9652CU+tX4nyK4/atnS6SRsJck96k80kdazEarMbZo5mZuCLJkPrR5h9ajFLTuybD/ADDR5h9ajpRRcLEm8+tG8+tMFLxRcLDt59aN59aaRRRcLDt59aNx9aZRRcdhxY00uaKjalcLDzIfWqs0p55qRjxVaalcpIZDMfNxmty2Ylc1zkBzMK6G1/1Yq6bJqolkY4qEsalYZFRMKuRnEbvNKJDTSKaazuy7Il800GQ+tQ0U+Zhyol8w0bzUY5pcUrsLIf5lL5h9aiIpKOZhZE/mn1pPNNQ0U+Zhyom840gnPrUBphOKXOw5UXPPPrTWuSB1qmXphfNHOx+zRaa6PrVeS+K96rTSYFZl1PSdRmkaSZpSaqV/iqWx1ZpZ0jU5ZjgD3rlZ5iT1rd8CWbXWsrIf9XAPMP17fr/KqpVJSmorqVUpQhByfQ9MjXZGq+gxTqKK908AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryrx1Z/YfEDyIu2O4HmD69/1/nXqtcb8T7bzNHguAPmilxn2I/wAQK5cZDnpN9jtwFTkrJd9Dh4ZulaEEtc5FMQa0raf3rxUe3KJvxvxU8cmCKzIZeBzVlHqrnO4mpG+RSvIEGWNU4XzUF1Ll8E07kKF2XGvVHQU6K8Rjg8VmRlHyC2MVB5224MecjqDSuX7NPQ6QcjjpS1RsJSVKk5Har2apMykrOwUUUhNMkWjNNJpCaAHE1G1KWpKQxp6VXmqd2AqrM1IuJFbr++rctj8tYtv9/Na1u2MVUHZk1Vct0wilzR3rYwIXGKhJqxJVZutZSNEKDS5qLNG6pKsTA0u6oQ1ODUXFYkzTWIUZNAaqt85CDFFxpXdglv4o855NQrqiE4xWVMcZbrSTCD7OWEh34yMGo5mdCpxN+O4SX7ppX4rCsZW2ox4NbTNlQaadzOUeVkTMaY0mBTZXwaqTSADrSuUlcLibg1kXMpLGp7iXg1myycnmpbN4xBmya9Q8BWS2+hpP/wAtLglj7AEgD+f515Wp3NXtPh6PydCsExgiBM/UjNduXxvUb7HHmUnGko92aFFFFeweIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVk+LLUXfh6+jIyRGXX6rz/StakdQ6MjDKsMEe1TOPNFx7lQlySUl0Pn6QFTUlvNtNWdRt/JuZov7jlfyNZzAq3FfOeR9Zurm7bT8Cr8cuQK5uCbFX4rjpzRcylC5uxSgHrTLhCxJU5qgk9WI7jHene5lytO6GmMseQc+1PhtSGyByanWQE54qZZB2xRYHJluzj8pBnrVrzKzlm9af53vVXsYuLepe8z3phkFUzLSCSncXIXfMpu+qwf3pwOe9FwsWQ1I0mKgL4qJ5M96Lgokrvxmq0jZpC5zShdxpFpWJ7RavxnBqtAu0VMDTWhnLUtBuKduqurZFPBrRMysPdqrOafI1V3apbLihSaaWxTGcUxn96guxLvxThJVUvSbzRcfKW/NpsxEiYqqXNAkPrRcOUrT27ZOBVYWmWyV5rU8z1prP+FTZGimyK3gCsC3btViWYYwKrSTgcA1VknwKd7C5XLVk0svWqU0uSajkmNVJJTU3NYxC4l4IFZzuWbippSW6UxI8cmpNkrEkALEADJPAFe7W0flW0Uf9xAv5CvGdBt/tGr2UWM7plB+mef0r2qvUy2OkpHk5pLWMQooor0zyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDybxla+Rr94APldvMH4jP8APNc48eeMV33xDt8ajbzY4ki2/iD/APXFcTIuDXz2Ihy1ZLzPp8LPmpRfkUHQrQshFX2i3CqstuQTisbnRoxVuPerEdz71ntEw9aVFYVRLRsx3PvVmO4z3rCVmFSpMwoIcTdE49aeJ/esRZm96njlY0yeU1xNR5uBWcrtTwxPrQTYvCf3qUXPHWs8ZpcNQS4outPnvUZm96rqjk9KnjtnYjimKyRJG+atxc0kVrjGam2Y6UyG7j1btUyVDGADViPk0yGOFIzECpAKCBTIKzSVA7jNXWjBqrNBzxSZSaK7sKiL0SRsuagcGpZqkS780heq+CDQSRSKsTGXHemmaqxY0xjnoKVyuUsmf3qNp/U1AFJpfLzQPlQ15j2qAuxqx5B70vlYHNId0iowJ65qMoSeauMAKgmcKKLFJldgAeaaSCOKjkfPSiME0i0jpvAUHm+I7ckZEas/04x/WvVa4L4ZWwMt7dEcqFjX8eT/ACFd7XtYCPLSv3PBzGfNWt2Ciiiu04QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlPiHEG062mxyku3PsR/8AWFefMoOa9S8YQibw9dcZKYcfgR/TNeXGvFx65at+6Pey581G3ZjkTIoEOTzUlvycVZ8uuPc7G2iqtorDkUpsV7Cra8VOhFUkZObMo2A9KT7Bz0rZCg09YxTsLnMZdPqZLLFa4T2p+z2pkubMtbXnpUq2vtV/ZzT0TNBDkyktqPSp0tV9KuLHUix07EubK8dsg7VOsSjoKlVKeENUkZuRXZahcYq4y4qrKKTRUXchJ9KsW/NVmqxa9KhFvYsiiiitDIKYy5p9BoArSRg1XaBfSrzDNRlaRSZSMC+lNNsp7VcKU3bSKuyk1qtRm1UdK0NopCtKyHzMofZh6UvkAVbYVE5NBSbImiGKpyoBmrMjsBiqcm8n2pFRKdy+zpVBg8h56VqNBuPNIYgo6CoZ0RaRmtFhRmlUAVPcEZwKiQEtSZa1PTPh1D5ehO/eSZj+AAH9DXU1keFLc23h6yQjBZN5/Hn+ta9fQ0I8tOK8j5jEy5qsn5hRRRWxiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdUg+06bdQ4yXiZR9ccV5DtzXtFeR6jD9n1O5hIxskYD6Zry8yj8Mj18rn8USrCCritKJQRVZEB5q7AuK8s9KTuBhzSrCRVpV71IqjuK1iznkyukRqdYTVhEU1IFFXYyciBYacIqsAClxTsTcriIVIsYqUCnKKaQnIaqCnqlOAp6CrSM2xAgpQvFPxSgVdiblaRaqSrV+UVUlFZzRpBlKReKltulRzcCn2prHqbvYt0lFOAqzITFFOpCKAuMNNIp5oxSAj20hWpMUYoGRbRTGHpVjFNK0BcqMpNNMfrVwrUbjFKw7lKSMVWkQCrczAVRmk64qWzWCbImwDVW5b0p7uSaiYZPNZnTHQqhCxyelTQwl5EjX7zsFH1NPICitHwvD9p8QWSH7ofef8AgIz/AEqoR5pKPcJT5YuXY9UjQJGqDooAFOoor6U+WCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzTxtD5GvysOkiq/6Y/pXpdcT8RLf95Z3A7gxn8OR/M1xY+PNSv2O7Lp8ta3c5WCTkVrQAECsRF7ita0fgZrxUz2prqjQRal2cUyMggVOvStEjlkxinFSBqQrSAVRGjHg08UxeKfVIljgKeopq1ItWiGLinKKTFOWtEiGOopaWqJIpBVSUVckNVZelZzNIGdc9KWzPzUXPSiy+/XP1On7JeApcUCngVokYXExSEVIBQRVWFchIpKewppFSUhtFFFIYUhpaaRmkA12AqtM5xxVhlqGVRSZasZ02STVZkJ61elHWqrnmpsbKRWZcVA5watPiqsv3qzbNokRJNdT8Pbfdqs0p/5ZxYH1JH+BrmAMV3Pw8hxBeTY+86oPwGf610YOPNWiYYyXLQkdfRRRXvnzwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVm63rmmaFHaPq95FaJd3CWkBkP+slfO1B7nB/KgDSooooAKKKKACiq+o3kOn6fc3t2zLb20TTSlUZyFUEkhVBJOB0AJPajTryHUNPtr20Zmt7mJZoiyMhKsAQSrAEHB6EAjvQBYoqlcarYW+qWmmz3kEeoXau8FuzgPKEGWKjvjvV2gAoorCl8W6Gmg/21Hfrc6Z5nk+faI9wC+/ZjEYY8NweOO9AG7RRRQAVzXj6HfoySDrHKD+BBH+FdLWV4ph8/QLxQOQm/wDI5/pWOIjzUpLyNsNLlqxfmeZw1oW4+UVlxNzWnaHIr54+iloaEJ4qyrVXiqfbWkTlmSgg0tQjIp6tVmdh9OFNpRTESLUy1CtTpWkTOQ7FKKWkNaECnpQDTCabu5ouFh0lVZKnc5qCSs5MuJRufu0ln96luOlJaferDqdP2TQWpBUYqQVqjBjhQaBSNVEEbUw9Ke1MaoZaG0UUUigoNFFADSOKhlwBUrtgVTnfikUtStcOBmqEknJqe4yc1TKnNQzeCHZyKrtyanIwtQuO9ZmyGmvSfBMXl+HoDjBkZnP5kf0rzNj1r1zQ4fs+j2UR4KxLn645rvy6N6jfkcOZO1NLuy9RRRXsHihRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkX7ScNy/h/wlcWlleXos/ElpdTJaQNM6xokpZtqgn/8AWK9dooA8I+KHjODxRomlJZ6FryWTX/lXFxeWt9bpb/IdrNHAVlkBJwACBkVy+g2ni278G+FdMurnxJCF8XvbSTR+fBMlltOCS2XVMk43k46Z4r6fooA+bfiJp82heJNag1tvFlxo9joWdAuLWe5dI5wrF3mkjIO8NzlzjaOe1czqsniHUNN8KS67e6imgz+HIDa3m29lRboj5nc2x3GXoRvyuPxr6P8AFPw/8LeK9RivvEOjw311HGIVd3cZQMWCkAgMMknBz1NdLbQRWtvFb20SRQRII440UKqKBgAAdAB2oA88D6xJ8AL0vcX9zrQ0G4VJ2hkiuZZRC4Rtp+cOcA+pJz1rgU0LWfEWreDrDWJvEUWnnwTG915NxPCGuwF4kIIy+eSDycc19C0UAfKH9n3Ei/CrW/HaeJlhXTry0v7mH7V50TKzeUG8v51Zs4z1YAZyBw7XB4oXx3rE2rahqthrsOsmTTmitb+fzrUMNkcIjPkGMrwQ4B65PWvq2igD5j0pdWk+M0kMv9q6yLrVZVkmzqFncWEByMMD/ozQgYxt+Y5GMZGMTw9YXWk/CLWNO0iPxNb+LrfUEW5t1F0AkX2wYKD7nK9SvJGc19b0UAfNXxD0TX7+5+KmpwTeJVu9NuLKTRUtbidYySqhzGinD9+gOOar/FhPEVz461Aa3eahYabJYW50a6ihvnSKXYDIVFqceb5meHBGMdOK+naKAOd0S41dvAOlXEaLea0bCB2S93W3mybFLb/lYxk88EHB60zRvE1nr32nS54ptO1pIj52m3gCyqDxuXBKyJn+NCR9DxXS1k+IvD2m+IbaOHU7fe8Tb4J42Mc1u/8AfjkXDI3uD7HIoavoNO2p5aAVkIPY4Natl1FcdrEuq+FNWurfVfN1XTI5Di/jjHnxLngyxqPmGOroPqo6102jXtvfW0VzZzxz28gykkbBlYexFfOSg4OzPpHUU0mjejHFWUqtCwIqytNGEhSvpTdtSUVRmItOHWkpaYiRamQ1AtTIauJEiYUjUA0Ma16GRE1NNObrTazZokJUUpqU1BN0pMqJSuDS2vWmTc1Jajmsepu9i8lSioVqUVqjBjxTWNFIaomwwmmHrTzTKhloSiiikMKrXN5Bb/66VVPpnn8qp6xqDQkQWzDzT94/3R/jVFbaIR75Dvc8kk1cabkdVLD3XNLYuf2tZu20S8+6mpWIdQVIIPQisCVFySqgA9OOtJb3M8BYQ8g9jyKHT7G8sKre4zXlSq0i4rOudauom+eGIr7Aj+tT21/FeoSmVcdVNZSi0ZuhUgrtaEjdKhkOKmaq0xrJlRGRJ5syp3Zgv517Si7UCjoBivH9HTzNVs09Zk/mK9hr0stWkmebmj1ivUKKKK9Q8kKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzLxugTxFMR/Gqt+mP6Vxsvh6SC7e/8ADlyNPvnO6WMrutrk/wDTSPsf9tcN65HFd18QF264jf3oVP6mse25xXgVm41ZW7n0VJKVCN+xX0PxKkt6mmazbtperNnZDI26OfHeGTgOO+OGHdRXWoc4rGvtLstXsHs9Ttorm2fqkgzz2I9COxHI7VkomueGOYftGvaMP+WbHde24/2Sf9co9Dh/d+lJWlsZTvHc7MUVjWPifR76zW5s76OZCSpVM71YdVZeqsO4IBFJc65mJvssEhbszAYHvVKLCFGc9YrQ1bi5htwDPKiZ6ZPWq39rWWf9f+SN/hXJEPLMZJZGaVuu/qauWx2N+9A2HjNWoX3OxYOKWr1OqtruC4JEMquR1APP5VbRq4m+kggxJHJscchgcYrT0TxFBcgQ3MgWUDiQ8K3/ANek1ysxq4RqPNDVHUBqQtVOG8t5m2wzxSN6K4JqbdRzHE4Nbj2OaTNNzQTRcLDiarzGpCahk5qWy4orOM1NAuKTbzUqDFQkW3oSrTwajFOFWjNkoNIaaDSk1RIw0yor67jtITJKfYAdWPoKxpL+/n+aEJCnbjJ/WkouWxvToynqtjbuJkt4mklbai9aw57y9ugzRnyIe2Op/Gsq+1C6e5igu5N0ecjgDmr3mtcRhFysfTjqauEF1O2nh/Zq8tTAmNzbT9HnDHqDlq1rbe6hpc/7h/rUsnk242jr3C8n8ay9Z1OSK18uG0lUEjc/H3e/FXZROrmc9Ei00oml2qfkB5PrWpbCBY8nGa5SO6wgZeVPen/2i4GA2BSjUS3LlRbVkaGtshPy4FYljKYrxGXpnpUV7dtIepNRRSCAC4nO2NSPx9qylLmZtGHLCzOxbpVeY9aljkWWJJIzlGGQahm6muZnlx3L3hxd2uWI/wCmy/zr1uvJ/CoB8QWOf+en9DXrFerlvwP1PJzT+JH0CiiivRPMCiiigAoorE8QeJ9M0G6tLa/+2vc3SSSxRWdhPduUjKB2IhRiADIgycfeFAG3RXCj4reFCcCfVyfT+w77/wCM1KPid4aYZU62fpoN/wD/ABmp5l3L9lNdGdrRXFj4meGz0/tw/wDcAv8A/wCM0v8Awsvw6O2u/wDggv8A/wCM07oXJLsdnRXFf8LN8Njr/bn/AIIL/wD+M00/FHwwOr60ProV/wD/ABmjmXcfs59mdvRXDj4peFjnEmsnHpoV9/8AGaUfFDwwTgPrRPtoN/8A/GaOZdw9lPszt6K4hvij4XRtrPrKn0OhX/8A8ZoHxR8MHo+tH/uBX/8A8Zpcy7h7OfZnb0VxQ+Jvho9P7c/8EN//APGaX/hZvhv/AKjn/ggv/wD4zT5kHs5djtKK4k/E/wAMjq2tj/uA3/8A8Zpp+KXhYdZNZH10K+/+M0cy7h7OfZncUVwZ+LPhEcG51UH30S+/+M1oJ4+0d1DJa+I2UjII8OagQR/34oTT2FKEo/ErHWUVyb+P9GjQtJa+I1Uckt4d1AAf+QKo/wDC1vCecefq+fT+w77/AOM0NpbhGEpbI7qiuG/4Wp4V/wCeusf+CO+/+M112k6ha6vpVlqWny+dZXkKXEEm0rvjdQynBAIyCOCAaE09glGUd1Yt0UUUyQooooA8/wDiMANTtT6xY/U1hWZziui+JSgT2Ddyrj8iP8a5uyPzLXg4rStI+gwrvh4m7CMLWLrusSpObOyOGH+skHb2FaskohtJJT0RC35CuJjlLIZDyzEkmogrs68NSU3zS6EVx4Zgu7v7dYzyafq2P+PuIA+Z7SIeJF+vI7EV28EESxDzME45I4rj4dSCHGcGpbjWHWP71dUaqS1OiWHbenU1NW+zhTggVBo12t3vgdlZh0z/ABCuVa5l1C4+dj5YPQd66rRtOjMYwqj8KmMueWhpOmoQtJ6ialpcZmjYIcDqpPFWII7ZcJMmw+4xVi4gkg+4+R6HkVU86GQ+WxEcn9xvut9KuyTMlJtblHW0gtMTQOVcHIKnFaeieJpnttt7byySD7roB8w96yrrSXe5WRSxRf4XycVftGe2PEYP0rNxu9SqkYTgk9TXj8S2vmBJ45ofdhkfpW1HIsqK8bBkYZDDoa4nWb2N7Ykqu4eoqpojajsZI7h4on52g4xUuOtkc08FGUeaOh6FTSM1yE2nXCIZBeShhzkOar2Ov6gHltgwlAGFlfqp/r+NKUGtzL6k2rwdztHZE5dgPqcU9CGGVII9RXJx6fDMpkupi8h6ljmsq+kksLuEWEzxlmwdp6im6bSuUsGpaKWvod3c3tvbHE0oDf3RyfyFU21+xj5kd1UfxFDisG0nijXdOd8h6k8k1U1lnuoGSGJiSOMLT5Fa5cMHC9pHQTa9577LAfJ/z0YdfoKhma5lQs93KD6K20fpWRY286IMgIMd+tXWiIQGV3IPqdoq4x01RoqVOnpEyPtMzakUuJ5JQv3d7E49cVtmdnQBDtT1qpHb2hkDM0akdy2TUofzX2Wxwg/j7n6U4qxrJp7IbNaJMQ0q8ddztin3V0kYEFtIrEjDup6ewqZtOwm5/mJ7nmuc1SJ7G881BiN/ve3vRK8UEEpvc6nSoISuXxUOuwwmM4I6VzcWpSpnDVWvdSllBBak6i5bWLVCXPzXK0uYZD5JwCeVPQ1DeX9nZhGvmaFn6YG7P5U+JS7F3ICLyWPQCqFpAmva685XNpbLsjz0bnk1itTom+XYemsWkpxY21xdSdvl2j8zUr6fe3JW41BtqrykS8KtdFDFbWcgEcSIMA8Ck1m7jlhAQ81fKrEKTbQvh24LRyQE8JytaMvWsHw7n+0OOm05rflHNcszkxEVGroaHhU48QWP/XT+hr1ivJ/C/wDyH7D/AK6/0NesV6mW/wAN+p4OafxF6BRRRXonmBRRRQAVxfiaXyPiDpEwODHoGqsPwmsa7SuE8aAt4104L1Ph7Vsf9/bGlLRMumrzSfc82tWxITW/aTnaBXPQkCStOGTbjmvFg7H29SNzooJPWrDSDFYsVxx1p5uT610KZxypXZauH9KoXTDFOabPWqN5LwcVnKRtCFtB9mciarlrzMpP94VR04E28z+4FW4MgMfTFJMqS3Q3Wv3d+3uAabby9KPEeWihuF6Ywaybe7A4zSk7SCnHmgjqUlGzNNMo9axRe/L1ph1BRwTVc5HsWadzMO1ZV5cfIaq3WpLz81ZU98HzzUSmb06TRM8m6UD3r0qfx4Ut4rfSbbiNAnmTd8DHAFeUxS7nA7scCuosIgEFOlUlG/L1IxWHp1be0V7F2+vNQ1WQte3Mjgn7mcKPwqKKx9BV23QZrSjVAK0UebVmLkqa5YqyMpLA46V3Hwn/AOSWeDf+wLZf+iErn9yiug+E/wDySzwb/wBgWy/9EJXXhla54uazcuS/n+h1VFFFdR5AUUUUAcL8S+ZtP/3X/wDZa5qyHzLXQ/Ec5v7NewjJ/X/61YFmPmWvBxf8eR9BhdMPH+uppzxmayniHV42UfiK4W0kVrVo2OG5Fdnqd6LDTZZ+NwGFz6npXnQtZ5naWKTG45IPSohdHp4KN4tvYrPdLHN9nuv3c3RW/hf8fWiZnEZ3ZrQi0kzzouoBGiPaodT8O3VvE8mm3RMSjmKX5gPoarkb1O11IxdivZyiIgDtXR2OrCKMAGuKt72Mv5V0Ps9yOCG6H6Gr6F15HT1FSpOBUoRmddcavvTrWMnmX1wS7EID271nM7svJ6Vo6U4SUAngVfO5PUj2agtDqtL0+UplJHXA7MakuzLDxMqyD1xg/nUlrfCKAbSAcVka3qRELEnJrobjGOhxKMpT1HP9ivuHmQMp5VzhhViMWqYVZ1P/AAI1haFB58mX5Zjk11EmmRxR7jjpUwvJXsXUtB8tyNrcyRkROWBH8L5qpbaV5GTtc5Oc5xWPrEm2ZEhJQk4JU44rY0e3SdVMjFvqc0JqTtYHGUI3uTeXGgIfyx9ZP/r1E1vaSkMWiBU5+9/9etO7sreOIlQM1yN+qHUIUAwucn8Kc/d3Qqfv7M6CNrdDhdze8Y/rRNd28ILPFMQPUir2ki3WEFhziszxMU+zuY/Sm9I3JjaU+VkkV+LpFNsvlqR1PJ/+tV+LT1kj3uxZj3PNcvo92EjiB/ugV0a36pHwwohJPcdSm4u0TI122CW8mByB2pNPu1TYRSardCSNhnrWPbuwTC9V/lWTdpaG8YOUNTszfgx4JrA1a7RwVwDVJ7mXbjvTbKwuL24AVSST0pyqOWgQpRh7zLGmaNNqKP5BHyjOCcVX17TJdDtBdXsEzxlto8rDc+/PFehaPYJp9sIxgueWNUPGs7R6UsK9Jnw2fQc/4VkckcZOdXkhseSTT3eqYjdDbWef9UnLP9TXVeHrUQWchCeWOFC960dItInj3EDIqZ0VJTt/iBFaxXU6pST0IbuAS2m5TiRRwPX2rFns7kISVAH1rebASBm6MT+mP8auX6RCyyCM4puPMKNRx0MbwwgUz7sCTAGPataXvWFpEhj1VQp4bKkVvzDGa5JowxKtUv3Lvhg41+x/66ivWK8l8MnGv2Of+eor1qvTy34H6ng5p/Ej6BRRRXonmBRRRQAVyWsRrL8TtBjcZV9E1NSPYzWNdbXK6l/yVPw9/wBgXU//AEfYUBseSapA+napcWsuQ8TlT/jRHP05rs/i7obrLHrFuMowEcwA6Hsf6flXmi3JQc14dWDpzcT7jCVliaMai+fqdAl3gdaVr0etc496e1ME8shwoJqOdnR7JM6E34H8VRNc+acCsuG2nkPIxWjbWMikEsKabYnGMTotPj26XnuxqS2GSw9RTtPlSa2EOMOg/Om2/EpFdC6HJd63JJIRc2slu/1U+lcXfxTWczI6Nx0I713owkUkh6KM1zkrG8nZ2HGeKipFOxVCTTfYwF+0yDhSB70NaXB5MldMtoMcCnfYsjpUezZu66RxstnMf4zUa2UoOTyPausubML2rOkjKE1LhYpVbmDaF0vMygqRxg9q7LT5gYxWHNElwAG+WQfdapNOnaGUxS8MKadiWro62N+hFTeeR3rKS6UL1qOW9A6GtuYwcLmx9oyeTXZ/Cf8A5JZ4N/7Atl/6ISvLTfcgZr1L4T/8ks8G/wDYFsv/AEQldeEd7niZxHl5Pn+h1VFFFdh4gUUUUAee/EVv+Jtbr6Qg/wDjx/wrDsvvCtbx+27XgP7sKj+Z/rWVYjmvn8S71pH0WHVqEfQreM8/2RGOxlGfyNYOjSrtw/Sus1+0N7otxGv31HmL9Rz/AI15xDdGM4BxUwlY9XCe/ScV0Onv5FAGD9KnuJM6e7g8MgP6iuYN6X4Y5rqbO3Mumwxy5USRnPsCTW8ZczZpOPIlcxrjT7LUbRluEXeBw2Oa5CCyvLTWrW3tppGilmSPb1BBIFdFfR3NlcNBKGyOhHQj1rS8GWiT69DJcnYY8ugbqzdv8fwrNy6WKmlCDnc64+EtPwQGlCn3Gf5Vx2s6Tc6VeMuCUJyrDowr1EUy4giuIjHPGroexFLc8mjjqlOXvao8rS/dVw2QarXk5lXknGa9BufCllKxMbyR+3UVCfB9o6FZJpD7qAKep3LHUNzj9Gu/KU4POa2ZNUdoyGaue1GwudHvXhmQ4ByrDow9RUPns3TNOM2lY63TjU99bE19LvuA2ema19MuykQ2tWVYabd6nNstoy7DknsB7mmPFc2cjRyIyspwQRSTadwkoy9y+p0VxqDGM5aufMpN6XPJwaYXmkOMVu6F4Zub9TNKTDGB8rMM7v8A63vTcnIhuFCN5Ow+y1DbGOaqapdecrAtxVm98MalbyHyo/NXsyHP6daZbeF9TuGAeIxr3LnFPmk1YiNSivf5kY1kGZiiZ65WrLPcr8uDXoGg6DDpSFsiScjBbHQegrVMa5ztXP0qTlqZlFSajG6PMLXS768cbY5GB9uK7HR/D0FvFuu0WSQjGOy1vUUHLWx06qstEZ/9jaeGyLZM/U1ajijhG2JFQeijFS0xjSucznKW7uJnmsvxTZPe6U3kgtLEd6gdSO4/z6Vo7uai1K9Ww0+W5YZ2DgepPAoKpuUZpx3PPrHUBCCucVYguRcXShee5x2qex0qPVJJJ5FXe7FjgcZNStpqaZNujUAN8re4raMZWu9j2pThey3GXAzpaOOsUnPsD/8AqrEvr9nG1WOB6VvMSlhdJ64X8zRDokclq0hA6cU5Rb2FCcY6y7mJ4e/fanHwflBYk109wK5SfdY3KvCdrKcjFdOsouLWOUDG9c1yzRni0+ZTWxY8PMF1+wJ/57oPzNevV4rZyeTf28n9yRW/I5r2qvQy1+7JHgZoveiwooor0zygooooAK5XUv8Akqfh7/sC6n/6PsK6quV1L/kqfh7/ALAup/8Ao+woA6O+tYb20ltrlA8MqlWU9xXzz4r0SfRNXms5FJXOY37MvY19G15T8U7mKfWoLZFUvDH87d8nnH5fzrjxtNShzdT2slrzhWdNbM89stOEhBk5PpW7a6YmBhcVNp9tnHFblvBjtXDCme7WxDRnRaeBjip2tVVTxW3HANvSq91GFU1t7NI5lWcmc4Ga3ulZema0M7bg46Hms/UPv/jVvd8sTd8Vmux0vWzLl4SNInI6nisjT0yoralHmaTOB1HNZWmehpy3RnTfuy9TVhhBAqVogq9KfBjFPlx3rVLQ55SdzLuYsg8Vi3kWM8V0kuCDWZeRgg8VnJG9KRys2VanyL50Hmp/rYxn6j0qS+jw3FRWUmyTHY1h1OzdBBcNIowatJG7+tb/AIP8DXuos1xOVgsWYmN8glhnsP8AGvTtJ8L6ZpyDbAJpP78oDfp0ropYac9XojzsTmdGi+VavyPGoNLuJ2Aiikcn+6pNer/Cf/klng3/ALAtl/6ISuoSNEGERVHoBiuX+E//ACSzwb/2BbL/ANEJXdRo+yvrueDjsc8Xy6WsdVRRRW5wBSEHIx+NLRQB5j40k8zxHcjqECr/AOOj/GqdiOKZr03n63fODkGZgPoDipbEfKK+cqvmqSfmfSwXLSivJFbxZePaaTiM4Mp2k+1crY2SXKhpEBz7V0XjiJ30qJ0GVST5vbIrA0u78pQDjinC3U9LDL9zeO5e/sSCMb2iXjmtK0kJhVWOfLbaPpVabUllj680mnSeYJ8dtv8AWulWT0HLmavInvlDai6NzgL/ACrJ1ImxuYbiA4aNgwq9q83k6puPR41YflisXVbkTrjdmpqNalUYtpdj1S2lE0Ecq/ddQw/EZqWqOiI8Wk2aSZDiJQQe3FXqyR4M1aTSCnAUg609RVGbIbmzgu4/LuYklT0YZxVBPC2kh932QfQu2P51tqKkUVaiCrTgrRbRVt7SG2jEdvEkaDsq4qK7061u+biCOQ+pHP51o4FIVquUhVJJ3vqZUOkaba/vFtYgRzlhnH51FNr1pExVTuxxwM1qzwrNGUcZU9q5m80i4tpGNunmRk5AHUVLutjSMlUfvs2bPU7e84jYFvTvVzaK5nStGuZLwT3KmFV6AdTXVKuABQrvcmoop+6RlajZas7aYy03EhSKxFNNSsKY1ZNGiZGTUUjcVI1QSnioZoiLd81UfFEZl0GfGcoVb9atbvmqyqrLE0cgDIwwQe4oTNYvkkpdjjNCvhAmM4qxqN6s+QWFZGqafNZ6m9rEysOqtnsemfek/s2525Mv4YrdTbVj2OSDfPfc0x+8hmTu6Bh9etRx6q0VuUPTGKnttpKMowCo49P84qg+mi6leRB8rHIAqndbEx5W7SMe8m85yR611GnxGPTIFYc7c/mc1z93YiylV8ZAOcGusSRZ7ZJY/usuRXPO/UnFy92KWxnSDBNe02cvnWcEv99Fb8xXjMw+Y1634dfzNCsG7+So/IYrqy1+9JHh5mrwizRooor1zxgooooAK5XUv+Sp+Hv+wLqf/o+wrqq5XUv+Sp+Hv+wLqf8A6PsKAOpYgAk9K8C1C8bUtevLljnzJWI+meP0xXuGuTG30a/mXrHA7D6hTXz7p74lBPrXBjJaxie9ksNJz9EdfpsYGK2kQBc1gWVwABWtDdArUQaOuspNlwOBVS7YEcU5pOM1VlfNU2RTi7mPqC5JNOibdbL7U+8G4Gq1s/yulc/U9BP3Ua9m2YnQnhxisu2by52TuDVi2l2gZ7VUuSBe7l6NzTfQmKs2bUU2BT3lBrNEvHXmmtPgVXMZuncuu49aoXcgwajM5J61VuZeDUuRpGNijdjOTWcpxMPrVu4l+U1no2ZxWLOqKPc/hrcGbw0qk/6qRk/kf611dcR8Ks/2Tdenmj+VdvXsUHemj4zHx5cRNLuFcr8J/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJWpyHVUUUUAFNlcRRPI33VUsfwp1ZfieY2+gXzjg+WV/764/rUzlyxcuxUI80lHueUljJKznqxya1rQYUVlwrlhWtbjAFfNH00x+p+R/ZN19r/1Ow7vX2x75xXmtlptxdMfLlwO2FruPGLFdFVR0aUA/TBP9KzfD8kcaAnFb04qTszrwrcKTkurMxPD92B/x8EfUVt6NaLbWjozbpS4yfbtWlc3MZT5aoW8mXkx2xXQoRi9C3UlOOpW160OpSQwxErIg5YenpWTLocunOlw7ebsIbaw4OOxroYZlj1Bt3oD+lTaxcxy27KMdKThGV29xwqSjaK2NjQNVi1az82MbZFO10z90/wCFalcB4ClKa1cwj7jx5/EEf4139YI8rF0lSqOK2HLUqColqaOrickiQCpBTBTxWqMmKKOKSiqEGKMUUooAMUYpRS4p2FcaajapDUbVLKRE4qI1M1RPWMjSJA9Vpjwasv0NVJ+hrJm8Stn5qtwmqJPzVahNSataHISMX127Mp+bzWH4A4H6V0LiD7KAAN1c/wCKyljrKyggecoYj0I4/pUB1VCg+eumnNJHp8jqRjJGlCgMu1em4j86l0SSNIwG69Kr6VJ5luZj0aTj8Ky9WlksNRlSMMY2O8YGcZ5xV81kpByc7cC74naNuVxzVjw+d2lLnsxArl7i7kuD8yt+VdnpcSRaZAsbBgV3Z9zWFSXNqLER9nSUX3Ks64NeneDXL+G7InsGH5MRXmt0Otd78PpxJojRd4ZWGPY4P9TWuXu1VryPHzBXop9mdPRRRXtHhhRRRQAVyupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYUAbmvQm40S/iUZZ4HUfXaa+dYiUkr6XIBBB6GvnXxRZvpms3dsRjy5Dj3GeP0rgxsdpH0GRzXv0/Rl6zn+Uc1p29xjvXK2tzWnDcVyRkexOnc6D7VxUbTg96y1myKcJKvmM1TSLMz5B5rPEvlzZqV3qpcDPIqGzWKLbzgEEHg1FPNlAR1Ws8TEDY1OEh6GlzFchoR3QcDBpWmrIDmFjz8p/SpfP3DrRzC5C40lV55MjrURl96rzScdaVylEjuH4NQWal7lR702aSruhwNLcAgEknAHrUbs02Vz2z4b25g8OByMebKzj6cD+ldVVPSLQWOmWtsBgxxgH69/1zVyvcpx5YpHwuJqe1qyn3YVyvwn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QlWYnVUUUUAFc34+l2aEEz/rZVX+Z/pXSVyHxFkxa2UfdnZvyH/1658W7UZM6cGr1oo4u3X5q04R0qhbitCHqK8BHvSY3XLI32kSxJjzFG9c+o/8ArZrzuCe4RsRRvxXc+J71reyjhjOGmODj0FVNE0+KeMs/JrohBy0R14WTp0nKWzObFxfkcR/rW9osLiyaSVgZHbBHpirN5AkGdoFQaW+7zF7ZB/nW0Y8r1Npz546Io+JIZ45oJLRgZCvKe3Y1gXNxfkESROPpXX3QEurOD/CFUfkKs3FtD5falKHM20OnV5Uk0Znw3WMXVzJcOFuWG1EbqR1Jrv68tvXNtdxywHbIjAgj1r02znFzaQzr0kQPj0yM1la2h5+YQfMqncsLUyVAtTJVRPNkTClpFpwrVGQUUopKoQUoFFOxTsK4AUtKKCKYhjVGwqQ0xqllIibpUL1M1QvWMjWJBJVOfpVqQ1TmPBrFnREqt96rEJqs/Wp4TUGr2OY8SbZ9dKSjKrGqgH8/60+10aB4i/lL+VSeLrYxTQ3yj5SNjex7f59qi0/VVEW0tXTTt1PRg26UeQdAvkGSIfd++vt61cW1W5v5iwB4X+QqjDMJr4KvIIP8qvT3H2S6jftJGD+I4rVWsKd76blHxBZx28PyqAfam+F5y1pNCxz5bZH4/wD6qh12/E68nineFYWFvPMRwxAH4f8A66wrW6FTT9h7xoXRrqvhpN+91CI9wjD9Qf6VytyOCa2vhvPjXriLs8BP5MP8anCO1aJ5mLV6EkelUUUV9AfOhRRRQAVyupf8lT8Pf9gXU/8A0fYV1VcrqX/JU/D3/YF1P/0fYUAdVXm/xY0Hzo01SBckAJNj9D/T8q9IqO4hjuIJIZ0DxSAqynoRWdWmqkXFnRhcQ8NVVRHzCMxSYNX7eTiuk8ceFJdIui8al7Rz+7k9P9k+9cmuYzg9a8eUHB2Z9pTqwrQU4O6ZprNipBMD3rLDk1Kj+9K43EvtLmoHk9agaX3pjn3p3BISY55FMjuARtbg0MeKqyLn61LLRcZtwwelQkmM5U5FVhKycN0oaXPQ0rjsTmbIqGWQ00fP2pwtZH6DNAWIkUyuAK9V+GHh3zZlvp1/cwnK5/if/wCtXM+AvDL61qTRlgkMOGmbuAegHucGvdLO2hs7aO3tkCRRjCqK7MJQ5nzvY8bNscqUfYw+J7+RPRRRXpny4Vyvwn/5JZ4N/wCwLZf+iErqq5X4T/8AJLPBv/YFsv8A0QlAHVUUUUAFcH8Q5d2o2kWeFjLfmf8A61d5XmvjSTzfEUo/uKq/pn+tcWYStSt3O7Lo3rX7IzYB8tXYetVIhwKtw14qPYnsYPjUMv2OX+HJU1R07U/JX72K6XxBFDNo06TnbkfIfRu1cPb6PcyD/Xf98iuiLa2O/CuM6VpdDWu9S8wHmnaIzFJXPQsAP1qidDlCZM5H1FbtnBHBawRx5IxliepbvWseZu7NJuKjaJm6pcm11MuTgMqn9KrTatzw4wa0tZhhvZo7ZkBKDlu/0qndeGolg3ovak1K7sOEoWXMZDy/aZ1VMs7HAA716vp0H2Wwt4D1jjVT9cV5jockWj61BK6KU3bWJGcA9x9K9WHtWZxZlJ+7FbDhUsZqEU9TTR5TRaXpTqjQ1JmtkYsUUtNpRVCFFLmgdKQ0xCg0bqbSUXCwrVG1PNRsallIaxqGQ9acxqGQ8VjJmsUV5TVOU9asymqkh61izogiE9ami61BnmpoutSalTxNMkejSq4yZCEUe/XP6VyNvp8ki7kYflXReMUY2UEgHyJJ834jiodCuoAhEhAOO9b04p7ndh24Ubx7lfSbc213mY5LIQp9Ksa3F54giUkEKWyOvWpLmeOS7QR44BP6U+Rl/tFQ3QRrW9law3JuSkc1d2JjG6QsR710Hh67S4svJCqrRcYAxketLr5he3AXGaxvCzFdVdR0KkVhViloaT/e0m30Ogul+U1Y8DSeV4stx/z0R0/TP9KguTwab4afZ4n05v8Aprt/MEVjQdqsX5nn1Y3pSXkz1+iiivpD5gKKKKACuV1L/kqfh7/sC6n/AOj7CuqrldS/5Kn4e/7Aup/+j7CgDqqKKKAILy1hvLZ4LmNZInGCrV5R4w8ETWG+5sQ01p1OBlk+vqPevXqCM1lVoxqLU68JjKmFleO3Y+ZHjeMkEUK/rXtniLwPY6lvmtMWtyeeB8jH3Hb8K851nwlqGmsftFsxjH/LSMbl/Pt+NeZUw86fofT4fMKOIWjs+zOYLYNMeWrU1my9KgNq/pWOp3KxD5pppYmrItJPSpYdMnmYLHG7seygk0rMG0jOfkVGsLnlRXb6V4E1a9Kk2xiQ/wAUx2/p1/Su20b4b2UADalM07f3I/lX8+p/StoYepPocdbMcPR3ld+Wp49AgjUNLxWnblWT5DzXuOr+GdN1HQJtIMCRWzr8hjXBjbsw9/5187TJfeH9an0rVBtnhbAPZx2YexHNFei6Nr6o2y3FU8epKOkl07ruaKXup6HfpfabO0Uy+n3WH91h3Fe2+AvFkHivSjMqiG9gIS4gznaexH+yecfQjtXj5liu7QhsZxVTwRrD+HfG1nMGItbhxbTr2KscA/gcH8D606FZ0ppX0ZWYYCONoSfLapFaPvbp/kfSNFFFewfBhXK/Cf8A5JZ4N/7Atl/6ISuqrlfhP/ySzwb/ANgWy/8ARCUAdVRRRQAV5Z4gcS+IL5h2kK/lx/SvUzxzXj7S+fdzSn+Ny35nNebmUrRij08sj70pFiPpVqKqqVZiryonpzMbxdKQtpEOhYsf0/8Ar1a0RUMWWxVPxgm2O1mP3QSpP6j+tZdtqQhTBbiuqlJRep20oc9FKJ0d7s+YDFUrRshR2DEVkvrCMCoOSa1bGMi2gY9Xya15uZ6F8jgtSmz7NZuQ3UOa077VFW1KADOKx/EEM8d0tzCufMHIHXIrFuY75wWYhR6Zqedxui401USbGXkhllB969RXUre0tIEnk3TCNQyKNzZx+n4149L9ojQ7uRnkr2Fdzos0P2WNwAwxUQXM9ScXSVRJPodCddXPyWsxHuQKlg1yEuFmjkiz/ERkfpWYdTiHGEFAnjuOAF/CtHTj3OJ4eFtYnVwTLIgZGDKehBzVhWrmbPzLRwYiTGeq9q34nyAexqb2PPrUuR6FoU4VEGpwarTOexKDxSE00NTS1VcVh4ppoDcU0tSbGgLYqJ2pXNQk1nJlpAxqGQ08mopDWTNEitKaqSGrMpqs1Zs6IoYKli60wCpI+tItlXXrq2h094bnLGZSFQdSfX8K42G1uAhZOnuK0dcfzPEkiyfcQKo/LP8AWtSSWIWgVAK6KcE0d9FeygrddTM0iFmaSSUjcvyAD371Lr8rW13BJGC26MAgdsGpNK+eRgP4pOv4URobuaWZuQThfYDpWtvdsi7+/dnPXV/JLlTkfWtjwhakGW6YcY2L7+tZWrRiOYFhxmuy09oW0+BrZdsRXIHp61zVG1oPEz5adorcguzwaqaW/l63YP6XEZ/8eFWbrnNUrM41K1PpMn/oQrCOkkcT1i0e20UUV9QfKhRRRQAVyupf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYUAdVRRRQAUUUUAFGKKKAKNzpOn3R/f2VvIfVoxmqR8LaKTn+z4fyNbdFS4Re6NY1qkdFJ/eZkOgaVCcx6fbA+8YNXoreKEYiiRB6KoFS0U1FLZEyqTl8TuAFFFFMgK8q+P+jCbw9ba1BGPtFjKFkYDkxMcc/Rsfma9VrlPirt/4V7rYfGDCFGfUsAP1xWVeKlTkmd+V1pUcXTlHul9+h8+2N8HtwUJyRyKqagZXCiMHzSw2465zxXV+EdBS8sWPygom4571mTwLH4j0+E/ca6iX/x8V4bg7J9z9GWIp88ordH1AM4GetFFFfQn5UFcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJQB1VFFFAFbU5fI066l/uRM35A15JaivUPE7FfD9+R/zyI/PivMLXpXj5k/fij2csXuSfmW1NWIjVcVLEea89HdJE15ax31pJbzD5HGM+h7GvNv7MYX0kMz8IxX5TwcGvSLib7PaTTf8APNGf8hmvO7O5Jl3ucsTkmto6nXgXJKXY6Kw0SFIw2wdPSpoGMcjRE/KhDD2qa3vx9mCj0qgZx9r5/jBFdWitY0TlJvmLt2nmahGG6eWCKi1K0AiJApLq5Eb28vXjYf6U28vQ8eM8U3bW4oqWljk9RjaIllNafhXTrnVHdIJFjgXBYk9CewFUdTlVg1bXw1kK30qj7rRn+Yrn2ZvXk40nJbo6OPwlahf3s8rN6jApB4fayYSWkrSKDyrda6LdTg1NSseL9aq9WVbSElQXFXVGOKRSKfmi9znnJydyRTxT6iU1l6xrcWnny1HmT4+7ngfWrRMacqkuWKNoGivP7jVNTvCf3zop/hT5R+lU8X6tuFzMD6hzVHYsvfWSPTKaa4Kz1zVLUgPL56ekgz+vWuj07X7e8YRygwSnjDHgn60mY1MHUp67ryNVzUZNPeoiazZigY1BI1Pc1A9Q2aRRE/JNQsKnIqJ6zNkRVHd3kdnFvflj91R1JqC51G3t5CruWYdVUZxWFqF+k9+HIYRgBVzVxhd6nTSoOb1Wgl3by30z3MgIZu68YqskF4sghBMgbgHuPrWyl0qw8YxS2qMS0zcFhgew9a6eRdDtVRxVrC2UJs7ZyTkpGzFvfFR2VykVrkEdKmu7gNZyxQrncpG89K497ma3zG447EdDTlLltYVKm6l2yXWpxK/B711PhwMuiw7u+SPpmuS0ywm1O7CKCEHLN2UV3aosUSxxjCINoFck3cWMklFU0Vrk9ao2ozfwD1lX+dWrw4Bqrpw36raLnG6ZBn0+YVkviRx/ZbPbqKKK+oPlQooooAK5XUv+Sp+Hv+wLqf8A6PsK6quV1L/kqfh7/sC6n/6PsKAOqooooAbI2yNn2s20E4UZJ9hXD+DfidpPirUdUtLew1ewOmAi7m1C3EMULggeWzbjh+c4PYGu4kLLGzIpdgCQoOMn0r50tfCXja88P/FSyuvCc1nL4kkkvbMvf2zjeWUCI7ZDg4JO44Hy9eRQB7tdeJNGtrLUbp9Ts2h06MyXXlzK5iAGfmAOQT2HeuK8N/F3Ttdn8OpHo+p20evXEsFnJMYiCI4xIXYK5wCDjHXPauRb4V3Fr4h1H+zfDllDpN34IOnyRxiFY5dS8wMNyZ5f5VPmEYyPvZqzonw91jS4fhILPRra2k0UTy6sEeJAkz24Tc20/OSwwSu48UAewWOu6RqF3Ja2Gq2F1cx53ww3CO6465UHIoXXdIaYQrqtgZijShBcIWKLnc2M9Bg5PbBr578D+AvGC+P/AAhrmq+Hjp8thc3I1B4FsYLZI2RgnlLFiRxzyXLHn6mjw98Gr2Oy8Dtqnhawa7t9YuptXaTyHL2zM2zzDuPmLjb8vOPQc0AfQ66vpraWdSXULM6cBuN0J18rGcZ35x1460i6zpjaWdSXUbI6cBk3QnXyuuPv5x196+er/wCF3iqPwKthZ6cUjsfFNxqUemRyW7ebaHiMoH3RZHJCOO54zUC/DnXY9GtpofDOpXenw+II9UutFv5rOM3a+WVZliixEoBx8h+96Y6gHung/wAZ6d4r1DXbbTFdl0m5W2ebcrRzEruDIVJyMGunrzD4L+G9S0LU/GV1qGhrolrqeoJc2dqskTBY9gBGIyQMHt/PrXp9ABXEfGcuPh3qfl5xuh3fTzVrsru5gs7aS4u5ooLeNdzyysFVB6kngCvL/iH4sl17wVq6eF9PN5pphPmatdEw2o5GPKGN0xz0KgJ/t1nVV4SXkdWBnyYmnK17SX5nIeDtSW0s5Q4B3JgZrJhf7Z4w0dEGS99CP/IgrA8P2E1sGuJ7q5ubhk2lnbCKOuFQfKOg55PvXS/D6Brv4m6NGRlUd5j7bUYj9QK8WL5nGC7n6FUgqcateSs7N/gfSlFFFe8fmYVyvwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQlAHVUUUUAY/i8keG74j+4P/QhXmNq9er69bNeaNeQJyzxkL9eorx6J9hrxsyXvp+R7WWNOnJeZrA8U9GqnFMCOtTK9eceg0Wp08+1li/56IV/MYrzSQNb3BVgQQa9Ijeuf8TaO05a5t1yTy4HUH1raDN8JUUJOMupkwXhCDBqK4umJVlPzKcispmkgOGB4phuWzWvMejyI3vtv2iJl9f0NUZLxtpVjhhxWaszI25Dj1HrT3lE+AR81HNcSgkR3MxbIzXb/De1ZY5rlhgY2j8f/wBVcxp2iyXV1CrsqI7BdzcCvVLCzisLOO3gHyqOvqfWp2OTG1lGHIt2Wt9KHqGlBpXPGsWA9SLJVTNKGppicRutaiLCyMi4MrHag9/WuLj3TTNJKxZmOST3qXxLfGfVvJBykI2/j3/w/CoIZAOtaxPVw1H2dO/VmxahRjpirbojLwBWZBKAOtWEmJPy810JilF3uNmgUnkYqnNamThSV9xWoj+ZwOW7qar3CsPuDn+6eDSaRUJNaCQtqaQjyrqXYowAef51Nba/Nbtt1FVZO7qMEfhUCag8aFHUj6is+6C3DfN0z0rOUY9A9lGd1NI6V9dseNruwPcIcVat7qC6QvBKrqOvYj61g2cUBjO/AOKxtSHkvmJyqswU4PUZqJUtLmawsJPli2jp59btEkKJvkx1ZRxVW/1aE22Ld/3rnaBjlfeq1gLcR4fGaztUjXJeEcrzxQ6SSuaQoU+axq6fYxMu6Q89eaqanaRZKoBzxiktJLmZFVIyo/vHgVowRxWwzNIPMP8AEeT+ArbRoptwle5U0/SjEqmeTzG7IB09jU9zKpnMCnIX759T6UXeqmGIi0twDjG+Q8j8K5i3vJIywkOXznPrSk1HRFQhOo+aR0l3PHHbEcZrmbR0n1SGOVQ8byAEexNNvL1mzk59KseFrN7rUlnI/dQncT79hWM53NuVUoOTO0SGK2j2QRrGvooqJzip3NVpmxmuVs8la7lC6bJNO0GPzdf09P8Apuh/Ig1HLzzWj4Lj8zxPZ5/hLN+SmnSXNUivNF1Xy05PyZ6zRRRX0x8sFFFFABXK6l/yVPw9/wBgXU//AEfYV1VcrqX/ACVPw9/2BdT/APR9hQB1VFFFABXGeHviZ4Z1/W4NIsrm7jv7lGlto7uxmt/tCKMsYzIgDYHPrj8a667jkmtZo4ZTDK6MqSgZKEjhsHrjrXivgf4Qa3o/jPwxr2s6ppt1PpDXYmnjE7z3oliKK8jyORkZ6AADnrngA7TRfiz4N1q+0u207U5pDqbNHaSvZTxRSuCQUDugXdweM/zFFv8AFnwbcahaWcOpzM1zdmxjlaynSHzwceWZGQKGJHAz/SvL/hF8PvFWqeCPAFt4jNvpei6FqD6otlJbSx3zTpPKUWTfgKuWLcDkEcd6PA3w+8Va/wCH4dL1c2+leHoPEMupSxTW0q3s2yYsoG7ChG4IYc/XuAerR/FDwnJ4iTRk1JzcvdfYEl+zS/Z2uf8AniJtuwv7Z9qrp8XPBUmtw6UmrsbuW8OnjNpMqC4B2+WXKBQc8DnFcJpfwTv9I1mNLd9DvdIi1IX8M179q+0wjzN+0IsgiLDoGI75I7Vs/wDCpr7/AIR7+zv7Ttt//CV/8JDv2Njy9+7y/wDe9+lAE3xK+Mul+HbbUbbQHXUNZsbmG2mRraVreNmkCsjSqNocAk43dRjrxW7N8RNM0m+8VNr+pWken6NPBC5trW5eS38xMjzsIRyehXIHcg1xWr/CPxJPpviLQbDWNITw/qmr/wBsK01vIblHMiuY8htuPlGGwT7DPG7rHw51mY/EI6ZqdhC3it4FDTwl/s8SxGOT5ejMQeOmM57UAdp4f8Y6B4hn1OPRdRS7GmsEupURxEjYzgSEbGwOu0nHes2TxjNq8pt/BOn/ANr87W1GR/KsIz0OJcEykekYYdiy1n/Cf4fz+A9E1Pw9Pd22p6DJM0lqJIQsoVxh0l42uPf6jpgD0CNEijWONVRFAVVUYAA6ACgDk7XwWt5cpeeL759fu0YPHDLGI7OBh0McAyMjszl2HYis3443Jt/h9cxqcCeaKI49N27H/jtegV5h+0OSPAsGM/8AH9Hn/vh6xxDtSl6HoZTFTxtJPujz/wAJ2q3OlyF+oHFaHwwRLb4pQLIcF7eVY8/3sZ/kDUfw6T7TaeWp5K5qprxudD1y31SzGJ7WUSKD0OOqn2IyPxryYe6oz7H22IvWqVsNfWSaX6H0dRVHQtUt9a0i01GzbdBcRh19vUH3ByPwq9Xtp3V0fncouEnGSs0Fcr8J/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJTJOqooooAp6xdfYdKu7kDJijZgPfHH614iu4816d8Rr42+kJaoRvuXwf91eT+uK88jjBFeLmM+aooroe5lkOWm5PqQozrVqKf1pREKcIOOK8+zPQbRaikBqzG1ZojZDxU0cpB5ovYlq5BqWhW16S6ARyHrgcGsGfwhcF/3TRkezV2EcgI61MrVqplxxFSCsmcXB4JuHP72eJB9STW9pfhGxtXWScmd15AIwv5d62lapVaqTM6mKqy0uc9rGliN2SD5YpQWQD+Fh2rX0O8a90uGWX/WjKP7kHGabqPzzWg/2j/KqvhnK6fL6ee+Ppmrl8KY5Pnopy3RsE04Got1OVqyucziSUjsEQsegGTSqc1BqZ26bdsOohc/oaq4lG7sefFmnlkmP33YsfxNTbmC5IqOyxgZrReEMo4reK0Pdk0nYoi9CtsDfN6etXLDUAjfNWffWAljO0lXHKsOxrOs7otOYLgBLpe3Zx6indoHGMkdTdXW5wyHBqzHdTsgMkfmL69655Jv3uD2Ga6TS76MR4cCri7sxqQ5Y7XATQt0cxn+64pWhWYf8sj7g4qvfzQyPkYAqG2iWdsKafkQo6X2Lf2F/7jkexpyWig/NCGP+2c057CSGPersv0NZ95qN3BE+yYkgdWGTTdluCvP4WaH2KGNcukUY/wBpiKYs1pCf9YP+AJn9ao2QW5AaVyxPPJq/cpbRQ/LgtQn1QOLvZsrz6pGZTFag5GMu3X8Ku2kaMN8xyT1J61y1xMFmDr2OD9Ktf2ltX73apU9dTV0dLRNXWpIUhZUIziuSUNMzKmSwORUt3dvKTz1rX8J6a7zfa5lIiXlc/wARrKcru5orUIXkVNP8O3l2waVTDF3Zxz+ArsLW3hsbZIIF2ov5k+pqxLLVKabrXPKVzzqledbfYkeTHeqU8wzUUkrMcKKRYWblqzvcSiluMZt1a3guVYPE1qZDgPuTPuQcfrWY0e0cVCjNFMjocMpDA+hFVTlyTUuwqkeeDj3PcKKr6dci8sLe5XpKgbHoSORVivpk7q6PlmmnZhRRRTEFcrqX/JU/D3/YF1P/ANH2FdVXK6l/yVPw9/2BdT/9H2FAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxvxd0ptX8AapDEpaaJROgHqpyf0zXZUjKGBDAEEYIPepnHni4vqbYes6FWNWO8Wn9x8pfD7XmsZwpOGQ4INdp4svbPULPzIiPMYfMPeqvxK+FV/pt9Jq/hSNri1YlntkGXj+g/iH6/wA682l1a8izFcQyq44II6GvEmp0U4SR+j0vq+ZSjiqMtev/AAT1j4E+JJLbXbrw7O2be4DT2+T91x94D2IGfw9691r5/wDgP4Yv7nxAPEV3C0NnCjLEWGPMZgV49QATzX0BXpYLm9kuY+Q4kVL69L2XZX9f6sFcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJXWeCdVRRTLiVYIJJX+4ilj9AM0bBueXeOLs3viKVAcxwARL9R1/Un8q+ftbvNa0r4l+Kde02Wa4s9Haz+12IY4e3khG8qOgKlQf17HPtLO09zLM33nYsfxOaji02yjury4S1hWe8CrcPsGZgo2qG9cA4r55V/flNq9/8/wDI+jlQ9yME7W/y/wAzyHwL4j1aXQPC2laZdRW8+r3F6xvbxDNsWNiQqruGWOehPArXtfHfiG5g0u1tRph1CTWbjSZLh43ME3lqCJFAbODn17dq76TwhoFzpMWmTaPZNYRMXjg8oBUY9SvoT7VoWvhzSLeCxig020jjsXL2yrEAImPVl9CfWtHVpt35f61MVTqJJc39aHmvibxP4tsL3W7O3udKV9H0yK+nc2zHzW53KvzcA475/rUumeLtZi1e8h1y405LaTw+NchkigYC3BbbtYZJfrn3xxXps+haZcy3ctxYW0kl3F5FwzRgmWMfwt6j2oPh/SjJ5jadas/2T7DkxA/6P/zy/wBz26UueDVnEOWad1I8csvFut3x1bStTYz2d1oM99BPJaC2cjbgEKJHypB74Pt6+h/C6Qr8PfDoP/PjF/6CKkh0HwdoOoRWMOn6bZ3l3BKiRiIB5YgMyDPcY65rW0FtMudFtJdCaFtM2bbcwjCbRxgewxU1ZJx91WKpJqXvO5qo4NSqapgFDWfq/iOy0p47d/NudQlGYbK2XfNJ7hew/wBpiFHc1jG70NZ2WpqXsvlTWrnoXK/mDUXh4BdOx382TP8A30a5250XVvEkROv3AsLM/MmnWj5Lf9dpRgt7qmB6lq6PRLFdNsEtkWNEQ/KkYwqL0AA9AK2bXLy3Gp3p2LzLTASpqYUpQNWdjNSsNSSkvj5mn3KDq0TD9DSGNgeKcFJBBHBpWsUmr3OAtSFOK2LchlrAmBt7uSJuqMVP4GtSxm+UV1QZ7VRXV0aJtwR0rD1zSo7mPJXDryGHUVvpJxzVO/lUg1o0rGEG72OAkutR0qYGQfaoF7N98D610FhqEV1CJbSQOvcd19iO1RXwSQMCBXK31g0Fx9ps5mgmH8Snr9axvY6+VpXO0nnZ9owRk1JaXrQkYPNdDpfh+O40KzkuXk+2PCrsxxgMV9Me9c5qWl3VnKRLGwXPDAZU/jS5uxlTrU6t4o031h3iKljWZLdeaxHr1qhtc8c1raNo11f7vJQhMcyNwoqnJvcvlhSXM9CtaXflKFJpbm/3IQCau3fhXU4m+SISD1RgaLTwlqUzjzUWFO7Ow/kKXMyXWo/FzIp6NYzarM0MWM4yWboBWq3hC83Y86HHruP+FdZo+lQaTbeXF80jffkPVv8A61TzSheprNyOCpjpuX7vY52w8MW9swe5fzmHO3GF/wDr1qSyBFwMADgAUk1yWJCUyK2eVstWbk3sYSqSn71Rld3ZzhRTktWblq1I7RUHSlZQOlCh3M3V7GcLZV7Uhj44q44qFxQ1YFJsoTJVRl5rQl71Sk65rNnRFno3gOfzdBWPPMLsuPbr/Wujrhvh1cATXduT95Q4H0OD/MV3NfQYSfNRifO4yHJWkgooorpOYK5XUv8Akqfh7/sC6n/6PsK6quf8Q+G21fVbDUrbWdS0m9s4ZrdZLJYG3xytEzBhNFIOsKEEAHr60AdBRXK/8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLQB1VFcr/wi+r/APQ9+JP+/Gnf/ItH/CL6v/0PfiT/AL8ad/8AItAHVUVyv/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi0AdVRXK/8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLQB1VFcr/wi+r/APQ9+JP+/Gnf/ItH/CL6v/0PfiT/AL8ad/8AItAHVUVyv/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi0AdVRXK/8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLQB1VU7nS7C6mEtzY2s0o6PJCrMPxIrB/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaTSe5UZOLvF2OpUBQAoAA4AFLXK/8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLTJOqrlfhP/wAks8G/9gWy/wDRCUf8Ivq//Q9+JP8Avxp3/wAi1teHtKg0HQNM0i0eV7bT7WK0iaUguyRoFBYgAZwBnAFAGhWH40uTbeHrnBw0mIx+J5/TNblcZ8SZ8W1lbg/fdnI+gwP5msMTPkpSZ0YWHPWijx34j6gdK8GXtyBefejUvaTGF0BcZYuASq+pAzjP1rzEa/rdn4M8d+VrF3KtmbB7O5FxJIV81xv2SOAxGOOR/Pn3uMYWqmvaLZeIdIuNL1SNpbOfb5iBypO1gw5HPUCvFo1YwXK11/yParUZTfMn0/zPJb7XLuE+MZPDWu6pfaPBpIkN1NKzeTeeYPljYgY+QkkDjP0pya9rRuNQk8EatqussuhmW889mmSC5yP9WCMB8bjtHXHQ17PqulWut6Vc6dqCGS0uU2SKGKkj6jkVs6fbR21tDBCMRxIEUZzgAYFbKtG3wnNKjK+588aFrmrrpuvyWPiZrz/iSSyfZxe3FzPDcLjEmXiURnkjaD16D027afxJo2pf6Bqer6lNe+FG1ARXj+cFugBjYuMA/wCz375r3tEpxSm6yf2SFTa6nzb4UngvPGHhC8stZ1TVrs6ddveyXcjv5E5hyyLuGFwcjaPQfUs1DXvEieAvB91o+o6rceKJ4bgy2wDSiWEGTMjqejLgbT1Pvjj6QaOmGOh1le/L/Wv+Y1SdrX/rT/I8+8Mw3Wr+B9G/sjXrnZLGDc3txH5lyx/iUbiQjbsjkMABxnrW7pGg2OixyCwhIklO6aaRi8szeruclj9TXQsmKhda55Ns6YWViqshHBqZGzUbx56URqVqEaOxYU1KpquGqRWqjNosDmnBRUaNUqmmQefeMLVrXWXfGI5hvU+/f9f51VspsCu58TaX/aelsqD9/H88fue4/GvOrUSb8bTVxdj3MLVValZ7o3EuDjFVLws/Q1es7N5SMitT+yNyZ21uk5A6kYM4a4gmc4QUunabCdQgOpbjbBxvC+ldbLpyxdRWXfqEUgDkVnKFtzRVVNWR6SqqyKUwUI4x0xQY89RxWD4GvWudNkgc5aBsD/dPT+Rro6zseBVg6U3B9CsLK3zkwRE+uwVYVQoAAAHpS01jxQQ23uBbFRPJgU2SUCqsjM1S2NRHTT9hVR0eU+1TpHk81ajiAHSptc05lEqQWoXqKvRxgCpEQCn1aVjOU7kT9KrSVZkqtJQwRXeon71K3WoWqWaIqTd6qSjg1cmqnJ3rKR0wNXwZcfZ9ftx2kJjP4jj9cV6lXitnOba+gmBOY3VvyOa9pUhlBByCMivWy2V4OJ5OZxtNS7i0UUV6R5gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnPxEl363DHniOEfmSf/rV6NXl3jWQyeJrodkCKP8Avkf41w5g7UreZ35cr1r9kZK9BUsfWoh0qaOvER7ci5BWlAOlZ0HatK3rZHLMuIKftpqVJWiMGRlaaUqcimMMCiwXKsi1UkFXZKrSCoZpFlNqbuxUsi1XYYNSarUlBzSqcVCDijfQOxbVqsRtVGNs1YjOKaIkixdyeVZTyDqsbN+Qrz+0cFs4Gc130y+fayxf30K/mMV5yN0MxRgQynBB9a0izuwCVpI67THTGD1rZjZStclp0/zDmtpJyBjNdlOegVqeozUioLVyWqygZra1WdhmuSvmeV9q5JJxisasjqw1Pqdd8N8sL9/4coB9fmrtaw/Cun/2VpEcT/65z5knsT2/AYrXMgxxWFzycVJVK0pR2Hu2KrySZ6UyWSq5Yk1LZmokijJ5qUIDUKmpgaAeg9EAqZQKhVqmWqRDHig0tIaZJDJVZ6tuKquKllxK7VC45qd6hepNEU5uhqlL3q9NVKUVnI6IFOT71ez6NKJ9IspR/FCh/QV4zKOa9W8FS+b4asyTyoZD+DGu/LXabXkcOZx9yMvM3KKKK9g8UKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryXxKxk8RX5P/PUr+XFetV47qbmXV7x853Tuc/8AAjXm5k/civM9PLF78n5EYHSpoxUaipoxXkxPWmWoK0res2HtWlb1qjmmXYxUyio4hVhRW0UczY3FRuKsYpjLTaEmUnWoGWrrpUDrWbRomUpFqtItX5FqrIOalo2iyqRTTUjio2qWaIRWxVmKUVTJpVbFK42rmqjj1rl/FunkP9ugHyniQDsfWtZJyDVglJo2SQZRhgiriwpTdGfMjjtNlJYVvhsKDmsAxGz1CSHsrce4rX8zMPvXTB6HpVbOzRX1CUEEdar+HUV9aiOwNtyeR0461V1CbaD610PhmxNta/aZhiWYZA/ur/8AXrKchVWqdJ+ZutIaYZfeopHqEvzWNzy1EnL5NAPNQq2alWhDehKlTCokqZRVIzY5BVmNajiWrkScVcVcxkxAvFIy1ZC0x1rTlM1IpuKrSCrsi1VlHWsmjWLKb96gerElV3qDVFWXvVOTrV2QVTlHNRI3gU5q9H+HMm/QXXP3JmH6A/1rzifgV33wyfdpt2vpKD+Y/wDrV04B2rIwzBXonZUUUV7p4AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjVyMX9wD18xv517LXkOrJ5et3y+k7/APoRrzMzXuxZ6mVv3pIjWpUqNetTJ2ry4nqTLEPatC37VQhFaVuK1RzSL0PQVZUVBCOKsLW8TlkOxTSKfSGrJIXWoHWrTConFQ0WmUZRiqclX5xVCbrWUkbwZXfpULVM3SoWrM2RC3Wm5p7io6ksbI+2liuO1RTjiqrEqaEyuW6KmuNt1RH/AL6D/CpFm/c1S1bzWmhlWNpEUEMF5IrEfXLi3d0+xTOo6HhT+RNbxmehSSlTS7F+5JlukT1IFd8zhVCjgDgCvPtNkuL+a3dbaRXEgLfKcKM85NdwzZrOb1McZZ8qHs+abmmZpy1BxkqdqsJUMYqygqkZyJEFToKjQVYjFWjKTJohVyIcVWiFWkraCMJsk7UxqdSN0rRmaK0gqnMOtXpBVSYdawkjaDKMneq0lWpBzVeQVmboqyVTlq5L3qlN1qJG8Clcng12/wALGzb6gP8AaQ/oa4e45Fdv8LBiHUD/ALSf1rfA/wAZf10Mcf8AwH8vzO7ooor3j58KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryjxOnl+JL5fV935gH+ter15h41Tb4muD/AHlQ/wDjorz8xX7tPzPRy1/vWvIzVqZOtQJ0qdK8iJ60y1BWlb1mw1pW/atUc0y/F0FWBVaKrC1vE5pElFApa0II2qJ+9TNUT1DKRVmqhMOavy1TlHWspG8Ci4qJqsSCoGHNZM6EyJqhbrUzVC9Sy0Rv0qtKKst0qCQUi0U24NOWfbNGnrmhxzVVzi9g/GmirGzC5NTZzVWE1YFIlki1LGM1CvWp46aIZYjFWEFQx1OlWjGROgqdBUMdWE7VaMpE8YqdKhjqZa2iYyHig9KUUHpVkEElVZRVt6rS1jM1gUJRVaQVcmFVZBWTN0VJRVGYVoSiqUw5qJG8DOnrufheP9Evz/tqP0Neb6vcXMMhRIvkfaqSAfdYnHPtn/J7el/C8Y028PrKB+ldGBX75GOPf7h/I7SiiivdPACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK838ert8QZ/vRKf5j+lekV598Q0xrFu/rAB+TH/ABrizBXondlztW+Rz0fSrEdV4qspXixPZmWYa0YOgrPiq7CeK1RzSNCI1YSqkR6VaStonPImFLSClzWpmNbpUL1K1RvUsaKswqlLV6bpVGWspG8Cq9QuKmeonrJnQiu/Wo3qZxUL1LNEQtUElTtUEgqS0QOKpzf8f1v+NWpDiqch/wBNg/GmizWjqdelQJ1qdelIlki1PFUCVPFTRnItR9asJVePrVlKtGLJY6tR1VSrUVXEykWEqZahSpVNbIwZIKQ0maCaokjeq0nSrDmq8lZSNIlOaqr1blqrJWTOiJVl6GqU1XZulU5KzZvE53ymOpTCaJCAxdW3HcB29mH8v1r1H4ZrjRrlvWcj/wAdWvJrdzLqi/vXKne4R+WGT0zkjHt2Kjgd/YPhyu3QG952P6CuvAr998jmx7/c/M6iiiivbPDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4f4jx/vbGT1Dqf0/xruK5P4iRbtOtZP7su38wf8K5car0ZHVgnavE4iLpVmOqsdWYzXgxPemW4quw1Rjq3EelbI5pF+I1bj6VRiNXIjWkTCSLA6UtIvSlrYxGNTGp7UxqTKRXlHBqjMKvyVSm71lI1gU5O9QvU0lQOeKyZ0xInqvIamc1XfvUmiImPNRueKVzgmo25FJmiK83eqTf8fVufer8g4qjPxcQH/aoRRsCp16VXj5FWF6UiWSLU8dQJU8dNGci1H1qylVo+tWY6tGMidBViOokqZBWiMWTJUq1ElSLWqMmOpKKKZIx6gkqdqgfpWcjSJVkHFVZKuSCqso61kzaJSlHBrPuZ44pFjaSMSuCURmwWxWlN0rC1yGe4ECQQQyAOGYyHG3BB/UZHeoZvEoWscn2pnuyguQhG1UAJBI5yPvdB2H05r1vwHHs8OQt/fd2/XH9K8kQoNRVFjMTbGYxZ+4QQMj2IP6eua9i8GLt8NWI/wBlj/48a7MvX71vyOXMXakl5m1RRRXsnihRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc947TdoDn+7Ip/p/WuhrJ8Vx+b4fvV9E3fkQf6VlXV6Ul5M2w7tVi/NHmMR4qxH1qrFVqMc185E+imWY6txGqiVairZHOy9FVyLtVOKrsVaROeZYXpS0inilrYxGGo3qVqiapZSIJOlU5qtydKqzVnI2gUpKrydKsSVXesmdESu9Qmp2qBqk1RXl61FnippKhNIsY44rPvDiWD/erQc8VnX/34v96mijVgOcVbXpVK16Cri1JLJU61NGagFSoaaIZcjq1HVOI9KuR1aMJFqPtU6VXjqzHWiMJEq09aYKetaIzYtL2pBSmqJI3qB6mc1C1ZyNIkEnSqkvSrUvSqkprJm0SpN0rHur2SO6kjS1lmRFUs0ZBIznscZ6dq15azLq3k84z2rqkpAVlcZVgM4+h5PNQzeJj27wSX91LHI0kzD5tylTGOy4PT+vWvZ/CgA8OWGB/yyBryLyJ/tEs84jQuoXZGxYHGeSSBzz6fnXsXh1Nmg6ev/TBD+gruy742/I48x/hxXmaNFFFeueOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBqEXn2FxF/fjZfzFT0HkUmrqw07O55AIGVulTRoRXRXWnbZGGOhNVjZY7V4DoOLPfWIUkZ6LVmMc1OLQinpbkHpRyNEOaY6GrkZqGOIip0QgVcU0ZSaJlNONNUGn7TWqMmMNRP3qYqcVE6mk0NMryVVlq46mq8qcVlJGsWZ8lV3q5Ihqs6Gsmjoiyq1QPVp1NV3U81NjVMqyVCasSIc9KhZDmkaED1n6h0j/3hWi6nNUb5CVXj+IU0O5o23AFXFqpCDgVbjBqRMkFSJTQpp6qaZDLERq5Eapxg8VciBq0YyLUdWY6rxqatRitEc8iUU4cUiinc1qZMUUGgUjUxETmomqVgSabsJrNq5oirJVOQcmtNoSc8VEbQk0uRstTSMeRST0qLyWbtXQJYEnpViPTvamsO2V9YUTmPsLN2r02wTy7G2T+7Gq/kK59bHHaumQbUUegr0MHR9ndnDjK3tLIWiiiu04QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCtNaJISccmqz6evYVpUVDpxe5aqSRknTx6U3+zx6VsYFGBUOjEr20jH+w+1H2PHatfAo2il9XiP20jIFqR2p32f2rU2j0o2D0pewQe1Zktbn0qNrc+lbOwelIYx6Unh0NVmYTW3tUL2vtXRGFfSmm3U9ql4YtVzlpLP2qu9kfSuvNqh7U02aelZvClrFWONbTyT0pjaaT2rtPsa+lIbJfSj6oX9bOGbSyT0pp0kntXcmxX0pfsK+lL6oP66zgzo5P8NVrnQ9wUY716N9hX0prWCHsKawiD66zho9GIHSpl0gjtXbfY19KBaL6UfU0L66zjf7KOOlIdNI/hrthar6UhtEPaj6mhfXGcdHYkdqsxWZ9K6f7GnoKeLZB2FCwgni7nPpaHHSpltSO1bggUdqXyl9KtYVGbxDMUWx9KX7KfStryx6Uvlj0p/VkT7dmMLU0v2Q+lbOwelGwelV9WQvbsxhZ+1OFn7Vr7B6UbR6ULDxD2zMoWftThaD0rT2j0pdoq1RSJ9qyjHagdqmEAHarGKXFWoJEubZX8kelWKKKpKxLdwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appendix is a thin pouch that hangs down from a part of the large intestine. Appendicitis is the term doctors use when the appendix gets infected and inflamed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34946=[""].join("\n");
var outline_f34_8_34946=null;
var title_f34_8_34947="Patient information: Medicines for Parkinson disease (The Basics)";
var content_f34_8_34947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16405\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"         Tips on taking medicines",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/40/13954\">",
"         Patient information: Parkinson disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/4/5188\">",
"         Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/50/28449\">",
"         Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/63/30708\">",
"         Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for Parkinson disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/medicines-for-parkinson-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12567020\">",
"      <span class=\"h1\">",
"       What do Parkinson disease medicines do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Parkinson disease medicines can help control or improve certain symptoms of the disease, such as trouble moving the body, stiffness, and shaking (called &ldquo;tremors&rdquo;). Currently, no medicines can cure Parkinson disease or keep it from getting worse over time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12567027\">",
"      <span class=\"h1\">",
"       Which medicines might I take?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can use different medicines to treat Parkinson disease. People might take 1 or more of these medicines. The right medicines for you will depend on your symptoms, your age, and how active you are.",
"     </p>",
"     <p>",
"      People do not always take medicines for their Parkinson disease right away. That&rsquo;s because even though the medicines can help, they can also cause problems of their own. Many people start taking medicines when their symptoms affect their daily activities. To decide when you should start, talk with your family and your doctor. Ask your doctor about the benefits and side effects of the different medicines.",
"     </p>",
"     <p>",
"      When you start taking medicines, your doctor will work with you to find the medicines and doses that work best. Let him or her know if you have any side effects or problems with the medicines (",
"      <a class=\"graphic graphic_table graphicRef59726 \" href=\"mobipreview.htm?32/6/32875\">",
"       table 1",
"      </a>",
"      ). &nbsp;",
"     </p>",
"     <p>",
"      This article has basic information on the main medicines used to treat Parkinson disease. For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12567062\">",
"      <span class=\"h1\">",
"       Medicines to treat Parkinson disease",
"      </span>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Levodopa, or &ldquo;L-dopa&rdquo; &mdash;",
"        </strong>",
"        This medicine can help people who have trouble moving the body. It can also improve stiffness and tremors. Doctors usually prescribe it first, because it is the medicine that works best for most people.",
"        <br/>",
"        <br/>",
"        The most common short-term side effects are nausea, headache, feeling dizzy, and feeling sleepy. These problems are not usually serious. Serious side effects can happen, especially in older people, but they are less common. These can include losing touch with reality and believing things that aren&rsquo;t really true (called &ldquo;delusions&rdquo;). To prevent problems with side effects, your doctor will work with you to find the lowest dose and best time of day to take each dose.",
"        <br/>",
"        <br/>",
"        Some, but not all, people who take levodopa for 5 to 10 years can develop muscle cramps or sudden muscle movements (called spasms) that they can&rsquo;t control. Also, the medicine&rsquo;s benefits can wear off suddenly before it&rsquo;s time for the next dose.",
"        <br/>",
"        <br/>",
"        Levodopa comes in different forms, including",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/6/31844?source=see_link\">",
"         carbidopa-levodopa",
"        </a>",
"        (brand names: Sinemet&reg;, Parcopa&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/17/18709?source=see_link\">",
"         levodopa-benserazide",
"        </a>",
"        (brand names: Madopar&reg;, Prolopa&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Dopamine agonists &mdash;",
"        </strong>",
"        These medicines control symptoms almost as well as levodopa, but they can cause more side effects. Side effects can include nausea, feeling tired, and delusions (believing things that aren&rsquo;t really true). These medicines might also cause leg swelling.",
"        <br/>",
"        <br/>",
"        Doctors sometimes prescribe dopamine agonists first for people younger than 65, so that they can put off taking levodopa. That way, they might avoid or delay getting the spasms that can affect people who take levodopa for 5 to 10 years. People who have severe Parkinson disease might take dopamine agonists along with other Parkinson disease medicines.",
"        <br/>",
"        <br/>",
"        Dopamine agonists include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/4/35908?source=see_link\">",
"         pramipexole",
"        </a>",
"        (brand name: Mirapex&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/46/20196?source=see_link\">",
"         ropinirole",
"        </a>",
"        (brand name: Requip&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/54/18277?source=see_link\">",
"         rotigotine",
"        </a>",
"        (brand name: Neupro&reg;), and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/23/35189?source=see_link\">",
"         bromocriptine",
"        </a>",
"        (brand names: Parlodel&reg;, Cycloset&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Others",
"        </strong>",
"        &mdash; Other medicines for Parkinson disease include MAO B inhibitors, COMT inhibitors, anticholinergics, and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/53/3925?source=see_link\">",
"         amantadine",
"        </a>",
"        . They are used less often than levodopa and dopamine agonists.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <strong>",
"         MAO B inhibitors",
"        </strong>",
"        &mdash; MAO B inhibitors are long-lasting medicines that help somewhat to reduce symptoms. Side effects can include nausea, headache, confusion, and trouble falling asleep.",
"        <br/>",
"        <br/>",
"        MAO B inhibitors include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/52/18246?source=see_link\">",
"         selegiline",
"        </a>",
"        (sample brand names: Eldepryl&reg;, Emsam&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/45/18133?source=see_link\">",
"         rasagiline",
"        </a>",
"        (brand name: Azilect&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         COMT",
"        </strong>",
"        <strong>",
"         inhibitors",
"        </strong>",
"        &mdash; COMT inhibitors are medicines taken with levodopa that help levodopa work longer and better. They are mainly used to treat patients whose levodopa &ldquo;wears off&rdquo; before the next dose. Side effects can include confusion, nausea, diarrhea, and abnormal movements.",
"        <br/>",
"        <br/>",
"        COMT inhibitors include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/60/34756?source=see_link\">",
"         tolcapone",
"        </a>",
"        (brand name: Tasmar&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/10/20644?source=see_link\">",
"         entacapone",
"        </a>",
"        (brand name: Comtan&reg;).",
"       </li>",
"       <li>",
"        <strong>",
"         Anticholinergics",
"        </strong>",
"        &mdash; These medicines can help control tremors. They are often used in younger people who have a tremor as their most severe symptom. Older people are more likely to get side effects, including dizziness, confusion, dry mouth, blurry vision, nausea, and trouble urinating or having bowel movements.",
"        <br/>",
"        <br/>",
"        Anticholinergics include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/30/39396?source=see_link\">",
"         trihexyphenidyl",
"        </a>",
"        (sample brand names: Artane&reg;, Trihexy&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/44/39620?source=see_link\">",
"         benztropine",
"        </a>",
"        (brand name: Cogentin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/11/29876?source=see_link\">",
"         orphenadrine",
"        </a>",
"        (brand name: Norflex&trade;).",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/53/3925?source=see_link\">",
"         Amantadine",
"        </a>",
"        (brand name: Symmetrel&reg;) &ndash; This medicine can help improve mild symptoms of tremor, stiffness, and trouble moving the body. Side effects can include hallucinations (seeing or hearing things that aren&rsquo;t really there), confusion, ankle swelling, and skin changes.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12567105\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=see_link\">",
"       Patient information: Parkinson disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/63/30708?source=see_link\">",
"       Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/50/28449?source=see_link\">",
"       Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/4/5188?source=see_link\">",
"       Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/8/34947?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16405 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34947=[""].join("\n");
var outline_f34_8_34947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12567020\">",
"      What do Parkinson disease medicines do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12567027\">",
"      Which medicines might I take?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12567062\">",
"      Medicines to treat Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12567105\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/6/32875\">",
"      Tips on taking medicines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/50/28449?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/63/30708?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34948="Cilostazol: Patient drug information";
var content_f34_8_34948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cilostazol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     see \"Cilostazol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pletal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you have a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, numbness, and tingling in the legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701806",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cilostazol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 30 minutes before a meal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12158 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-124.240.187.80-687012310B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34948=[""].join("\n");
var outline_f34_8_34948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029608\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029610\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029609\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029614\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029615\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029617\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029612\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029613\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029618\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029619\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=related_link\">",
"      Cilostazol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34949="Cisplatin: Pediatric drug information";
var content_f34_8_34949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cisplatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"    see \"Cisplatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/20/14661?source=see_link\">",
"    see \"Cisplatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      see \"Cisplatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: I.V. (refer to individual protocols):",
"     <b>",
"      TO PREVENT POSSIBLE OVERDOSE, VERIFY ANY CISPLATIN DOSE EXCEEDING 100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     <b>",
"      PER COURSE",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent dosing schedule: 37-75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 2-3 weeks or 50-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 4-6 hours, once every 21-28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Daily dosing schedule: 15-20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Osteogenic sarcoma or neuroblastoma: 60-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recurrent brain tumors: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily for 2 consecutive days every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bone marrow/blood cell transplantation: Continuous infusion: High dose: 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 72 hours; total dose = 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (50 mL, 100 mL, 200 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: Administer according to protocol; rate of administration has varied from a 15- to 20-minute infusion, 1 mg/minute infusion, 6- to 8-hour infusion or 24-hour infusion; rapid I.V. injection may be associated with increased nephrotoxicity or ototoxicity compared to a slower I.V. infusion. Avoid extravasation. Needles or I.V. administration sets that contain aluminum should not be used in the preparation or administration; aluminum can react with cisplatin resulting in precipitate formation and loss of potency.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F151935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, anidulafungin, aztreonam, bleomycin, caspofungin, chlorpromazine, cimetidine, cladribine, cyclophosphamide, dexamethasone sodium phosphate, diphenhydramine, doripenem, doxorubicin, doxorubicin liposome, droperidol, etoposide phosphate, famotidine, filgrastim, fludarabine, fluorouracil, furosemide, ganciclovir, gemcitabine, granisetron, heparin, hydromorphone, leucovorin calcium, linezolid, lorazepam, melphalan, methotrexate, methylprednisolone sodium succinate, mitomycin, ondansetron, paclitaxel, palonosetron, pemetrexed, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, teniposide, topotecan, vinblastine, vincristine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amphotericin B cholesteryl sulfate complex, cefepime, gallium nitrate, piperacillin/tazobactam, thiotepa.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted powder for injection is stable for 20 hours at room temperature; do not refrigerate reconstituted solution since precipitation may occur; protect from light; incompatible with sodium bicarbonate; do not infuse in solutions containing &lt;0.2% sodium chloride; stable when combined with mannitol (12.5-50 g mannitol/L)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of testicular, bladder, and ovarian cancers (FDA approved in adults); has also been used in the treatment of breast cancer; osteosarcoma, Hodgkin's and non-Hodgkin's lymphoma, head and neck cancer, gastric cancer, esophageal cancer, cervical cancer, nonsmall cell lung cancer, small cell lung cancer, neuroblastoma, prostate cancer, sarcomas, myeloma, melanoma, mesothelioma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F151938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CISplatin may be confused with CARBOplatin, oxaliplatin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doses  &gt;100 mg/m",
"       <sup>",
"        2",
"       </sup>",
"       once every 3-4 weeks are rarely used and should be verified with the prescriber.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F151934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Local: Tissue irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity (acute renal failure and chronic renal insufficiency)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (as tinnitus, high frequency hearing loss; more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia (mild), anaphylactic reaction, arrhythmias, arterial vasospasm (acute), autonomic neuropathy, bradycardia, bronchoconstriction, cerebral arteritis, cerebrovascular accident, dehydration, extravasation injury, heart block, heart failure, hemolytic anemia (acute), hemolytic uremic syndrome, hypercholesterolemia, hyperuricemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypotension, leukoencephalopathy, Lhermitte's phenomenon, limb ischemia (acute), mesenteric ischemia (acute), mouth sores, myocardial infarction, myocardial ischemia, neutropenic typhlitis, optic neuritis, orthostatic hypotension, pancreatitis, papilledema, phlebitis, reversible posterior leukoencephalopathy syndrome (RPLS), seizures, serum amylase increased, SIADH, spinal cord injury, stroke, tachycardia, tetany, thrombophlebitis, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, vision loss, visual color perception changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cisplatin, platinum-containing agents, or any component; pre-existing renal impairment, hearing impairment, and myelosuppression",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All patients should receive adequate hydration prior to and for 24 hours after cisplatin administration with a sodium chloride-containing I.V. solution to promote chloruresis, with or without mannitol and/or furosemide, to ensure good urine output and decrease the chance of nephrotoxicity; reduce dosage in renal impairment and in infants &lt;6 months of age due to their decreased renal function and renal tubular secretion; serum magnesium, as well as electrolytes, should be monitored before and within 48 hours after cisplatin therapy. Patients who are magnesium-depleted should receive replacement therapy before the start of cisplatin. The development of acute leukemia has been reported when given in combination with other leukemogenic agents. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Anaphylactic reactions have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; facial edema, bronchoconstriction, tachycardia, and hypotension may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines may be used to treat reactions. Cumulative renal toxicity may be severe",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; dose-related toxicities include myelosuppression, nausea and vomiting (incidence: 76% to 100%); renal toxicity is potentiated by aminoglycosides. Ototoxicity, especially pronounced in children, is manifested by tinnitus or loss of high frequency hearing, inability to hear normal conversational tone, and occasionally, deafness",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; reported in up to 31% of patients with single dose; unclear whether otoxicity is reversible; risk increased with cranial irradiation (previous or concurrent) and related to the peak plasma concentration; monitor hearing function at baseline and prior to subsequent doses. May cause severe and potentially irreversible neuropathies with higher doses or more frequent dosing. Cisplatin may cause fetal harm; avoid pregnancy during use. Doses &gt;100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once every 3-4 weeks are rarely used and should be verified with the prescriber",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: CISplatin may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: CISplatin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: CISplatin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: CISplatin may enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2523502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and embryotoxicity. Women of childbearing potential should be advised to avoid pregnancy. If used in pregnancy, or if patient becomes pregnant during treatment, the patient should be apprised of potential hazard to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function tests (serum creatinine, BUN, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ), electrolytes (particularly magnesium, calcium, potassium), hearing test, neurologic exam (with high dose), liver function tests periodically, CBC with differential and platelet count, urine output, urinalysis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platination of DNA leads to reactive intermediates that bind to DNA and form intrastrand and interstrand DNA cross-links",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: Rapid tissue distribution; CSF unbound platinum concentration: 40% of the plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%; only the free (unbound) platinum and parent drug are cytotoxic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes nonenzymatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Free drug: 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total platinum: 44 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;50% of dose excreted in urine within 5 days in an inactive form",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Minimally removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Mild",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Mild",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 18-23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21-40",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Costello MA, Dominick C, and Clerico A, &ldquo;A Pilot Study of 5-Day Continuous Infusion of High-Dose Cisplatin and Pulsed Etoposide in Childhood Solid Tumors,&rdquo;",
"      <i>",
"       Am J Pediatr Hematol Oncol",
"      </i>",
"      , 1988, 10:103-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reece PA, Stafford I, Abbott RL, et al, &ldquo;Two-Versus 24-Hour Infusion of Cisplatin: Pharmacokinetic Considerations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(2):270-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/8/34949/abstract-text/2536803/pubmed\" id=\"2536803\" target=\"_blank\">",
"        2536803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13162 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34949=[""].join("\n");
var outline_f34_8_34949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708671\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046356\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046349\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151858\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151843\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046360\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151935\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046352\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046359\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151938\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151934\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046363\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046348\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046347\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299049\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151852\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151854\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523502\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046355\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046346\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046362\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046364\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13162|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=related_link\">",
"      Cisplatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/20/14661?source=related_link\">",
"      Cisplatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34950="Emergency complications of Hirschsprung disease";
var content_f34_8_34950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency complications of Hirschsprung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34950/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/8/34950/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung disease (HD) is a motor disorder of the colon caused by the failure of neural crest cells (precursors of enteric ganglion cells) to migrate completely during intestinal development. The resulting aganglionic segment of the colon fails to relax, causing a functional obstruction. In the majority of patients, the disorder affects a short segment of the distal colon, with a transition zone in the rectosigmoid. In other patients, the aganglionosis involves longer segments of the colon; in rare cases, the small bowel may also be involved.",
"   </p>",
"   <p>",
"    HD occurs in approximately 1 in 5000 live births, with an overall male:female ratio of 4:1. When the entire colon is involved, the gender ratio more nearly approaches 1:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review focuses on emergency complications of HD, the most important of which are intestinal obstruction and Hirschsprung-associated enterocolitis (HAEC). Colonic volvulus, a rare complication, also is discussed. The pathogenesis, diagnosis, and clinical management of HD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE OBSTRUCTION IN THE NEONATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD accounts for a substantial proportion of cases of neonatal bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/2\">",
"     2",
"    </a>",
"    ]. Infants who become symptomatic during the first few days of life typically present with failure to pass meconium (present in about 95 percent of neonates with HD), abdominal distension, vomiting (which may be bilious or feculent), and other signs of intestinal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Their clinical condition may deteriorate rapidly unless they are treated promptly. Most newborns with HD can be resuscitated and stabilized by nonoperative means, allowing for a full diagnostic work-up and definitive elective surgery. Emergency surgery is seldom needed, and exploratory laparotomy in undiagnosed cases of HD is to be avoided. Those who present later in infancy have similar symptoms, but are less likely to develop acute obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link&amp;anchor=H5#H5\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, infants with undiagnosed HD may present with Hirschsprung-associated enterocolitis (HAEC), which is discussed below. The clinical presentation includes fever, lethargy, anorexia, vomiting, abdominal distension, and diarrhea; an explosion of gas and liquid stool may occur following digital rectal examination. Because HD is increasingly diagnosed in the first few months of life, fewer children present with HAEC than in the past. Most cases of HAEC occur after a pull-through procedure, as discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Enterocolitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HD is suggested by a plain film of the abdomen, showing an airless rectum, a cone-shaped transition zone (the presence of which is diagnostic of HD), and dilation of the segment of colon immediately proximal to the aganglionic segment, best seen on lateral view. These findings are more clearly demonstrated by a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    or water-soluble contrast enema, which should be performed in any patient in whom the diagnosis of HD is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link&amp;anchor=H6#H6\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these findings, infants with acute obstruction have marked bowel dilation, which may extend to the small bowel. Rarely, there may be evidence of perforation.",
"   </p>",
"   <p>",
"    The differential diagnosis of infants presenting with acute distal intestinal obstruction includes meconium ileus, intestinal atresia and stenosis, anorectal malformation, duplication cyst, meconium plug syndrome, and neonatal small left colon syndrome. Calcifications usually suggest meconium ileus or atresia, but have also been reported with long-segment HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with HD almost never need to be brought to surgery urgently, even when they present with acute obstruction or HAEC. Neonates and infants with acute obstructive symptoms, and any child presenting with HAEC, should be resuscitated and stabilized with intravenous fluids, nasogastric or orogastric suction, broad spectrum antibiotics, twice daily rectal irrigations, and daily digital rectal examinations. Once stabilized, the patient should have a full diagnostic work-up, including a contrast enema and rectal biopsy to establish the diagnosis of HD. It should be noted, however, that the rectal manipulation from digital examinations or irrigation may occasionally decompress the bowel so effectively that it can cause the contrast enema to appear normal in patients with HD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link&amp;anchor=H6#H6\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By stabilizing the patient and fully establishing the diagnosis prior to surgery, newly diagnosed cases can be treated with a one stage definitive pull-through rather than a diverting colostomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENTEROCOLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung-associated enterocolitis (HAEC) is the most severe and potentially lethal complication of HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/5\">",
"     5",
"    </a>",
"    ]. With advances in technique and medical care during the past 50 years, mortality rates for HAEC have decreased from as high as 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] to less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The incidence of HAEC ranges from 24 to 34 percent in different series of patients with HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HAEC can occur prior to surgical intervention, in the immediate postoperative period, or even years after definitive repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Postoperative HAEC usually occurs soon after definitive pull-through repair, ranging from 3 weeks to 20 months postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study, HAEC developed in 33 of 105 postoperative patients (32 percent), at a mean of eight months after repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually present with explosive foul-smelling diarrhea, fever, vomiting, and abdominal pain and distension. Mild cases may be misdiagnosed as gastroenteritis. Rectal bleeding and shock may be present in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ]. A clinical grading system has been developed to facilitate diagnosis (",
"    <a class=\"graphic graphic_table graphicRef71348 \" href=\"mobipreview.htm?9/51/10043\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,14\">",
"     6,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An obstructive picture with air-fluid levels and dilated bowel loops is often seen on plain abdominal films. Findings specifically associated with HAEC include distension of the proximal colon and the \"cut-off sign\", or absence of air in the distal rectosigmoid colon, with an abrupt cut-off at the level of the pelvic brim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. A combination of the cut-off sign and at least two air-fluid levels has been strongly associated with a diagnosis of HAEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/11\">",
"     11",
"    </a>",
"    ]. Pneumatosis intestinalis is occasionally seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A consensus panel of clinicians determined that diarrhea, explosive stools, abdominal distension, and radiologic evidence of bowel obstruction or mucosal edema are the most important clinical predictors of HAEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A contrast enema may demonstrate a \"sawtooth\" appearance of the irregular mucosal lining of the colon; however, this study should",
"    <strong>",
"     not",
"    </strong>",
"    be performed if HAEC is suspected because of the risk of intestinal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ]. Computed tomography (CT) has been described as showing thickening of the wall of the entire large bowel and terminal ileum, with enhancement of the mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms underlying HAEC are not fully understood. Contributing factors include stasis and reduced production of protective mucin, which lead to bacterial overgrowth in the lumen of the bowel proximal to the involved segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/17\">",
"     17",
"    </a>",
"    ]. Commensal bacteria (eg, bifidobacteria and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/5/1108?source=see_link\">",
"     lactobacillus",
"    </a>",
"    ) are reduced, and in some cases, pathogenic bacteria (eg, C. difficile) are isolated; rotavirus and staphylococcus aureus may also have a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,6,18-21\">",
"     1,6,18-21",
"    </a>",
"    ]. The bowel wall in the affected area is subsequently invaded by colonic organisms, which can lead to intestinal perforation, peritonitis, systemic sepsis, shock, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic examination of involved colonic tissue reveals neutrophils within the crypts of the mucosa, with mucin retention, abscess formation, and, in the most severe disease, transluminal necrosis and perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ]. Two forms of HAEC can be differentiated on pathologic examination of colonic tissue: inflammatory enterocolitis, involving the mucosa only; and necrotizing or ischemic enterocolitis, involving the entire thickness of the bowel wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with increased risk for",
"    <strong>",
"     preoperative",
"    </strong>",
"    HAEC include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,10,12,14\">",
"     6,10,12,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delay in diagnosis of HD (&gt;1 week of age)",
"     </li>",
"     <li>",
"      Increased length of the aganglionic segment",
"     </li>",
"     <li>",
"      Trisomy 21 (possibly caused by an underlying immune deficiency in these children)",
"     </li>",
"     <li>",
"      The presence of other associated anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors associated with increased risk for",
"    <strong>",
"     postoperative",
"    </strong>",
"    HAEC include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coexisting intestinal neuronal dysplasia (IND) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/22\">",
"       22",
"      </a>",
"      ] or hypoganglionosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/23\">",
"       23",
"      </a>",
"      ] proximal to the resected aganglionic segment. The utility of resecting these proximal segments is not yet established. One study failed to show any advantage of resecting a longer margin of ganglionated bowel (&gt;5 cm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/8\">",
"       8",
"      </a>",
"      ], whereas another study described reduced rates of HAEC in patients in whom the IND-involved segment of the colon was resected in addition to the aganglionic segment, as compared to historical controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger age at resection (within the first six months of life) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/8\">",
"       8",
"      </a>",
"      ]. This finding contrasts with the increased risk for",
"      <strong>",
"       preoperative",
"      </strong>",
"      HAEC among neonates diagnosed after the first week of life.",
"     </li>",
"     <li>",
"      The presence of an anastomotic stricture or leak, or of any form of intestinal obstruction, has been associated with up to a 3.5-fold increase in the incidence of HAEC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,7,24\">",
"       1,7,24",
"      </a>",
"      ]. Intestinal obstruction also can be caused by an aganglionic segment if it is unrecognized and left in place.",
"     </li>",
"     <li>",
"      Children who have had HAEC before their definitive surgery are more likely to develop it in the postoperative period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with two or more crypt abscesses per high-power field on histologic examination of colonic mucosa, in both ganglionic and aganglionic segments, also appear to be at increased risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/25\">",
"       25",
"      </a>",
"      ]. An alteration in the intestinal mucus and the intestinal immunologic defense system of HD patients has been described and may contribute to susceptibility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6,21,26\">",
"       6,21,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of HAEC includes volume resuscitation and intravenous antibiotics, which should provide broad-spectrum coverage against aerobic and anaerobic organisms. Patients should be treated with repeated rectal irrigation through a rectal tube with saline; this decompresses the colon and often decreases the severity of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of postoperative HAEC can be successfully managed nonoperatively. The rare patient that does not respond to this management may require urgent surgery to divert the fecal stream through colostomy. Recurrent enterocolitis should raise the suspicion of mechanical obstruction or a residual aganglionic segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rectal irrigation may also help to protect against the development of HAEC. In one study, rectal irrigation for six months after surgical repair significantly decreased the incidence and severity of HAEC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar results were found in a separate study combining rectal irrigation and bowel decontamination with antimicrobial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the case of preoperative enterocolitis, the traditional treatment has been to create a diverting colostomy, usually without resection of the aganglionic bowel, as soon as the patient has been stabilized and the diagnosis has been established with a view to performing the definitive repair at a later date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the current trend is to resuscitate and stabilize the patient using the nonoperative measures noted above so that a definitive one-stage repair can be accomplished. Surgical resection and colostomy are indicated in the presence of ischemic bowel or a frank perforation, or failure to improve with nonoperative measures. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VOLVULUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volvulus is a rare complication of HD. It has been described in children and adults with previously undiagnosed short-segment HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The volvulus usually involves the sigmoid colon, and less commonly, the transverse or cecal segments. The cause is thought to be related to torsion of an enlarged colonic segment filled with meconium or feces. Excessive mobility of the sigmoid mesentery may also have a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/33\">",
"     33",
"    </a>",
"    ]. HD should be suspected in patients in this age group presenting with otherwise unexplained colonic volvulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations are similar to those seen in patients with volvulus caused by other conditions, including abdominal pain, distension, and vomiting (which may or may not be bilious). Typically, patients also have historical features, such as failure to pass meconium (in the neonate) or chronic constipation (in older children), suggesting the underlying disease.",
"   </p>",
"   <p>",
"    The diagnosis is suggested on plain abdominal radiographs, which will reveal distended intestinal loops and air-fluid levels consistent with obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34950/abstract/33\">",
"     33",
"    </a>",
"    ]. The diagnosis can be confirmed with a contrast enema, which may also de-torse the volvulus. Intravenous fluids and antibiotics should be administered. Surgery is indicated if detorsion is unsuccessful or if bowel necrosis or perforation is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/18/20770?source=see_link\">",
"       \"Patient information: Hirschsprung disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HD is a common cause of neonatal bowel obstruction. Infants who become symptomatic during the first few days of life typically present with failure to pass meconium, abdominal distension, vomiting (which may be bilious or feculent), and other signs of intestinal obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute obstruction in the neonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hirschsprung-associated enterocolitis (HAEC) is the most severe and potentially lethal complication of HD. It can occur prior to surgical intervention (preoperative HAEC), in the immediate postoperative period, or long after definitive repair (postoperative HAEC). Young infants and those with Down syndrome are at increased risk for HAEC. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Enterocolitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HAEC usually present with explosive foul-smelling diarrhea, fever, vomiting, and abdominal pain and distension, and sometimes rectal bleeding and shock. Mild cases may be misdiagnosed as gastroenteritis. Therefore, HAEC should be considered in any child known to have HD presenting with symptoms suggestive of gastroenteritis. Radiographs show an obstructive picture, with air-fluid levels and dilated bowel loops. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of HAEC includes volume resuscitation and intravenous antibiotics. Repeated rectal irrigation with saline decompresses the colon and may decrease the severity of disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infants presenting with HAEC prior to definitive surgery for HD should be stabilized, then treated with surgical resection of the aganglionic segment. Emergency surgery and a diverting colostomy are rarely necessary, except in the presence of ischemic bowel or a frank perforation, or failure to improve with nonoperative treatment.",
"     </li>",
"     <li>",
"      Postoperative HAEC generally responds to antibiotics and irrigation, and rarely requires surgical intervention. Patients with recurrent or refractory postoperative HAEC should be evaluated for mechanical obstruction or a residual aganglionic segment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volvulus is a rare complication of previously undiagnosed short-segment HD. The cause is thought to be related to torsion of an enlarged colonic segment filled with meconium or feces. Clinical manifestations are similar to those seen in patients with volvulus caused by other conditions, including abdominal pain, distension, and vomiting. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Volvulus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/1\">",
"      SWENSON O, NEUHAUSER EB, PICKETT LK. New concepts of the etiology, diagnosis and treatment of congenital megacolon (Hirschsprung's disease). Pediatrics 1949; 4:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/2\">",
"      Fitzgerald JF. Constipation in children. Pediatr Rev 1987; 8:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/3\">",
"      Pearl RH, Irish MS, Caty MG, Glick PL. The approach to common abdominal diagnoses in infants and children. Part II. Pediatr Clin North Am 1998; 45:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/4\">",
"      Cowles RA, Berdon WE, Holt PD, et al. Neonatal intestinal obstruction simulating meconium ileus in infants with long-segment intestinal aganglionosis: radiographic findings that prompt the need for rectal biopsy. Pediatr Radiol 2006; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/5\">",
"      Imamura A, Puri P, O'Briain DS, Reen DJ. Mucosal immune defence mechanisms in enterocolitis complicating Hirschsprung's disease. Gut 1992; 33:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/6\">",
"      Sherman JO, Snyder ME, Weitzman JJ, et al. A 40-year multinational retrospective study of 880 Swenson procedures. J Pediatr Surg 1989; 24:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/7\">",
"      Bill, AH, Chapman, ND. The enterocolitis of Hirschsprung's disease: Its natural history and treatment. Am J Surg 1962; 103:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/8\">",
"      Haricharan RN, Seo JM, Kelly DR, et al. Older age at diagnosis of Hirschsprung disease decreases risk of postoperative enterocolitis, but resection of additional ganglionated bowel does not. J Pediatr Surg 2008; 43:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/9\">",
"      Suita S, Taguchi T, Ieiri S, Nakatsuji T. Hirschsprung's disease in Japan: analysis of 3852 patients based on a nationwide survey in 30 years. J Pediatr Surg 2005; 40:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/10\">",
"      Teitelbaum DH, Qualman SJ, Caniano DA. Hirschsprung's disease. Identification of risk factors for enterocolitis. Ann Surg 1988; 207:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/11\">",
"      Elhalaby EA, Coran AG, Blane CE, et al. Enterocolitis associated with Hirschsprung's disease: a clinical-radiological characterization based on 168 patients. J Pediatr Surg 1995; 30:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/12\">",
"      Menezes M, Puri P. Long-term outcome of patients with enterocolitis complicating Hirschsprung's disease. Pediatr Surg Int 2006; 22:316.",
"     </a>",
"    </li>",
"    <li>",
"     Orenstein, JB. Hirschsprung disease. In: Pediatric emergency medicine: Concepts and clinical practice, Barkin, RM (Ed), Mosby-Year Book, Inc, St Louis 1997. p.850.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/14\">",
"      Blane CE, Elhalaby E, Coran AG. Enterocolitis following endorectal pull-through procedure in children with Hirschsprung's disease. Pediatr Radiol 1994; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/15\">",
"      Pastor AC, Osman F, Teitelbaum DH, et al. Development of a standardized definition for Hirschsprung's-associated enterocolitis: a Delphi analysis. J Pediatr Surg 2009; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/16\">",
"      Sheth J, Nour S, Dickinson F. CT images of Hirschsprung's associated enterocolitis: a rare finding. Arch Dis Child 2009; 94:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/17\">",
"      Mattar AF, Coran AG, Teitelbaum DH. MUC-2 mucin production in Hirschsprung's disease: possible association with enterocolitis development. J Pediatr Surg 2003; 38:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/18\">",
"      Shen DH, Shi CR, Chen JJ, et al. Detection of intestinal bifidobacteria and lactobacilli in patients with Hirschsprung's disease associated enterocolitis. World J Pediatr 2009; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/19\">",
"      Hardy SP, Bayston R, Spitz L. Prolonged carriage of Clostridium difficile in Hirschsprung's disease. Arch Dis Child 1993; 69:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/20\">",
"      Thomas DF, Fernie DS, Bayston R, et al. Enterocolitis in Hirschsprung's disease: a controlled study of the etiologic role of Clostridium difficile. J Pediatr Surg 1986; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/21\">",
"      Teich S, Schisgall RM, Anderson KD. Ischemic enterocolitis as a complication of Hirschsprung's disease. J Pediatr Surg 1986; 21:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/22\">",
"      Estev&atilde;o-Costa J, Fragoso AC, Campos M, et al. An approach to minimize postoperative enterocolitis in Hirschsprung's disease. J Pediatr Surg 2006; 41:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/23\">",
"      Wu X, Feng J, Wei M, et al. Patterns of postoperative enterocolitis in children with Hirschsprung's disease combined with hypoganglionosis. J Pediatr Surg 2009; 44:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/24\">",
"      Hackam DJ, Filler RM, Pearl RH. Enterocolitis after the surgical treatment of Hirschsprung's disease: risk factors and financial impact. J Pediatr Surg 1998; 33:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/25\">",
"      Wilson-Storey, D. Microbial studies of enterocolitis in Hirschsprung's disease. J Pediatr Surg 1994; 9:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/26\">",
"      Elhalaby EA, Teitelbaum DH, Coran AG, Heidelberger KP. Enterocolitis associated with Hirschsprung's disease: a clinical histopathological correlative study. J Pediatr Surg 1995; 30:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/27\">",
"      Marty TL, Seo T, Sullivan JJ, et al. Rectal irrigations for the prevention of postoperative enterocolitis in Hirschsprung's disease. J Pediatr Surg 1995; 30:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/28\">",
"      N&uacute;&ntilde;ez R, Torres A, Agulla E, et al. [Rectal irrigation and bowel decontamination for the prevention of postoperative enterocolitis in Hirschsprung's disease]. Cir Pediatr 2007; 20:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/29\">",
"      Ghosh A, Griffiths DM. Rectal biopsy in the investigation of constipation. Arch Dis Child 1998; 79:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/30\">",
"      DEAN GO, MURRY JW. Volvulus of the sigmoid colon. Ann Surg 1952; 135:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/31\">",
"      Neilson IR, Youssef S. Delayed presentation of Hirschsprung's disease: acute obstruction secondary to megacolon with transverse colonic volvulus. J Pediatr Surg 1990; 25:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/32\">",
"      Tan FL, Tan YM, Heah SM, Seow-Choen F. Adult Hirschsprung's disease presenting as sigmoid volvulus: a case report and review of literature. Tech Coloproctol 2006; 10:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/33\">",
"      Sario��lu A, Tanyel FC, B&uuml;y&uuml;kpamuk&ccedil;u N, Hi&ccedil;s&ouml;nmez A. Colonic volvulus: a rare presentation of Hirschsprung's disease. J Pediatr Surg 1997; 32:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34950/abstract/34\">",
"      Venugopal KS, Wilcox DT, Bruce J. Hirschsprung's disease presenting as sigmoid volvulus in a newborn. Eur J Pediatr Surg 1997; 7:172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5891 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34950=[""].join("\n");
var outline_f34_8_34950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE OBSTRUCTION IN THE NEONATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENTEROCOLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VOLVULUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/51/10043\" title=\"table 1\">",
"      Hirschsprung enterocolitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/18/20770?source=related_link\">",
"      Patient information: Hirschsprung disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34951="Evaluation and management of strabismus in children";
var content_f34_8_34951=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of strabismus in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34951/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/8/34951/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of strabismus in children will be reviewed here. The causes of strabismus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=see_link\">",
"     \"Causes of horizontal strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=see_link\">",
"     \"Causes of vertical strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strabismus is the term used to describe an anomaly of ocular alignment. Strabismus can occur in one or both eyes, and in any direction. The terms used to describe strabismus depend upon the direction of deviation, the conditions under which it is present, and whether it changes with the position of gaze.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal deviation (relative to the fixating eye) is described with the prefix \"eso\", and temporal deviation with the prefix \"exo\". As a general rule, the prefix \"hyper\" is applied to the eye that is more superior in vertical deviations, regardless of which eye is fixating. However, the prefix \"hypo\" is sometimes used to denote an eye that is depressed relative to the fixing eye, usually when there is a restrictive hypotropia.",
"     </li>",
"     <li>",
"      A \"latent\" strabismus is present only when fixation is interrupted and is known as a \"phoria\" (eg, esophoria, exophoria). In children with latent strabismus, ocular alignment is maintained by fusion as long as fixation is uninterrupted. Strabismus that is present without interruption of the visual axis is \"manifest\" and described as a \"tropia\".",
"     </li>",
"     <li>",
"      Manifest strabismus can be intermittent, occurring only when fusional capabilities are exceeded (eg, when the child is tired) or constant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Manifest strabismus can be monocular, when deviation always involves the same eye, or alternating, when either eye may deviate.",
"     </li>",
"     <li>",
"      Deviation that is the same in all positions of gaze is described as \"comitant\". Deviation that changes depending upon the position of gaze is \"incomitant\" and usually is present with paralytic or restrictive strabismus.",
"     </li>",
"     <li>",
"      Unsteady ocular alignment is often present in normal newborns during the first few months of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/2\">",
"       2",
"      </a>",
"      ] and can be described as \"ocular instability of infancy\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three pairs of extraocular muscles move each eye in three directions from the primary position: vertically (superior and inferior), horizontally (medial and lateral, or adduction and abduction), and torsionally (intorsion when the top of the eye rotates nasally and extorsion when the top of the eye rotates temporally) (",
"    <a class=\"graphic graphic_figure graphicRef80501 \" href=\"mobipreview.htm?22/3/22577\">",
"     figure 1",
"    </a>",
"    ). The following muscles are responsible for these movements (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The superior rectus and inferior oblique muscles are both responsible for upward vertical movements",
"     </li>",
"     <li>",
"      The inferior rectus and superior oblique muscles are both responsible for downward vertical movement",
"     </li>",
"     <li>",
"      The lateral rectus is responsible for abduction",
"     </li>",
"     <li>",
"      The medial rectus is responsible for adduction",
"     </li>",
"     <li>",
"      The superior oblique is primarily responsible for intorsion",
"     </li>",
"     <li>",
"      The inferior oblique is primarily responsible for extorsion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The superior oblique muscle is innervated by cranial nerve IV (the trochlear nerve), the lateral rectus muscle by cranial nerve VI (the abducens nerve), and all others by cranial nerve III (the oculomotor nerve) (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The understanding of strabismus requires knowledge of the two major principles that govern ocular motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hering's law &ndash; Agonist muscles in both eyes receive equal innervation to ensure coordinated binocular eye movements. Thus, when the right lateral rectus muscle is activated to abduct the right eye, the left medial rectus muscle is equally activated to adduct the left eye.",
"     </li>",
"     <li>",
"      Sherrington's law &ndash;",
"      <span class=\"nowrap\">",
"       Agonist/antagonist",
"      </span>",
"      muscle pairs within each eye receive reciprocal innervation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/4\">",
"       4",
"      </a>",
"      ]. Thus, when the right medial rectus muscle contracts to adduct the right eye, its antagonist, the right lateral rectus muscle, relaxes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strabismus occurs in approximately 2 to 4 percent of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Risk factors for strabismus include, but are not limited to, a positive family history and low birth weight (particularly those premature or low-birth-weight infants who have a history of retinopathy of prematurity or neurologic complications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=see_link&amp;anchor=H31#H31\">",
"     \"Retinopathy of prematurity\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conditions that predispose to strabismus include vision deprivation (as occurs with corneal scars, cataracts, severe ptosis, and longstanding vitreous hemorrhage), muscular abnormalities, hyperopia, cerebral injury, anisometropia, amblyopia, and impairment of binocular fusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Strabismus is a common presenting sign of retinoblastoma when it involves the fovea and thus decreases the visual acuity in an eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link&amp;anchor=H14#H14\">",
"     \"Cataract in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants, true strabismus must be differentiated from pseudostrabismus and ocular instability of infancy. As described above, ocular instability of infancy is the unsteady ocular alignment that is often sporadically present in normal newborns during the first few months of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pseudostrabismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoesotropia is the most common form of pseudostrabismus. It is the apparent esotropia that typically occurs in children with a wide nasal bridge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large epicanthal folds during the first year of life. It is not a true strabismus, but rather an optical illusion in which the wide nasal bridge or epicanthal folds hide the nasal sclera making the eye appear esotropic, particularly when the child looks to the right or left, adducting one eye (",
"    <a class=\"graphic graphic_picture graphicRef70572 \" href=\"mobipreview.htm?41/1/42005\">",
"     picture 1",
"    </a>",
"    ). Normal ocular alignment is demonstrated by the corneal light reflex and the cover and",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    tests. The use of a diagram may help in explaining the concept of pseudoesotropia to the parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pseudoexotropia also can occur. Pseudoexotropia is most commonly seen in children with temporal dragging of the macula secondary to retinal traction. Retinopathy of prematurity is the most common cause of pseudoexotropia; other causes include vascular abnormalities, choroiditis, and other peripheral retinal disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/18\">",
"     18",
"    </a>",
"    ]. As with pseudoesotropia, pseudoexotropia can be differentiated from true strabismus with the",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    test and alternate cover test. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Apparent deviation in ocular alignment also can be caused by the use of cosmetic contact lenses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/19\">",
"     19",
"    </a>",
"    ], orbital deformities, or orbital tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Strabismus",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish between congenital and acquired strabismus, as some forms of acquired strabismus can be caused by a life-threatening or vision-threatening condition (",
"    <a class=\"graphic graphic_table graphicRef78228 \" href=\"mobipreview.htm?10/50/11053\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of primary&nbsp;strabismus include idiopathic infantile esotropia, intermittent exotropia, and the strabismus associated with various syndromes (",
"      <a class=\"graphic graphic_table graphicRef59573 \" href=\"mobipreview.htm?1/17/1308\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Important causes of secondary&nbsp;strabismus include retinoblastoma (sensory strabismus), head trauma with cranial nerve palsies or orbital fracture, myasthenia gravis, and Graves' disease. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Acute onset of acquired strabismus may occur with intracranial hemorrhage, abscess, encephalitis, Guillain-Barr&eacute; syndrome, tuberculous meningitis, diphtheria, measles, ventriculo-peritoneal shunt failure, lead poisoning, myasthenia gravis, tumors (intracranial, intraocular, or intraorbital), and botulism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Forms of esodeviations include accommodative esotropia, idiopathic infantile esotropia, esotropic Duane syndrome (sometimes referred to as Type 1), Moebius syndrome, sensory esotropia, and abducens nerve palsy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of horizontal strabismus in children\", section on 'Esodeviations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Forms of exodeviations include intermittent exotropia, oculomotor nerve palsy, exotropic Duane syndrome (sometimes referred to as Type 2). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of horizontal strabismus in children\", section on 'Esodeviations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Causes of vertical deviations include trochlear nerve palsy, oculomotor nerve paresis, orbital fracture, thyroid-related ophthalmopathy, Brown syndrome, double elevator palsy, and congenital fibrosis of the extraocular muscles. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=see_link\">",
"       \"Causes of vertical strabismus in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric healthcare providers can detect strabismus with several simple clinical tests. It is most important to detect manifest deviations because they have greater potential to cause amblyopia, a functional reduction in the visual acuity of an eye caused by disuse or misuse during the critical period of visual development. Latent deviations are rarely associated with amblyopia. In addition, after leukocoria, esotropia is the most common presenting sign of retinoblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of amblyopia\", section on 'Definition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important questions to include in the history for a child with ocular misalignment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Developmental/birth",
"      </span>",
"      history?",
"     </li>",
"     <li>",
"      Is there a family history of strabismus?",
"     </li>",
"     <li>",
"      Has the deviation been present since early infancy?",
"     </li>",
"     <li>",
"      What is the duration and severity of the deviation?",
"     </li>",
"     <li>",
"      When is the deviation present? (eg, constantly? With fatigue? Only in certain positions of gaze?)",
"     </li>",
"     <li>",
"      Is there any history of trauma?",
"     </li>",
"     <li>",
"      Is there any history of any other medical problems (eg, headaches)?",
"     </li>",
"     <li>",
"      Is there a history of exposure to toxins or medications?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include assessment of general health and neurologic status, including an assessment of development. The presence of a consistent head tilt or turn should be noted.",
"   </p>",
"   <p>",
"    The primary care provider's ophthalmologic examination should include assessment of visual function, pupillary reactivity, eyelid position, and extraocular movements",
"    <span class=\"nowrap\">",
"     (ductions/versions),",
"    </span>",
"    as well as the corneal light reflex, cover test, and",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the ophthalmologist's examination should include funduscopy, anterior segment evaluation, and cycloplegic refraction. These tests can be used to characterize strabismic deviations as horizontal or vertical, manifest or latent, constant or intermittent, alternating or monocular, and comitant or incomitant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Corneal light reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The corneal light reflection test, also called the Hirschberg test, often is used as an initial screen for strabismus. In this test, an accommodative target (eg, a small toy) is held several feet in front of the child's face, and a penlight is held next to the toy. If ocular alignment is normal, the light reflection is positioned at the same point in each eye (",
"    <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"     figure 2",
"    </a>",
"    ). Deflection of the corneal light reflection is noted if a moderate to large deviation is present. Each millimeter of deflection is associated with approximately 15 to 20 prism diopters of deviation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/22\">",
"     22",
"    </a>",
"    ]. Because the corneal light reflection test can overlook small deviations, it should be used in conjunction with the cover test and the",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cover test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cover test is one of the most important tests used in the detection of tropias. In this test, the child is asked to visually fix on a target at distance or near. The examiner covers one eye while observing the opposite eye for movement. No movement is detected if the child has normal ocular alignment. Manifest strabismus (tropia) is present if the eye that is not occluded shifts to refixate on the target when the fellow, previously fixating eye, is covered. The test should be repeated on each eye. The child should be referred to a pediatric ophthalmologist if manifest strabismus is detected because such a finding may indicate or lead to the development of amblyopia or other serious problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cover/uncover test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    test is used to detect latent strabismus (phoria) and need not be performed if the cover test is positive (ie, if the uncovered eye shifts to refixate on the target when the other eye is covered). In the",
"    <span class=\"nowrap\">",
"     cover/uncover",
"    </span>",
"    test, the child is asked to visually fix on a target at distance or near. A cover is placed over one eye for a few seconds and then rapidly removed. The eye that was under the cover is observed for movement. Once it is uncovered, this eye must shift back into the orthotropic (straight-ahead) position to refixate on the object if it became deviated while covered. If such movement is detected, latent strabismus is present (",
"    <a class=\"graphic graphic_figure graphicRef68374 \" href=\"mobipreview.htm?17/61/18386\">",
"     figure 3",
"    </a>",
"    ). Latent strabismus is held in check by ocular fusion. Small, barely perceptible phorias are common in normal subjects. Children who have phorias that are easily detected on clinical examination should be evaluated by an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Br&uuml;ckner red reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Br&uuml;ckner red reflex test, also known as the simultaneous red reflex test, is another test that is useful in detecting small-angle strabismus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In this test, the examiner positions himself or herself 18 to 20 inches away from the child's face and uses a direct ophthalmoscope with the largest diameter of light to view both of the child's red reflexes simultaneously. The lenses on the ophthalmoscope are adjusted until the skin around the eye is in focus, and the child's attention is directed toward the ophthalmoscope. This permits both pupillary red reflexes to be examined at the same time. They should be identical in size, shape, color, and hue. The child should be referred to a pediatric ophthalmologist if a difference in any of the above between the two eyes is noted, because such a finding may indicate a serious problem, including strabismus, significant anisometropia (imbalance of refractive error), or media opacity (",
"    <a class=\"graphic graphic_figure graphicRef66431 \" href=\"mobipreview.htm?31/47/32506\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5496?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the child with leukocoria\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for further evaluation depends upon the suspected etiology of strabismus. Blood tests (including complete blood count, erythrocyte sedimentation rate, or C-reactive protein)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuroimaging studies may be indicated, but are rarely required for routine strabismus. Neuroimaging studies should be considered in children with craniofacial malformations, neurologic abnormalities, trauma, or acute onset of paralytic or restrictive strabismus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=see_link\">",
"     \"Causes of horizontal strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=see_link\">",
"     \"Causes of vertical strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of strabismus include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amblyopia (occurs in up to one-half of younger children) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of amblyopia\", section on 'Strabismic amblyopia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diplopia (in acquired strabismus in patients &ge;3 years old)",
"     </li>",
"     <li>",
"      Secondary contracture of the extraocular muscles, limiting extraocular mobility and binocular visual fields; secondary contracture develops over a course of weeks to months if strabismus is not treated",
"     </li>",
"     <li>",
"      Adverse psychosocial and vocational consequences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with ocular misalignment should be referred for ophthalmologic evaluation under the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They have constant esotropia at any age",
"     </li>",
"     <li>",
"      They have persistent esodeviations after four months of age",
"     </li>",
"     <li>",
"      The corneal light reflection test or cover test demonstrates deviation",
"     </li>",
"     <li>",
"      Asymmetry of appearance on the Br&uuml;ckner simultaneous red reflex test (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"mobipreview.htm?31/47/32506\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      They have incomitant deviations (deviations that change depending upon the position of gaze)",
"     </li>",
"     <li>",
"      They have torticollis that is not explained on a musculoskeletal basis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/26/8616?source=see_link\">",
"       \"Acquired torticollis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parental concern exists about ocular alignment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for strabismus depends upon the etiology. Specific therapies are discussed separately. Improved ocular alignment and binocularity (including stereopsis) are the goals of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34951/abstract/31\">",
"     31",
"    </a>",
"    ]. A trial of medical intervention may precede surgical therapy in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=see_link\">",
"     \"Causes of horizontal strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=see_link\">",
"     \"Causes of vertical strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vision impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of strabismus addresses vision impairment caused by amblyopia. Therapy may include the prescription of eyeglasses for children who have significant refractive errors and the treatment of amblyopia with occlusion or pharmacologic or optical penalization of the preferred eye. In addition, surgical procedures may be necessary to correct conditions that obstruct the visual axis (eg, cataract, ptosis, hemangioma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of amblyopia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both medical and surgical interventions are used to correct alignment. Medical therapies to correct alignment include the prescription of spectacles with or without optical prism, miotic drops to manipulate accommodation, patching, and visual training exercises.",
"   </p>",
"   <p>",
"    Surgical procedures to improve ocular alignment include recession and resection of the rectus muscles and a variety of other procedures that are beyond the scope of this topic review.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rectus muscle recession involves repositioning of the muscle insertion posterior to the original insertion on the sclera, which effectively weakens its influence on globe position.",
"     </li>",
"     <li>",
"      Rectus muscle resection involves shortening the rectus muscle, which permits it to act as a passive restraint, effectively increasing its influence on globe position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general rule, recovery from strabismus surgery is rapid, and serious complications are rare. Nausea and vomiting are common on the first postoperative day and sometimes require treatment with antiemetics. Pain is typically mild and can be managed with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . A small amount of blood-tinged discharge from the operated eye(s) for the first 24 to 48 hours is normal, and the eyes are typically red for two to three weeks, either from conjunctival inflammation or subconjunctival hemorrhage. Temporary diplopia is not uncommon. The most serious, and fortunately rare, complication is postoperative infection, the most serious of which is endophthalmitis. Warning signs of infection include marked swelling of the conjunctiva and lids, decreased vision, purulent drainage, and occasionally pain. Children with these complaints should be seen by the ophthalmologist emergently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/58/27553?source=see_link\">",
"       \"Patient information: Crossed eyes and lazy eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strabismus is the term used to describe an anomaly of ocular alignment. Strabismus can occur in one or both eyes, and in any direction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three pairs of extraocular muscles are responsible for eye movement (",
"      <a class=\"graphic graphic_figure graphicRef80501 \" href=\"mobipreview.htm?22/3/22577\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"       table 1",
"      </a>",
"      ). Ocular motility is governed by two major principles (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Neuroanatomy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Agonist muscles in the left and right eyes receive equal innervation to ensure coordinated eye movements (Hering's Law)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Agonist/antagonist",
"      </span>",
"      muscle pairs within each eye receive reciprocal innervation (Sherrington's Law)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major considerations in the differential diagnosis of strabismus in infants are pseudostrabismus and ocular instability of infancy, which is frequently present in normal newborns during the first few months of life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoesotropia is an optical illusion in which a wide nasal bridge or epicanthal folds obscure the nasal sclera, particularly when the child looks to the right or left, adducting one eye (",
"      <a class=\"graphic graphic_picture graphicRef70572 \" href=\"mobipreview.htm?41/1/42005\">",
"       picture 1",
"      </a>",
"      ). Normal ocular alignment is demonstrated by the corneal light reflex and the cover and",
"      <span class=\"nowrap\">",
"       cover/uncover",
"      </span>",
"      tests. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pseudostrabismus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older children, it is important to distinguish between congenital and acquired strabismus because some forms of acquired strabismus can be caused by a life-threatening or vision-threatening condition (",
"      <a class=\"graphic graphic_table graphicRef78228 \" href=\"mobipreview.htm?10/50/11053\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Strabismus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the history include:",
"      <span class=\"nowrap\">",
"       developmental/birth",
"      </span>",
"      history; family history of strabismus; onset of deviation (eg, early infancy?); duration and severity of the deviation; whether the deviation is constant or intermittent and, if intermittent, what exacerbates it (eg, fatigue, positions of gaze); and history of trauma, other medical problems (eg, headaches), or exposure to toxins or medications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the primary care provider's physical examination include assessment of general health and neurologic status, and the presence of a head tilt. The eye examination should be comprehensive but focus mainly on the assessment of visual function, pupillary reactivity, eyelid position, and extraocular movements",
"      <span class=\"nowrap\">",
"       (ductions/versions),",
"      </span>",
"      the corneal light reflex (",
"      <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"       figure 2",
"      </a>",
"      ), cover test,",
"      <span class=\"nowrap\">",
"       cover/uncover",
"      </span>",
"      test (",
"      <a class=\"graphic graphic_figure graphicRef68374 \" href=\"mobipreview.htm?17/61/18386\">",
"       figure 3",
"      </a>",
"      ), and the Br&uuml;ckner red reflex examination (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"mobipreview.htm?31/47/32506\">",
"       figure 4",
"      </a>",
"      ). In addition, the ophthalmologist&rsquo;s examination should include cycloplegic refraction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for further evaluation depends upon the suspected etiology of strabismus. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for ophthalmologic referral include (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Constant strabismus at any age",
"     </li>",
"     <li>",
"      Persistent esodeviations after four months of age",
"     </li>",
"     <li>",
"      The corneal light reflection test or cover test demonstrates deviation",
"     </li>",
"     <li>",
"      Asymmetry of appearance on the Br&uuml;ckner simultaneous red reflex test (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"mobipreview.htm?31/47/32506\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deviation that changes depending upon the position of gaze",
"     </li>",
"     <li>",
"      Torticollis that is not explained on a musculoskeletal basis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/26/8616?source=see_link\">",
"       \"Acquired torticollis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parental concern about ocular alignment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of strabismus include amblyopia, diplopia, secondary contracture of the extraocular muscles, and adverse psychosocial and vocational consequences. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for strabismus depends upon the etiology. The goals of treatment are improved ocular alignment and binocularity (including stereopsis). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     McManaway JW III, Frankel CA. Strabismus. In: Primary Pediatric Care, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/2\">",
"      Archer SM, Sondhi N, Helveston EM. Strabismus in infancy. Ophthalmology 1989; 96:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/3\">",
"      Ono H, Mapp AP. A restatement and modification of Wells-Hering's laws of visual direction. Perception 1995; 24:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/4\">",
"      Ciuffreda KJ, Stark L. Descartes' law of reciprocal innervation. Am J Optom Physiol Opt 1975; 52:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/5\">",
"      Abrahamsson M, Magnusson G, Sj&ouml;strand J. Inheritance of strabismus and the gain of using heredity to determine populations at risk of developing strabismus. Acta Ophthalmol Scand 1999; 77:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/6\">",
"      Greenberg AE, Mohney BG, Diehl NN, Burke JP. Incidence and types of childhood esotropia: a population-based study. Ophthalmology 2007; 114:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/7\">",
"      Williams C, Northstone K, Howard M, et al. Prevalence and risk factors for common vision problems in children: data from the ALSPAC study. Br J Ophthalmol 2008; 92:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/8\">",
"      O'Connor AR, Stephenson TJ, Johnson A, et al. Strabismus in children of birth weight less than 1701 g. Arch Ophthalmol 2002; 120:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/9\">",
"      Holmstr&ouml;m G, el Azazi M, Kugelberg U. Ophthalmological follow up of preterm infants: a population based, prospective study of visual acuity and strabismus. Br J Ophthalmol 1999; 83:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/10\">",
"      Pennefather PM, Clarke MP, Strong NP, et al. Risk factors for strabismus in children born before 32 weeks' gestation. Br J Ophthalmol 1999; 83:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/11\">",
"      Mohney BG, Erie JC, Hodge DO, Jacobsen SJ. Congenital esotropia in Olmsted County, Minnesota. Ophthalmology 1998; 105:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/12\">",
"      Podgor MJ, Remaley NA, Chew E. Associations between siblings for esotropia and exotropia. Arch Ophthalmol 1996; 114:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/13\">",
"      Aurell E, Norrsell K. A longitudinal study of children with a family history of strabismus: factors determining the incidence of strabismus. Br J Ophthalmol 1990; 74:589.",
"     </a>",
"    </li>",
"    <li>",
"     The eyes. In: Pediatric diagnosis: Interpretation of symptoms and signs in children and adolescents, 6th, Green M (Ed), WB Saunders Company, Philadelphia 1998. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/15\">",
"      Weakley DR Jr, Birch E, Kip K. The role of anisometropia in the development of accommodative esotropia. J AAPOS 2001; 5:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/16\">",
"      Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     Harley RD. Pediatric Ophthalmology, WB Saunders Company, Philadelphia 1983. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/18\">",
"      Damms T, Damms C, Schulz E, Haase W. [Pseudo-esotropia caused by nasal dislocation of the macula in patients with high infantile myopia]. Ophthalmologe 1994; 91:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/19\">",
"      Eustis HS, Creed JC, Newsom SR 3rd. Pseudostrabismus secondary to use of cosmetic contact lenses. CLAO J 1990; 16:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/20\">",
"      Hoyt CS, Good WV. Acute onset concomitant esotropia: when is it a sign of serious neurological disease? Br J Ophthalmol 1995; 79:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/21\">",
"      Committee on Practice and Ambulatory Medicine, Section on Ophthalmology. American Association of Certified Orthoptists, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology. Eye examination in infants, children, and young adults by pediatricians. Pediatrics 2003; 111:902.",
"     </a>",
"    </li>",
"    <li>",
"     Von Noorden GK. Atlas of Strabismus, 4th, Mosby, St. Louis 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/23\">",
"      Arnold RW. Vision screening in Alaska: experience with Enhanced Br&uuml;ckner Test. Alaska Med 1993; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/24\">",
"      American Academy of Pediatrics, Section on Ophthalmology, American Association for Pediatric Ophthalmology And Strabismus, et al. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/25\">",
"      Paysse EA, Steele EA, McCreery KM, et al. Age of the emergence of negative attitudes toward strabismus. J AAPOS 2001; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/26\">",
"      Coats DK, Paysse EA, Towler AJ, Dipboye RL. Impact of large angle horizontal strabismus on ability to obtain employment. Ophthalmology 2000; 107:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/27\">",
"      Uretmen O, Egrilmez S, Kose S, et al. Negative social bias against children with strabismus. Acta Ophthalmol Scand 2003; 81:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/28\">",
"      Lukman H, Kiat JE, Ganesan A, et al. Strabismus-related prejudice in 5-6-year-old children. Br J Ophthalmol 2010; 94:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/29\">",
"      Mojon-Azzi SM, Kunz A, Mojon DS. Strabismus and discrimination in children: are children with strabismus invited to fewer birthday parties? Br J Ophthalmol 2011; 95:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/30\">",
"      Birch E, Stager D, Wright K, Beck R. The natural history of infantile esotropia during the first six months of life. Pediatric Eye Disease Investigator Group. J AAPOS 1998; 2:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34951/abstract/31\">",
"      Donahue SP. Clinical practice. Pediatric strabismus. N Engl J Med 2007; 356:1040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6269 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34951=[""].join("\n");
var outline_f34_8_34951=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pseudostrabismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Strabismus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Corneal light reflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cover test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cover/uncover test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Br&uuml;ckner red reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vision impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alignment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/3/22577\" title=\"figure 1\">",
"      Extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/23/29040\" title=\"figure 2\">",
"      Corneal light reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/61/18386\" title=\"figure 3\">",
"      Cover uncover test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/47/32506\" title=\"figure 4\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/1/42005\" title=\"picture 1\">",
"      Pseudostrabismus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6269|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/58/38827\" title=\"table 1\">",
"      Actions extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/50/11053\" title=\"table 2\">",
"      Causes strabismus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/17/1308\" title=\"table 3\">",
"      Syndrome associated strabismus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41800?source=related_link\">",
"      Causes of horizontal strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=related_link\">",
"      Causes of vertical strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/58/27553?source=related_link\">",
"      Patient information: Crossed eyes and lazy eye (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34952="Tardive dyskinesia: Prevention and treatment";
var content_f34_8_34952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tardive dyskinesia: Prevention and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/8/34952/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/8/34952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tardive dyskinesia (TD) is a hyperkinetic movement disorder that appears with a delayed onset, usually after prolonged use of dopamine receptor blocking agents, mainly the antipsychotic drugs (also called neuroleptics) and the antiemetic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    TD has numerous clinical manifestations that include chorea, athetosis, dystonia, akathisia, stereotyped behaviors, and rarely, tremor. The term \"tardive\" differentiates these dyskinesia from acute dyskinesia, parkinsonism, and akathisia, which appear very soon after exposure to antipsychotic drugs. TD is a clinical diagnosis, but tests may be performed to exclude other causes of the patient's symptoms.",
"   </p>",
"   <p>",
"    This topic will review the prevention and management of TD. Other aspects of TD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of tardive dyskinesia (TD) and the early detection and treatment of potentially reversible cases of TD are of paramount importance. The only certain method of TD prevention is to avoid treatment with antipsychotic drugs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of antipsychotic drugs, particularly for longer than three months, requires careful evaluation of indications, and risks and should be limited to situations where there is no safer effective therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      should NOT be used continuously for longer than 12 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an iatrogenic disorder, TD has medicolegal implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, it is important to inform patients of the risk of developing TD before treating with antipsychotic drugs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    . Although there is no consensus, some experts also advocate obtaining written informed consent from competent patients or from family members of patients who are unable to consent. Once started on these medications, patients should be monitored periodically for the development of TD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Guidelines for antipsychotic drug treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Psychiatric Association Task Force report on TD lists specific indications for short- and long-term antipsychotic drug treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This is particularly important since TD is often irreversible despite cessation of the offending drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=see_link&amp;anchor=H4#H4\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Task Force made the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term use of antipsychotic drugs in neurosis, depression, anxiety, personality disorder, and chronic pain states should be discouraged.",
"     </li>",
"     <li>",
"      Even in schizophrenia or related chronic psychosis, efforts should be made to maintain patients on the lowest effective dose of antipsychotic drugs while reexamining the need for continued treatment at least every six months. After remission of a first acute psychotic episode, the dose of antipsychotic drug should at least be decreased, and probably best discontinued, within 6 to 12 months. Plans to continue treatment beyond six months require discussion with the patient and family regarding the indication for prolonged antipsychotic drug treatment and the risks of TD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"       \"Pharmacotherapy for schizophrenia: Side effect management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Particular care is indicated for patients age 50 and older, patients with affective disorder, patients with treatment-resistant schizophrenia and negative symptoms, and possibly women.",
"     </li>",
"     <li>",
"      Since acute antipsychotic drug-induced parkinsonism and akathisia are an indicator of the extent of D2 receptor blockade, these adverse effects should be avoided by dose reduction or by use of a less potent agent. Drug-induced parkinsonism may also mask signs of dyskinesia. It is prudent to use the smallest effective dose required to control an individual patient's symptoms.",
"     </li>",
"     <li>",
"      Except for prevention of acute dystonic reactions, chronic use of prophylactic anticholinergic drugs should be discouraged since they do not prevent TD and can aggravate the involuntary movements once they emerge.",
"     </li>",
"     <li>",
"      Early antipsychotic drug withdrawal results in a better prognosis for recovery. Thus, patients on antipsychotic drugs should be carefully monitored for signs of TD at regular intervals with use of a standard dyskinesia rating scale such as the Abnormal Involuntary Movement Scale (AIMS), which is useful to heighten awareness of mild manifestations of TD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/4\">",
"       4",
"      </a>",
"      ]. The AIMS is available at",
"      <a class=\"external\" href=\"file://www.cqaimh.org/pdf/tool_aims.pdf\">",
"       www.cqaimh.org/pdf/tool_aims.pdf",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Where possible, antipsychotic drugs should be tapered and discontinued as soon as the diagnosis of TD is made, although control of the patient's psychosis may ultimately be the most critical factor in the use of the offending drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who are developing signs of TD while receiving first generation (conventional) antipsychotic drugs, but still require treatment for psychosis, it is now considered prudent to switch to second generation (atypical) antipsychotic drugs that may be associated with a lower risk for TD. However, there is no convincing evidence that altering the medication regimen ameliorates the course of TD once symptoms have developed. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Second generation antipsychotic drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Discontinuation of metoclopramide treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    is used primarily as an antiemetic agent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as a prokinetic agent for the treatment of gastroparesis. It should be stopped immediately if the diagnosis of TD is made, and alternative treatments of the gastrointestinal symptoms should be used. As a preventive measure, metoclopramide should not be used continuously for longer than 12 weeks.",
"   </p>",
"   <p>",
"    The association of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and TD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link&amp;anchor=H13#H13\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\", section on 'Metoclopramide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have evaluated various pharmacologic treatments of TD, but few therapies have produced more than slight to moderate benefit in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, prevention, early detection, and management of potentially reversible cases are the cornerstones of modern treatment.",
"   </p>",
"   <p>",
"    When clinically appropriate, pharmacologic interventions may be considered for patients who are developing signs of TD. The two main strategies are discontinuation of the offending drug and switching from first to second generation antipsychotic drugs",
"   </p>",
"   <p>",
"    For patients with a diagnosis of TD, additional pharmacologic interventions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of benzodiazepines, botulinum toxin injections,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      , or anticholinergic drugs to control symptoms of TD",
"     </li>",
"     <li>",
"      Paradoxically, resuming treatment with antipsychotic drugs in order to suppress TD (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Resumption of antipsychotic drugs'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for drugs to control symptoms of TD should be carefully assessed, since symptoms are often mild and not sufficiently bothersome to require treatment. In some cases, family members are more disturbed by the involuntary movements than the patient, who may be relatively unaware of their clinical manifestations. However, this is more common among chronic or institutionalized patients than in ambulatory patients, many of whom are in psychiatric remission when TD appears.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Discontinuation of dopamine receptor blocking agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;When feasible, immediate tapering and discontinuation of the offending antipsychotic drug or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    is recommended if TD becomes apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/5\">",
"     5",
"    </a>",
"    ]. Antipsychotic drug cessation (or dose reduction) must be carefully considered because of the potential for relapse or worsening of psychotic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/6\">",
"     6",
"    </a>",
"    ]. The dyskinesia may abate within several weeks of drug cessation, but recurrence is possible if antipsychotic drug treatment is reintroduced.",
"   </p>",
"   <p>",
"    The effectiveness of discontinuing the offending agent is not proven, since no randomized controlled clinical trials have studied complete cessation of antipsychotic drugs for ameliorating TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/7\">",
"     7",
"    </a>",
"    ]. A systematic review published in 2006 identified two trials that evaluated antipsychotic dose reduction versus dose maintenance in a total of 17 patients with TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/6\">",
"     6",
"    </a>",
"    ]. Pooled data showed that dose reduction was associated with a trend toward a clinically significant reduction in TD severity, but the findings just missed statistical significance (relative risk 0.38, 95% CI 0.1-1.0).",
"   </p>",
"   <p>",
"    New onset dyskinesias may occur during antipsychotic drug withdrawal. Such dyskinesias often clear spontaneously over several weeks and do not require specific treatment. On the other hand, more persistent dyskinesia may recur if antipsychotic drugs are resumed, which should prompt the use of alternative pharmacologic management of the underlying psychosis.",
"   </p>",
"   <p>",
"    Some patients with bipolar disorder do not require persistent therapy with antipsychotic drugs, as mood-stabilizing medications may adequately control the psychiatric symptoms. However, temporary reintroduction of an antipsychotic drug may be necessary if the patient has an acute exacerbation of psychotic symptoms. When a high-potency antipsychotic is chosen, it should later be replaced by a second generation agent, preferably one with demonstrated low risk for TD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Second generation antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some reports suggest that the second generation (atypical) antipsychotic drugs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/8-11\">",
"     8-11",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] have ameliorating effects on TD severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, these observations may be due to either masking effects of the drugs or, more likely, due to an antipsychotic drug \"sparing\" effect, in which gradual improvement of TD occurs during treatment with weaker (second generation) rather than more potent (first generation) dopamine blocking agents. Thus, it is unclear if clozapine has definite antidyskinetic effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of eight uncontrolled open studies published in 1991, the response of TD to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      was variable and of uncertain significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/8\">",
"       8",
"      </a>",
"      ]. However, in several later uncontrolled studies, clozapine produced an apparent therapeutic effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. It has been particularly effective in some cases of severe tardive dystonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/8,10\">",
"       8,10",
"      </a>",
"      ], possibly related to its anticholinergic potency.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      appears to have a low or even nonexistent tendency to cause TD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/15\">",
"       15",
"      </a>",
"      ], and may alleviate TD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the available data are limited and somewhat conflicting, we suggest changing to a second generation antipsychotic drug in patients who are developing signs of TD if treatment for psychosis remains critical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast to possible benefit in early TD, there is no convincing evidence that altering the medication regimen is effective for ameliorating the course of TD once symptoms have fully developed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is the preferred second generation agent in this setting, but requires frequent blood testing, as discussed in the next section. Clozapine has weak affinity for dopamine receptors whereas most of the other second generation antipsychotic drugs are potent D2 receptor blockers that carry the risk of causing or perpetuating TD. While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    may be capable of exerting clozapine-like therapeutic effects in TD, the evidence supporting its use for ameliorating TD is limited. The risk of TD with second generation antipsychotic drugs is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=see_link&amp;anchor=H8#H8\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\", section on 'Second-generation antipsychotic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clozapine dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    titration begins with an initial dose of 25 mg daily. The dose can be increased by 12.5 to 25 mg increments every one to two days, according to the clinical response and as tolerated. The optimal dose for treating TD is uncertain, but maintenance doses of 300 to 600 mg daily are usually required for antipsychotic efficacy.",
"   </p>",
"   <p>",
"    Systemic side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    are frequent and include potentially life-threatening agranulocytosis, reported in 1 to 2 percent of patients during the first six months of treatment and occurring less frequently thereafter. Other side effects include orthostatic hypotension, weight gain, sedation, dizziness, vertigo, salivation, sweating, dry mouth, tachycardia, syncope, nausea, and constipation. (See",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/41/8854?source=see_link\">",
"     \"Clozapine: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    treatment requires weekly monitoring of the white blood cell count during the first six months, biweekly monitoring for the next six months, then monitoring every four weeks for the duration of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of evidence for gamma-aminobutyric acid (GABA) depletion in some primate models of TD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/17\">",
"     17",
"    </a>",
"    ], GABA agonists have been tested in patients with TD with modest success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/18\">",
"     18",
"    </a>",
"    ]. Benzodiazepines operate through a GABA mechanism, but evidence of benefit in patients with TD is limited and inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review published in 2006 identified three randomized trials that compared benzodiazepines with placebo or no intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/19\">",
"     19",
"    </a>",
"    ]. The trials included a total of 56 patients with schizophrenia or other chronic mental illnesses who had neuroleptic-induced TD. In two trials with 30 patients, there was no significant difference between benzodiazepine treatment and placebo for clinically important improvement, defined as a &ge;50 percent improvement in any validated scale for TD (relative risk 1.08, 95% CI 0.57-2.05). However, in one trial with 24 patients, benzodiazepine treatment resulted in a statistically significant improvement in abnormal movement scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fourth double-blind, randomized controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/20\">",
"     20",
"    </a>",
"    ] was not included in the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/19\">",
"     19",
"    </a>",
"    ] because the data were only presented in graphs. In this trial, 19 patients with TD were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    (2 to 4.5 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/20\">",
"     20",
"    </a>",
"    ]. Clonazepam reduced dyskinesia scores by 35 percent compared with placebo. The reduction in dyskinesia scores was greater for patients with predominantly dystonic symptoms than for those with predominantly choreoathetotic manifestations (41 and 26 percent, respectively). However, in five patients participating in an open study carried out immediately following the double-blind study, the antidyskinetic effects disappeared after five to eight months.",
"   </p>",
"   <p>",
"    Although evidence of efficacy is limited, we suggest the use of low doses of a benzodiazepine, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    , to reduce both dyskinesia and associated anxiety in patients with mild TD. Patients with more severe manifestations of TD are less likely to show a significant reduction in TD with benzodiazepine treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clonazepam dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    is initiated with 0.5 mg daily and titrated by 0.5 mg increments every five days according to response and as tolerated, up to a maximum of 3 to 4",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Previous benzodiazepine dependency may be a contraindication. Central nervous system depressant effects may be potentiated by barbiturates, hypnotics, anxiolytic, antipsychotic, or antidepressant drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Botulinum toxin injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the effectiveness of botulinum toxin for TD is limited to retrospective case series and case reports. In one multicenter study, botulinum toxin produced marked or moderate improvement in 29 of 34 patients with relatively localized TD manifesting as cervical dystonia or blepharospasm in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/22\">",
"     22",
"    </a>",
"    ]. In another retrospective study, botulinum toxin treatment was associated with similar improvement in tardive cervical dystonia (n = 7) and idiopathic cervical dystonia (n = 156) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest botulinum toxin injections for patients with localized forms of debilitating tardive dystonia, such as cervical dystonia, retrocollis, or blepharospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/5\">",
"     5",
"    </a>",
"    ]. Adverse effects are excessive weakness of injected or neighboring muscles. Botulinum toxin should generally not be used in patients with myasthenia gravis or other neuromuscular conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin type A,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    , is currently available in the United States as Botox. The dose depends on site of injection. The most common forms of TD treated with botulinum toxin are cervical dystonia and blepharospasm (involuntary forced eye closure). Cervical dystonia requires highly individualized dosing, usually in the range of 150 units to start, increasing empirically to a maximum of 300 units according to individual clinical response. Blepharospasm requires a total dose of approximately 25 units injected in multiple sites in the orbicularis oculi muscles.",
"   </p>",
"   <p>",
"    Botulinum toxin type B,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/30/7653?source=see_link\">",
"     rimabotulinumtoxinB",
"    </a>",
"    , is available as Myobloc and may be given in unit doses approximately 40 to 50 times higher than botulinum toxin type A, but only in the event of failure to respond first to botulinum toxin type A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tetrabenazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that deplete dopamine storage in presynaptic vesicles, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    , may be the most effective therapeutic agents for TD, and particularly for tardive dystonia.",
"   </p>",
"   <p>",
"    Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    is useful for the treatment of TD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind study with six patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      100 mg daily showed mild to marked improvement in TD that was not greater than the effect of the active control,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a double-blind, crossover trial with 24 patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      up to 150 mg daily produced marked reduction or disappearance of dyskinesia in 70 percent of patients compared with no change for placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open-label study in a small group of patients with chronic psychosis found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      was less effective for TD than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/26\">",
"       26",
"      </a>",
"      ]. Several open-label studies have demonstrated improvement in TD with tetrabenazine in doses of up to 200 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite limited evidence of effectiveness, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    (where available) for patients with disturbing and intrusive TD, particularly those with tardive dystonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tetrabenazine dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     Tetrabenazine",
"    </a>",
"    is initiated with 12.5 mg daily for one week and increased by 12.5 mg increments every few days, according to clinical response and as tolerated, to a level of 75 to 150 mg daily. Potential adverse effects include parkinsonism, sedation, fatigue, depression, anxiety, akathisia, tremor, insomnia, confusion, nausea, vomiting, hypotension, and dizziness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anticholinergic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     Trihexyphenidyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    are usually ineffective or may even exacerbate dyskinesia but are sometimes helpful in tardive dystonia. This is consistent with observations that anticholinergics may be useful in primary dystonia but often exacerbate choreiform disorders.",
"   </p>",
"   <p>",
"    Retrospective studies have shown improvement in tardive dystonia following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    (10 to 32 mg daily) in three of eight patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/27\">",
"     27",
"    </a>",
"    ] and with trihexyphenidyl (6 to 12 mg daily) in 8 of 21 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    for patients with severe and more widespread tardive dystonia that is refractory to other interventions, such as botulinum toxin injection, which is indicated in relatively localized dystonia. We recommend NOT using trihexyphenidyl to treat TD unless accompanied by severe tardive dystonia. Similarly, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    for more generalized tardive dystonia when localized use of botulinum toxin is not practical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Trihexyphenidyl dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     Trihexyphenidyl",
"    </a>",
"    is initiated at 1 mg twice daily and titrated to a total dose of 4 to 6 mg daily as tolerated.",
"   </p>",
"   <p>",
"    Narrow-angle glaucoma, confusion, and dementia are contraindications to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    . The possibility of exacerbating underlying psychosis is a particular concern in patients with TD. Trihexyphenidyl should be used with caution in people over 60, and in patients with benign prostatic hypertrophy or obstructive gastrointestinal disorders. Other anticholinergic side effects include dry mouth, blurred vision, constipation, urinary hesitancy or retention, tachycardia, pupil dilatation, and increased intraocular pressure. Patients may develop tolerance to these effects with continued low-dose treatment. Additional side effects of trihexyphenidyl include dizziness, confusion, memory impairment, nausea, vomiting, and anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Resumption of antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a last resort, it may be necessary to resume treatment with a first or second generation antipsychotic drug in order to suppress TD in some patients with permanent and disabling or life-threatening TD that is treatment-resistant, even in the absence of active psychosis.",
"   </p>",
"   <p>",
"    Data supporting this approach are equivocal, since both short- and long-term studies of conventional antipsychotic drugs have produced mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there is some evidence that treatment with second generation antipsychotic drugs may be associated with amelioration of TD. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Second generation antipsychotic drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Fortunately, continued antipsychotic drug exposure does not appear to worsen the severity of TD once it becomes established or chronic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the reciprocal relationship between dopamine and acetylcholine in basal ganglia, it had been predicted that cholinergic drugs might ameliorate TD. In available trials, treatment with choline, lecithin, deanol, and other cholinergic medications has been ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin E has been used for the treatment of TD based upon the hypothesis that this antioxidant may reverse a possible toxic effect of free radicals produced during chronic administration of antipsychotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials of vitamin E in relatively small numbers of patients with TD have produced conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. However, in a systematic review published in 2001 that included six placebo-controlled trials with 256 patients, vitamin E treatment was not beneficial for a clinically relevant improvement in TD (relative risk 0.95, 95% CI 0.89-1.02) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/41\">",
"     41",
"    </a>",
"    ]. Vitamin E was given in doses of 600 to 1600 units daily for up to 20 weeks in most of these trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other drug treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large variety of miscellaneous agents have been studied for treatment of TD in case reports and open-label trials without convincing success, including beta blockers, calcium channel blockers, serotonin antagonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , vitamin B6,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/7,42\">",
"     7,42",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    , an antiepileptic agent with therapeutic effects in levodopa-induced dyskinesia, reduced the severity of TD in two small open-label trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental GABA agonists, such as progabide, muscimol, and tetrahydroisoxazolopyridinol (THIP) or gamma-vinyl-GABA, a GABA-transaminase inhibitor that elevates brain GABA levels, have been studied in relatively few clinical trials with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/45\">",
"     45",
"    </a>",
"    ], while valproate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    have not shown significant promise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DEEP BRAIN STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis for using deep brain stimulation (DBS) of the globus pallidus as a treatment for TD is the established benefit of this procedure for treatment of levodopa-induced dyskinesia and idiopathic dystonia.",
"   </p>",
"   <p>",
"    One of the larger prospective studies of DBS for TD involved 10 patients with resolved or stabilized psychiatric disease who had severe TD refractory to medical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/46\">",
"     46",
"    </a>",
"    ]. All were treated with bilateral DBS of the internal part of the globus pallidus. At six months after surgical lead implantation, using double-blind evaluation of stimulation on or off, the Extrapyramidal Symptoms Rating Scale score was significantly lower with stimulation-on compared with stimulation-off (mean decrease, 50 percent; range, 30 to 66 percent).",
"   </p>",
"   <p>",
"    In case reports and small series, patients with severe forms of TD manifesting primarily as dystonia were successfully treated with DBS of the globus pallidus or subthalamic nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. These patients displayed various combinations of orofacial, cervical, and truncal dyskinesia and dystonia that improved dramatically within a relatively short period of time after surgery. One unblinded and uncontrolled study of nine patients with refractory tardive dystonia found that benefit of DBS persisted for longer than one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/8/34952/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who have permanent, disabling TD that is unresponsive to pharmacologic treatment modalities, we suggest DBS in the globus pallidus when it can be performed at centers with expertise in this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/10/1186?source=see_link\">",
"       \"Patient information: Tardive dyskinesia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only certain method of TD prevention is to avoid treatment with antipsychotic drugs or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      . The use of antipsychotic drugs should be limited to situations where there is no alternative effective therapy. Metoclopramide should NOT be used continuously for longer than 12 weeks. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for TD treatment should be carefully assessed, since symptoms are often mild and not sufficiently disturbing to require treatment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacologic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop dyskinesia during treatment with a dopamine receptor blocking agent (ie, antipsychotic drug or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ), we recommend immediate discontinuation of the offending medication if feasible. However, antipsychotic drug cessation or dose reduction must be carefully considered because of the potential for relapse or worsening of psychotic symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Discontinuation of dopamine receptor blocking agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are developing signs of TD but still require treatment for psychosis, we suggest using a second generation antipsychotic drug rather than a first generation agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      is the preferred second generation agent, but requires frequent blood testing because there is a 1 to 2 percent risk of agranulocytosis.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      in low doses is an alternative second generation agent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Second generation antipsychotic drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clozapine dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with relatively mild TD and associated anxiety, we suggest the use of low doses of a benzodiazepine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our preferred agent is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Benzodiazepines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clonazepam dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized forms of severe tardive dystonia, such as cervical dystonia, retrocollis or blepharospasm, we suggest treatment with botulinum toxin injections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Botulinum toxin injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have disturbing and intrusive TD or tardive dystonia not amenable to treatment with botulinum toxin, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tetrabenazine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Tetrabenazine dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticholinergic drugs are usually ineffective or may even exacerbate dyskinesia but are sometimes helpful in tardive dystonia. For patients with severe debilitating tardive dystonia that is refractory to the interventions above, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"       trihexyphenidyl",
"      </a>",
"      (where available) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anticholinergic drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Trihexyphenidyl dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with permanent, disabling TD that is treatment-resistant, we suggest TD suppression by resuming treatment with a first or second generation antipsychotic drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Resumption of antipsychotic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have permanent, disabling TD that is unresponsive to pharmacologic treatment modalities, we suggest deep brain stimulation in the globus pallidus when it can be performed at centers with expertise in this technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Deep brain stimulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/1\">",
"      Tancredi LR. Malpractice and tardive dyskinesia: a conceptual dilemma. J Clin Psychopharmacol 1988; 8:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/2\">",
"      Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs. Am J Psychiatry 1980; 137:1163.",
"     </a>",
"    </li>",
"    <li>",
"     Tardive dyskinesia: a Task Force Report of the American Psychiatric Association. American Psychiatric Association Press, Washington, DC 1992.",
"    </li>",
"    <li>",
"     Guy, W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-358. U.S. Department of Public Health, Education, and Welfare, Washington, DC 1976. p.534.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/5\">",
"      Tarsy D. Tardive Dyskinesia. Curr Treat Options Neurol 2000; 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/6\">",
"      Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006; :CD000459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/7\">",
"      Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007; 27:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/8\">",
"      Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/9\">",
"      Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 Suppl B:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/10\">",
"      Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/11\">",
"      Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/12\">",
"      Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/13\">",
"      Sasaki Y, Kusumi I, Koyama T. A case of tardive dystonia successfully managed with quetiapine. J Clin Psychiatry 2004; 65:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/14\">",
"      Bouckaert F, Herman G, Peuskens J. Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. Int J Geriatr Psychiatry 2005; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/15\">",
"      Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/16\">",
"      Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 Suppl 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/17\">",
"      Gunne LM, H&auml;ggstr&ouml;m JE, Sj&ouml;quist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/18\">",
"      Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry 1982; 39:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/19\">",
"      Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006; :CD000205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/20\">",
"      Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990; 147:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/21\">",
"      Bobruff A, Gardos G, Tarsy D, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981; 138:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/22\">",
"      Tarsy D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997; 20:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/23\">",
"      Brashear A, Ambrosius WT, Eckert GJ, Siemers ER. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/24\">",
"      Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 1971; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/25\">",
"      Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972; 27:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/26\">",
"      Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973; 130:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/27\">",
"      Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/28\">",
"      Lang AE, Marsden CD. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982; 5:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/29\">",
"      Suzuki T, Hori T, Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol 1999; 19:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/30\">",
"      Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988; 8:38S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/31\">",
"      Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/32\">",
"      Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/33\">",
"      Tammenmaa IA, Sailas E, McGrath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/34\">",
"      Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/35\">",
"      Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/36\">",
"      Dabiri LM, Pasta D, Darby JK, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994; 151:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/37\">",
"      Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; 1:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/38\">",
"      Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/39\">",
"      Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/40\">",
"      Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997; 41:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/41\">",
"      Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001; :CD000209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/42\">",
"      Soares-Weiser KV, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003; :CD000208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/43\">",
"      Bona JR. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. J Clin Psychopharmacol 2006; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/44\">",
"      Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord 2006; 21:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/45\">",
"      Soares K, Rathbone J, Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2004; :CD000203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/46\">",
"      Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007; 64:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/47\">",
"      Trottenberg T, Paul G, Meissner W, et al. Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001; 70:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/48\">",
"      Eltahawy HA, Feinstein A, Khan F, et al. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004; 19:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/49\">",
"      Franzini A, Marras C, Ferroli P, et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J Neurosurg 2005; 102:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/50\">",
"      Trottenberg T, Volkmann J, Deuschl G, et al. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005; 64:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/51\">",
"      Tai CH, Tseng SH, Liu HM, Wu RM. Bilateral deep brain stimulation of subthalamic nucleus alleviates tardive dystonia. Neurology 2006; 66:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/8/34952/abstract/52\">",
"      Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4908 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34952=[""].join("\n");
var outline_f34_8_34952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Guidelines for antipsychotic drug treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Discontinuation of metoclopramide treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Discontinuation of dopamine receptor blocking agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Second generation antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clozapine dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clonazepam dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Botulinum toxin injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tetrabenazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tetrabenazine dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anticholinergic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Trihexyphenidyl dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Resumption of antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other drug treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DEEP BRAIN STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/41/8854?source=related_link\">",
"      Clozapine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/10/1186?source=related_link\">",
"      Patient information: Tardive dyskinesia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_8_34953="Electron micrograph type 3 MPGN";
var content_f34_8_34953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph type 3 membranoproliferative glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in type 3 membranoproliferative glomerulonephritis (MPGN) shows marked thickening (more than three times normal) of the glomerular capillary wall and complex disruption of the glomerular basement membrane with large lucent areas (arrows) and variable decrease in thickness of the lamina densa (LD). A red cell is present in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34953=[""].join("\n");
var outline_f34_8_34953=null;
var title_f34_8_34954="Anterior view of shoulder anatomy";
var content_f34_8_34954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74486%7EPI%2F53479%7EPI%2F63139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74486%7EPI%2F53479%7EPI%2F63139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Anterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 436px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG0AlgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACio7ieK2gea5ljhhQZZ5GCqo9ST0rl28Wyam5i8J6dJqfO03kh8m1U/75GXx6KD9amU1HcqMHLY6wkAEk4ArPstZsL+d4rC6juihw7QHeqH0LDgH2rD/4RW51VvM8WanJfpnP2G3BgtR04Kg7pOR/Ece1dNaW0FnbpBaQxQQIMLHEoVVHsBwKScn0shtRS3uyaiiirICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5+58W6db+MLbw24nN7PGHEiqPKQkOyozZyHZY5CBjopqwvijQGuZrZdc0s3EDiOWIXce+NiwUKwzkEsQMHucVzl78PIrvUL3VW1O6XWptQjvoLhXkEUIj2iNDAJNj4QFSSMne3TpTYPAd2miWmhz6raTaPZ3kN1BGbA+aRHOJdkj+aVfIBUnYOuTnkEA6a28TaFd3cFpa63pk11cIJIYY7uNnkQ8hlUHJHuKqL448JsMr4o0IjIXI1CLqeg+93wcfSsy48EzS6/NdLqca6dNqUWrSW5td03nRqqgCbfwnyLxtJ6gHBxVCH4aRxeH003+0ELJ4fl0ITfZR/Hj99jd2P8OfxoA6ufxNpNml5Jqd/Z6fDa3P2Vpbq6iRWfYr4zvODhh8rYbjOMEErqHiXRrGSOGbVdPW7mj823t2ukWScEcbBnLA9iAa5keALm21B9Q03V4I777XLcIbiyM0QWS3hhZSgkUk/uQQ2R94jBHV3h7wJdeHC8Wk6vAbO4t4YLpLqyMkj+XHszG6yKEBH8JVgD06mgDX0Dxno+p2GiNc6hp9nqWqWkF1Hp8l2nnDzUDBQpwW64zjnFXr3xHpdtp6Xi3tpPHJG00IjuYh5yKQGZGZgpALDJzgZHrXDv8ML5/wCwoX8TSvY6ULDZA0MoXdbBMlVWYRjfsz8yOVJ4NXpPhrCY/ECJqLhNRQxWiNCCtjG0plkRRkbg0hJ7YAUduQDqrjxNoNvezWdxrelxXkK7pYHu41kjHHLKTkDkdfWq+reJrXT9c0vTVaCV7u4e3nYTgG1227zgsOeoQcHHDZrDuvA15NpWuaOmr26aTqU09yqmyJnilkfzMmTzAHUP2KZxgZ4zUI8AahNrEuq3niBP7QkuXufMtbLyghNm9su0GRsbdwbJJ6Y75oA6m08U+H722e4s9d0q4t0dY2livI3VXbopIOAT2FadpcwXltFc2k0U9vKoeOWJwyOpGQQRwQfWvN9J+GFxb38t3qeu/b5ZZ7KZ98Mrbvs7O2CZZpD82/sQBjgc4r02gAooooAKKKKACiiigAooooAKKiurmCzt5Li6mjhgjG55JGCqo9STXLHxHqOt4TwjZB7duDqd6CkA90ThpO/TC+9TKajoVGDkdNfXttp9q9zfXEVvboMtJK4VR+Jrmh4j1HW8r4V04tAf+YjfgxQfVF++/wCQHvU9h4QtftCXmuzy63qK8iW7A8uM/wDTOIfKn5E+9buo39npdo91qV3b2dqmN01xII0X6sSAKm0pb6FXjHbU5+18IQzzpdeJLuXWbtTuVZxtgjP+xEOPxOTXUIqooVAFUDAAGAKq6ZqVjq1oLrS722vbYkgTW0qyIT6ZUkVbqoxUdiZSctwoopskiRRvJK6pGgLMzHAUDqSaokdRVC81iws7O1u57lPs11LDDDKgLrI0rBY8Fc8EsOenOc4q/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB578Q/EOp+Hdft5rOKK6iOlXk8cP74FXjaHLOFfa64kB+5uAVsN8xrHXx1fz6jaIlzpeqRQ3cyJf6f5sdvNiwlm27RKysVZQDlnHOQFYZHpCaHYLr7a15cr6iYjAJJJ5HVEO3IRCxVM7VztAzjnNaVAHimv+MPEz6dp4utQ0yxLrpWqtdwQSxpDFLcbXSXMvzIMAscqCu5SBncPY9Ol8/T7ab7RBc+ZEr+fAMRy5AO5BlvlPUcng9T1qxWNoOrSX1/rFjdxrFd6fc7Nq5w8LgNE4z6gkH/AGkagDZooooAKKKKACiiqOs6tY6NZNd6ncx28A43OeWPoo6k+w5pNpasaTbsi9XNat4oVLx9N0G3Oq6svDxxtiOD3lfov06+1Uwut+KwfNFxoWiN0UHbeXA9/wDnkvty30rpdJ0yy0ixS0023jt7dOiIOp7knqT7nmovKfw6Iuyh8WrMG18KtfXEd74ruRqd0h3R24G21gP+zH/ER/ebJ+ldUAFAAGAO1FFVGKjsTKTluFcr420+9nv/AA/qVjYDU10y7aaSz3qjsGjZQ6FyE3qTkBiO/INdVUN7cpZ2VxcyhjHDG0jBepAGTj8qok8z8RWPiTUZ3ubTQNVsbeSGcR2un6pFbSi6OzZcTlJFVgQCMbpMbehzT7jQ/FS6Tr085vr7U5LuNLWNNTkhjEBigEjxqksfO9ZCFZ06HBUMS2rH8S9O8qFrnS9YtnnW1lgikjiZ5o7iQRo6hJG43EZBw3PQ1ZHj6zW6aO60vVLWCK4SzuLqUQmK3uHUMImKyEk/MoJUMoLAbqAOO0jR/GMdtZDxBba9fWEct3m1sdUFvcjcyGFnf7TllC+Yu0zMQSM7uovppHi7+3JnVdWVzPeM90+pA2sls0bi3ijh8w7JFJiy20cqx3Nmtq6+JOn2Wh2+r3+malZ2F48aWUly9tELrerMCu6YBBtUtmTZ1HfimWHxP0bUbjSIbG3upm1Jd0ZMtvGq4kaMjLygSEMjZEe/jB5BGQDmLjw74ru73Sl1Oz1S8eC70qdJxqSi3gji8kziSLzR5km9ZG3bXzkYIxivY65rwl4ws/E9xeRWVrcQi1O12mlgznJGDGkjSIeM4dVrpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKwvHOvp4X8Kalq8nllreP92sjBVaRiFRSSRgFiAT6Vu1T1LTLTUvsv22LzRazrcxDcQBIudrEA84znByM4PUCgDi/DfxDj1DRbAm3GrazPcXFq0GjtG0btCfnkVpJAoQqUYZbPzgcmr0/j60ha9VtI1dmtLpLGQKkXNw6xlIl/ecsfNAyOBgkkDBOlqPg7RNQv5b6e2mjvZJBK1xb3U0EgYJsyGjZSMrgHGMgDOcCpH8KaM+n3tk9q7QXsy3M5aeQu0qqirIH3blYCNOQQcrnrk0AY0/xCtY/KiTRdZmv2lnhks0WHzIWhRXfcTKE+66kFWIOeOeKqxfEi0vY7HyLLULE3bWMkDXVvG4nguZhGrKEl+Xr1bkZB2t0PRWPhLRbIwm3tG8yIzMJJJ5JHYygCRmZmJckKOWJPHFMHg7QQtgoseLGK3gt/30nyJbuHiH3udrAHnOe+aAMaT4l6XFYT301hqkditrNeW85jj23kcRAcx4fIPIIDhMg5rf8ADviGPWri/tjY3thd2TIssF2E3YddysCjMMEe+RjkCqH/AAgPhspdxtp7tFdQyW7xtczMiRyHLpGpbEQY4J2belamjrpc1/ql7ppVrqSYW94wZs+ZEMBSD0IB7DkEHnINAGrRRRQAVyniL/iT+KtH1xeLe5I0q9Ps7Zgc/SQ7P+2xrq6z/EOlQ63ol9plwWWO6iaPev3kJHDD3BwR7igDQornvDOvrdeFY7/WZYLW5tt0F+XYIkc8bFJOTjALAkexHrVNfE1/rII8J6YZ4T01C+zDb/VRjfJ+AA96mU1HRlRg5HW1h6n4s0LTZPLutTthN2hjbzJD/wABXJqgvhKbUCJPE2r3eok8/ZoWNtbj22Ict/wJjW7pukabpaBNOsLW1UDH7mJV/kOam83srf1/XUq0Fu7/ANf10MH+3Nb1gbdA0lrSBul7qYKAD1WIfM347ataP4Vt7S9Go6lPLqur44u7kD937RoPljH059zXRUU1DrLUTn0joFFFFWQFFFBIAyTQAVX1K2+26ddWu/Z58TxbsZ27gRnHfrUhmiHWRB/wIU5ZEb7rK30OaVwOT0P4f6Jpmn2kMsU15cwi2LXM9xM7M0DBoyu5yUUON2wHb7Gp9Q8P+Gx4jtru8g/4mV3N5scZml8uWVI/9YYg3llggxvK54Az0rp65PQh/bXjDVNZbm1sAdLsj2LAg3Dj6uFj/wC2R9aYEsXgXQYrIWkcF6tsjrJDGNRucW7LkAw/vP3OAzD5NvBx04qafwfpNyLVbr+0biO2KlI59TuZEYq+9S6tIRIQ3OXB6AdAMdDRQBkaT4c07Sr+a9tVunu5kEbTXV5NcsEznapkdtq5OcDArXoooAKKKKACoby6gsrSa6u5khtoUMkkkjbVRQMkk9hU1ZHi7Rzr/hrUdLWYQPcxFFkK7grdQSO4yBkUAZLfEDQibdYjfvJPLBFGj2UsBYTSrEsi+aqhk3OuSueOma62uG1TS/FeuxWEOpxaHaxW15Z3TG3uZZGkMU6SMRujXaCqthfm5I+auU0v4XavJq+qT6vLpUEF9Yz28jaeEjLTGVJIpgiQR4Klc/O8hB6Hk0Aevy3CRTwwsJS8xIUrEzKMDPzMBhfxIz0HNVLzVoLTWdO0yRJTPfLK0bKBtAjClt3Of4hjANcA3gHWrqxhlu9RtYtcuGvZr68ty/yyTW5hj8rIzhBsHOPukjk1DN8PtRubKKGzsdC8OSJaXVu0ulysxkeWNFWQ/ukOcqc5JOD1JoA9Vorh/hd4Tu/CtvqCXiwxG4aMiK3njeIFVILBUtoApPGeGJwOa7igAooooAKKK8HbQpne8h0nSLqW7uYL8SXdxo0tpew745CBJcMTFc7mKoFAOAQRjGQAe8UV4jd6r40s7TSbfRJ9W+xLYRlZ73TJFc3AYhopY47J22KAoHEeQSd7dumuX8XzRzypqGoW7Prf2JIorKIiO0MuPN+aMk4XOHPy45IJ5oA9IqK6uIbS2luLqWOG3hQySSyMFVFAyWJPAAHOTXk17q3jK3jlgubjXI47c30dtc2mkpPLdypLiASqIiqoyc7gqK3PzDFLrlz4h1PRvFllrB1qK/k0+6itdMtNN8yzmBtDj9+ImJcsW48xfmAXB6EA9cRldQyEMrDIIOQRS15GdY8XHxnYWFlFrFtphmW1mEtoHiSPyD++Q/ZgAA+3lp2OcgoAeJobzxfqdnbyarYyobTUtOs3gexRxM6XC/aLtcqcIVwVYYC7SwIIBAB6tUL3VvHdRW0k8S3Mys8cTOA7quNxA6kDcuSOmR615fBrPidNLS7muNebVYr2FtQsP7I/cRW/2gCUQMIcy/u/7ruxGSMHpUvdR8QXWrrrQ0zW5BbQ6slqEsvKmSNja+VhXjIycORuVidp4OMUAew0V5B4Z1TxzqV7b2V3NqdtavqbRNevYDeLc2bPnMlvEOJQAGMS/NgHcOvrsalY1VnZyAAWbGT7nHH5UAOooooAKKKKACiiigAooooAKKKKACiiigAooooACcDJ6VmaT4g0bWJpYdI1fT7+WH/WJa3KSsnbkKTj8as6tEZ9KvIhALkvC6iEvs8zKkbd38Oeme1eVpoXiz+y7y30q21GzWDS/s9p9vmtBcJIroVihmgOfL2qwPmEEnb70AepXmpWlneWFpcy7Li+kaK3XaTvZUZyMgYHyox5x09auV5FrOk+JdX8Qx6ne6Lrf9nRamJ47ODUoY7iOH7E0RKMs6hMyHkK4OCetUtS0j4hta6RHDFem7t4YibmLUWbJ84sySg3CISse1Sxjl388jg0Ae1UV5ZLpHidrPWIzDr39ty3DNFqMeqqLVoTcqyiOIy4QiLjmMfdYZOeZtV0HxHb+IWXSzrMtuJ7VrK6OqsYLeMMDOs8bybpS3z4+V+CoBXFAHptRRXMEs80MU8TzQECWNXBaMkZG4dsjnmvKofB3iOUWbXV9rwklttQa7C61KoE3mL9lChZMAbS33eOPmpdR03xs+nyI1te3LytaFjHfsjxbbUCUosdxDnMuQR5ig53YbAoA9NTUrR9Xl0tZc30UCXLxbTxG7MqtnGOSjDGc8fSrleefDjRvEVnqkV74ljkNwdFtrSWaSZZGaVJ7hiCQxJO10Oec56k5r0OgAooooAKKKKACuP8SqfDWsf8JPbqTYyhYdXjHaMcJcAeqdG9UP8AsCuwpsiJLG0cqq6MCrKwyCD1BFACqwdQyEMpGQQcgilrkPDDt4d1b/hFrpibQo02kSsfvQj70BP96PIx6oR/daul1LULPTLVrnUbqG1t16ySuFH05obtuFr6ItVzuteJVt7xtM0a3OpayRnyEbCQj+9K/RR7dT2FUDf6v4pbytGWfStGP39QmTbNMv8A0xQ/dB/vsPoK6DQ9GsdEshbadCI0zudidzyN3ZmPLE+prPmc/h27/wCRpyqHxb9v8zgdP8Niz8fxv4qeHUX1dGuoEAK28N3GAGCxk4JMWwhjz+6Y16fXP+OtPuL3QWm05C+p2Ei31moOC0kfOz/ga7kPs5qOfxhpq6bZXlsXuReQpcQogwdjDILelDcKS5noJKVR2R0lFcBP4x1SU/6NZ20Q/wBss5/pUB8ReIH/AI4V/wB2L/HNcksyoLqdCwdVno1Vb3ULSxXdd3MUI/22AP5V51Lfa3eEiW9nCn+FMIP0xRb6JJK2+QMx7luSaxnmi/5dxuXHBW+OR1N34xsI8i0jnum7FV2r+Z/wrMm8S6vdf8e8MFqh6E5kb8zgfpVdLJYfl2jirCoqivOq5lXlonY6YYalHpcqSPqd0cz6jcn2Rtg/JcVGuiLK2ZQ0jernJrTVgp4FSC62DtXN7Vz+OTNbcvwoop4dhI/1S/lQ/huA/wAAzVttTK/xAVA+rkfxCr5qXmT+8MXxNHd6Fo0kunXM6XcrLb2saysA8znagwO2Tk+wJrR0K21Tw/pNrp9neM8NugUeYiksepYnGckkk89TWG+rf2t4yi3ENaaMm/HZrmRcD/vmMn/v6PSuoTV42+9it/a8iSjJojkcneSTLcXiLUYh/pNnDKB3jYof1zV2DxVZMQLmOe2Pcsm4fmM/yrPjvbaXgkCnvbwTDjaa3hjK8dpJmUqNN7qx0Nnqdlef8e11DIfQNz+XWrlcBdaNC5yowfUUkI1Oxx9lvZto6K53D8jXRDNEtKkfuM5YNP4JHoFFcbB4n1C3IF7aRzL3aMlD+XI/lWpa+KtNmwJXktnPaVMD8xkV2U8bRqbSMJ4apHob1FQ211b3S7raeKVfVHDfyqaulO+xg1YDx1rC8G6lc6zpUupzsv2a6uJHs1C4xbg7Yz77gu//AIHjtUHj+5mXQhp1m7JfavMunwMvVN+fMce6RiR/+A1v2dtFZ2kFtbII4IUWONB0VQMAfkKYEtFFFABRRRQAUUUUAFFFFABRRRQBkeKNbi0DTBeTAENNHCNyyFAWYDLGNHKj3IxnAJGc1l33jzQ4ItREN2Gns4biTMsM0cEhhUmRVlEZDbcHds3kYPBIxVjx1pWo65o6abpwtFjmniaeaeVlMaJIj/IoU7ydpGCVxnOT0rJn+H2kXX2yxk1PUWtmjudliJY9tp9qDrI6DZuyd0m3eWAycCgDSXx1oP282LXU5ulkEDBLOdoxKYxIIxJs2lipyBnJ6AZ4qfwJ4mi8W+GbLV4rWe0M8as8UsbqFYgHCsyrvXn7yjBqGHwZp8JYrNdndqUeqnLL/rUiSML937uEHHXOee1XfCegR+GtGi0u2vLu6tIPlgFzsJhQAAICqrkDHVsn1JoA2aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz/TvGstp4g1yz1i3vZbNNZWwtbtEi8mHdBEyRN8wckszc7SPmAJHGPQK5//AIQ/RP7bbVjbTG8a4F2Q11MYvOCBBJ5Rby94UAbtueKAMpviRo66XY35ttQ8m7sF1GNREpYRtLHGAQG+9mVeBngHnOAZovHVs3iKPRZ9Lv7W+ZQ7LcTWqbVIJyAZtzjAySgbGcHByA+1+Hnhi2L+Vp8uGiEAVrudlSMSLIEQFyEUOikBcAfQmtHU/C2k6pqAvNRiubl1ORFJeTGAHaVyId/l5wTztzznrQBneDvHemeKtRvrCyjliurNEkkVpoJhtYsOGhkkXIKnIJBHHHNbGu67Z6F9mk1MyQ2kz+W11tzFCx+75jfwAk4DHjPUjIzV8P8AhLR/D901xpcFwkzQJa75ruacrEhJVF8x22qCTgDHWtuaKOeF4pkWSKRSro4yrA8EEHqKAHghgCDkHoRRXFtZah4MPmaNDPqPh0cvpy/NPZj1gz99P+mR5H8PZa05vGnh6LT7e8GpwSx3AzCkOXlkPTAjHzZzwRjg9cUm0ldjSbdkdDSOwRSzkKoGSScACuU/tHxLrC/8SrTY9Itj0n1P5pSPUQqeP+BEfSnR+C7W6cS+Iby71qXrtuXxCPpEuF/PNRzt/Ci+RL4mS3fjbRYp2t7KaXVLtcAwadEbhh9Svyj8SKjXVPFF+D9h0K20+Mn5ZdSustj18uMH8twrpLW2gtIVitYY4Yl6JGoUD8BUtHLJ7v7hc0VsvvOD8QeEvEWvWyfbPE0NtcQOLi1+x2AQQzKDtbczM2OSCBjKkjvS+BdI0m/t1v76C4utes3Nvdf2jM1xJbzLgkLu4A5DKygZUg967eeeK3jLzSKiDqWOK828V62NH1v/AISHRInkiMYh1Rdp2PEM7ZgO7R5P1Qt6Cs6kqVL42XH2k/h/yPRru7gtIy88ioo9awbjxPkkWduzj+85wPyrHQSX5W4ll88uAysDlcHpj2rUtdP4G4AV5VTMK1aXLRVkdccNTpq89WQjX9TJz5VuF+h/xry7TXNh4u1TSZ18uN3N7arnjy3J3KPZX3DHYFa9fmsYwmQeleYfE7TpYp9N1qyXdPp8h80A43QN98fhgN+FYVJ1n7lZ3T/M2p8l7wR1lhEjAYArajsEZAeK5/R51khRo2yrAEGtpbllXFcdOUIt86Naik/hLgighXkAtVa5vMfKmBVOe4ODzVCa5VcksKude6tDQmNLW8i+0g6k1BJcqvesifUF6BqpS3o9awUGzaxsy6gFBxVCe/duh4rLkuSzYXJJ6AVs6b4a1fUQG8n7NCf45vl/TrW1OhKbtFXFKUYK8nYzpLliTufH41R1PVIdPsLi7nkykKFyByTjsPc9K9CsfAVinzX00tw/cL8q/wCNUtX0HS73xXpOh2tlCLe1A1O+OM5VSVhQk/3pAW/7Yn1r0aeWTestDlnjaa+HU8/8OWz2umILiYfbJ2M9wR0MrnLD6DoPYCtNobnO6ObdXrn9i6Z/z4W3/fsVBP4c0qYf8eiofVCVP6Vc8sqN3UkTHHQWljygz3kPLKSKtWutOhw+5a7m68GwnJtLuWM9lkAYVg6h4Q1CMExxxTj1jbB/I1yzwNaH2b+hvHE0p9RttrO4DLZrRi1BJBziuJvrK5sZMSwzQN6OpFMg1GSLh8keorlcZLQ15YvVHfbo3HaoJbaF+qiuatdZU/xVrW+oo4HNZSuHLYkk0uMsGjyrjoRwRU0NzrNp/qL6V1/uy4kH68/rT47lD0NWEmU+lXTrTh8LaJlFS3VzAtvEV/feNWuby0iuIdGhMCCNig8+UKzNznJWMKB/10auzt/F2nPgXC3Fs3ffHkfmua53wzpY0/SxFdSJLeTSPcXEijhpHYscewzgewFaUlhG44Ar0Y4+vF6NNHK6FJrVWOns9Ssr3H2W7glJ7K4J/LrVuvP7jRUf+AVHHb39n/x63lxGPQOSPyPFdEc1t8cDJ4NP4ZHolFcJHrutW5AcxTqP76YJ/EYq1F4xmTi600/WOT+hFdMMxoS62MpYSqtlc7GiuXh8a6a3+viu4D/tR5H6E1fh8T6PKMi9RP8ArorJ/MV0RxFKW0kZujUW8WbNFUYdX02c4hv7Rz6LMpP86tpLG/3JEb6HNaqSezM2mtx9FFFMQVy/gb/Tv7X1xuf7Su28k+lvF+6jx7NtaQf9dKteOb6ew8M3Zsm239zttLU+k0rCND9AWDH2BrU0qwg0vS7OwtF2W1rCkES+iqAAPyFAFqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKbIwSNmJVQASSxwB9a8ksvFuuaHYvf+Ibq9u7gabc3wttto1ndmJd5+zyw5kRQO8gOQfUcgHrtFcHqPj6aPVW07TtLhurkyWUSb7zy03XEcrjcQjEBRGOxyGzj1bo3j+fVLuO3j0qCJkjuJLuWS9PlQrBceTIVYR/OOCynAz0O3kgA76ivMdP8AibfXov4rfw61xdW8MFzGLd7lo5YpXZfMG62WQqNucpG+QeM8069+JtzBbTXNvpFldWtpp0eo3ckeoOu1WmliKRhoQWcGI8ME5yOMcgHplFecyeOtQivZLSw0xb6Zp9RObu8EAjS1aMYGyEnnzOAQSMcseojf4oBtQ0eK002O4t9Qa1jLiabdbyXCBkWQiAxD7y8eZuwche1AHpVFebeCvGuqzab4dTxDa2rSalb3M4u47nPEIBO5fLUKTuPAJwFz9LOh/EC71O60PzdFSxsdUggljuZ55drNIm7y0KwlGYdMM6E44FAHoFFFIzBVLMQFAySeAKAFrI13xDp2iCNL2ZmuZf8AU2sKGSaU+ioOT069PeseTW9Q8RzNb+FSsNgp2y6tKm5T6iFT98/7R+X61raD4csNFaSaBHmvpv8AXXk7eZNKfdj29hge1Z8zl8H3mnKo/F9xlGLxL4gJ8+T/AIR7TW/5ZxESXkg925WPt03EeoqofAyaBeHV/BoSHVSP9Iju3aRL4Zyd7nLK/o4/EEcDuaKaglq9WJzb0WiMbw54gttbSaMRyWmo2xC3VjcYEsDH1HQqezDKnsa2axPEfh2DWGhuYppbHVrYH7NfwY8yL/ZIPDoe6NkH2OCKmj+Ipo9Rj0bxNFHZau4PkSR5+z3wHVomPRu5jPzDtuHzVZB01c5q2uyCRoNNCuwOGlPIB9vWtHxDO1vpUzISrNhMjtk4P6Vy0SKkYCDivJzLGSo2pw0bO3C0Iz9+Qx4pLiTzLuV5n/2jwPoKtwxJswyqVPBGOKryyrEpZyABWXda0FyI1OB3PArwlJyfM9T0eW6sjT8N2cegWLWMMpktEkY26MP9TGeRGD3CnOPQYHatNr7LZDAV55e+I0jJ8y8t4h/tOKojxfYA4Oq25P8Av10+0qsn2MUenS3mYyC1c5rc0csflMA27gg9xXODxLbTLiPUbTP/AF1X/GqNx4i0+0czXd/FKw6JE28/QAUnTq1HqmOKhDqXvB90ba0e1mf5raR4hn0U4H6YroLjWYUX74JryWy8TPHcXUt3YymOeZpUaLqoPYg1YfxVC3EWn3UjHpuIX/Gt5ZfWctYsSr0mr3O7utZMjERk1Se5kYEkmuUh1fUpQDDp8cQ/28mrH/CT6xYuPKitLdxyrm3VyPoXzj8K2WW1Iq81ZGlKUaz5ack36nZ6Zomqamoa0tpCh/5aN8q/mev4ZrqbHwJDEok1e+7ZKx8Af8CP+Arx288V+JL0ESaxesD1EblB+S4rGmW+ujmeSeQnvI5P8zXTTw1GG6ubPBVpbzS9EfSltc+FtFU+XeaZAy9WadS/5k5qtdfEbwpbEh9YhYjtGjv/ACFfN39lTk5JUfVqnTR2P3pEH0BNdSq8qtFWI/sik3ec2/6+Z7bffGPw5bhjDFfzhRncsYVf/HiD+lcVoHxaFtJqepf2M811qdx5+6SfbsiACxJjaeigE/7TMe9eearpiu9tYCUlrljvwuMRLyx/Hhf+BVrjS4QMBpPzA/pQ6srFwy7CqVrNpeZ21x8aNWYn7PpVlGO29nf+RFZ8/wAXvE8mfLi0+L/dhY/zY1zX9mwgdHP/AAM1G9hCP4D/AN9Go9rLudMcHhltBGxN8T/GMn3dQjj/ANy3j/qDVObx94vlzu1qcZ/uIi/yFZr2NsOsYphtrUf8sV/Kl7SXc2WHoLaC+5El14o8SXKFJ9c1B0PVfPYA/hVS31fU4Gz9qaQeknzZ/OntHbDpAn5VBIsPaFPyqJWn8WpqqcLWUUa9v4lPS6tx/vRt/Q1s2OvWr48u68tv7snFchZ6ZLfy7LW1DnuQvA/Gulj8GQ2lmbjUAHf+GNRgZrjrU6Ed3ZnLWp0Y76M6a31WQjKsrj1U5q/DrRH3sisy18KWiRxRRoYpcZLRkrz+FWLrwtqcC7rW7Mg/uyqG/XrXnvkZwu1zat9bQ4+atK31ZT/HXATW2rWv/Hxp29f70Lf0NRLqkMRAmaW2b0lGP1pcnYTimepx6kpHJFWBfRMOcV5xbXrSKDFOrj1DZqyuoToeTmmpTXUh0kegiSB+uKRre3kHauLg1dh97NXYdWDfx0+fuifZPozoX0uFvu7T+FQPpKj+EYqlDqWejVdS8Zx96lzQfQXLNdSu+kwseUH5VGdBgb/lkvPsK1Ytz8jmpN7xnkcVXLG1xc8tjMTQYUGSMVFLBHaZaOSSPHdHK/yq/e34VDk4FcrqGoea5JbCLUOWvuMuCb+I09B1K41/xrYaZcS+dbaTG+olmPzF2BijB9RhpWye6j8PTa8L+Fesi3vtb1lraSdr2Xy4cEKBEnyjn3xu/wCBGvR4PGsG7F3Y3EI/vLhx/Q17+HxVOMFCpLU86th5uTlCOh1tFZlnr2l3e0Q3sO4/wO21vyPNaYIIyDkGu6MlLWLucji46NBRRRVCCimySJEheR1RR1LHAFY914o0e3yDeJKfSEF/5cVMpxh8TsVGEpfCrm1RWDaeLNIuJBH9pMLHp5yFAfxPFbwIIBByD3pQnGavF3CUJQ0krBRRRVkhRRRQAUUUUAFFFFAAQCCCAQeCDWTp/hrQtNluJNO0XTLSS4UpM8FpHGZVPUMQOQfQ1rUUActfeAPDF1awWq6Lp9tax3KXLwW9rEkczIGCrIu3DL87ce9blppGm2axraafZwLFCbdBFCqhIiclBgcLnnHSrtFAGAngzwukEsCeG9EWGXHmRiwiCvg5GRtwcEk1m3/hnwnYeItM1C9sLMXEyRaXp8DWqNFCyebMvlgJ+7bG8k5A+Ud+vY1yHxF8Lt4kh0Z4rHS7+TT74XLW2o8RTJ5boyFtj45ZW+6RlBQB0Q0nTllMo0+0Ep8zLiFc/vMGTnH8W1d3rgZ6VTHhbw+L2C8GhaV9rgCLFP8AY498YTAQK2MjbgYx0wMV5Y3wo1kx66hubR7i9tbuBLs3KoZfOOV85Ftg7AcfelfGOBg4rc1T4cSpqU76TY6NLo5vIbr+x7hmitp9sDRsZAqMA24q4+VsleecGgDpND0jwp4g0VbuDw5pgtZ7iSYxzWMWTKrshkIAI3ZB+brg1q2/hnQba+hvbbRNMhvIEEcU8dpGskahdoVWAyABwAO3FeYSfC/VzpFvaeVoc0gsXtInkkkUaZIZ5JPOtgE5ba6jHyHMa8kcV0UPgGWHxAmsILEX41xr5roZEptTCUMW7bnliCVzt75zQB3tteW100y21xDM0LmOURuG8th1VsdD7GuQkaTxzdywxSPH4VgfZI6HB1BweVB/55DoSPvHgcVQ8Z6HY+J/EyaXYwG1vVQPqOp2rGKaOE9It643F/RsgDJxzWraWviTw1bRW1oltr2lwIEjjAW1u0UcADGIpOMf886zfvu3Q0XuK/U62GKOCJIoUWOJAFVEGAoHQAdhT6wdH8WaVqd2LLzZLPU8ZNjexmCf8Fb7491JHvW9WhmFFFFABVLWdKstZsJLLU7dZ7d8HaeCpHRlI5VgeQRgg9Ku0UAef6vc6h4c024sfEEsl9orLiDVyMyQHqq3IHbPHmjj+8B1NbRbjzrQZcNg4BznI7V6PIiyIySKGRgQykZBHpXkni/wvP4OR9U8NyMdK3fvdLzzHnq0H/xs8f3SOh83MMFLEWlDdHZhsRGneMti5rpnjieSJd5C/KPevLdV0vXtXuS11di1t8/d3c4+g/rXYWWstrkUclnN50TcZHGD3BHYj0PIq6+kSlcsCTW2DyeNNKVd3fZGdfMpP3aSPP7fwhpkR3XBnvJO/mvhc/Qf41oR6FZKgWO1iQf7KgV166PIB92p49MYdV/SvYhSo0/hijzpVas/ikzh/wDhGLNmz5XNWIfDtpEQRCM+9dn/AGa+eFNOXTW/umr91dCeab3ZziafHjBRcfSpo9PjHSJR+FdENNYc7aeLPA6U+ZCszAWxDZGKxdUtMHY33W6ex7Gu2eNYVJJFcnrsqtMqqeSaa9/R7ApOm1KOjRzkT7owRGfzAp2JeyRj8Sf6VFb3AZD5aO2WYjH1NdV4d0J7wrPeKUj6qh6n3NfNVakaSbkffOpaKlIyNP0i/vvmRkSP+8U/l61qjwtdbctdv+EQ/wAa9EsrGOGNVjUAAYHFZXjSe4tdINvYZF/eutpAwGdjP1f/AICoZv8AgNea8XVnL3dEcUsVLoePwW0/2u61KV5Gt3Y29vIuMFEYgnp3bd9QBVgTLnmSX/vof4V6RLpMUdhDZ20QFvBGIkQjI2gYA/KvPfE2iyabKskUjfZ5DgccqfQ11UcUqjszpw01JcstyPz4h3kP1emvPER91v8Avs1kFZP+ex/IUxjKP+Wv6V1XOz2aNGSSM9A3/fZqrMQTwWH4mqbySr/y0X8RVOa+kTPzIfw/+vRYpRsXZM/3m/Ouj8JeFLjWJFnnZ0tc/wDff/1qz/AGiXPiTUDJOu2xhPzHH3z6V7rZ20drbpFEoVVGABXDi8V7P3IbnJiMTy+7Dcz9M0e20+EJFGqhfasvxEwe5s4l+6ZVz+YrX1e+W3TGea4PWtbgivLYSyEy+YrbV7DPevPpxlN3OCKcnpqd1ZLuvCxFbcvAFZduRHKG7HkGtdxvjBFSldMyloysyhhgiuU8aeHm1TTm+zIPPjO9R/e9q6yis4ycXdFp2PHNN0VLgdXilU4YDKkGtRdE1CL/AFOoS49H+b+dd9qGlx3LGWIiK4/vgZB+o71DZKUjMOpxLHIDxOv3CP6V2U7VVo9ezCU2tbHCmHWojhZIJR6MmKm0t7y41eHT7uCOCSU4SQMdpPauq1GxEbB42DIeQw6GsrVEeMwXcXEsTBgR2I5pL3ZWmg5uZaF+/wBE1XSB5s8LNbjrLGdyj69x+Iqaxu9wGDXpWjX6appVrdx42zJkj0PQj881xXjbw9/ZxOp6Ym2En99Eo4X/AGh7V3YnAJQ9pSd0clHFc0uSorMs2lxgAg1FqurJEmOrelc9Dqflw5Y4OK57U9UYu205J715kVLbodfIm7mrqWovKGZ22r6CsVba711ZILWQwRspXzsZ2nHUetWNN0i4v9sl3uSHtH3b6+ldzplilvGoRAoA4AFNyUNtynZEGh6NbaVp9vaW6YigRY0HsBitUW6uOVFOYAYpUcqayvd+8Z9NCncaPFIc+Wp/CoYbCe1b/RJ7iDHOIpCB+XStpLgY5FPE0ZPIreNlrGVjNyls0Zy3mtR8LqMpH+1Eh/pTvtOrS8S6jNg/3ERf5CtEtER2pjPGK2dWrb+I/vISh/KvuMebS1uHDXUk07DvK5b+dSx2MEI+WNR+FXnnUdKrPMGNcs3fd3Notle6soLiMq8a/lUelapeeHnEUge507+5nLR/7p/p/KrYbNDosi4YZBoo150Zc0WE4KatI7HT7621G2W4s5VliPcdQfQjsfarNearbXGn3JutMlMMvcDlWHow7102ieKYLyRba/QWt4eBk/I59j/Q/rX0OFzCFbSWjPMrYWUNY6o6SiiivQOUKKKKACoZrq3gmghmnijluGKQo7gNIwUsQoPUhQTgdgTXJ/Eu0murfRzLZ3F/osV7v1Ozt0MjzReW4XKDl1EhQlADkDocYrgtOsNVg1W0n0PQIoYrXULiW0MGlz6fFITp0wUvDIx8seYwTPyhjz3FAHt9FeN6Fqnjy9tRHcXV9E0tzZxu5sH86AMzCYjzLSKMpjHTftxyxBFTXureMreOWC5uNcjjtzfR21zaaSk8t3KkuIBKoiKqjJzuCorc/MMUAesQ3VvPNPDDPFJLbsEmRHBaNioYBgOhKkHB7EGpq8otIPFFn4o1TVIvt0H2rV9OS4tI7ZXglja2gSaTcULYQ7huVgAVOc81UbxJ42l0mC3gt9XTVLfS7n7ZI2lEI12Jolj2Ex7X+QyEbcqQc844APYqK8yj/wCExstdnU6rqt/Z22rWtqizWMAS4tpIkaSRmSIHCszDcpAG3BzzWFpOufEWW0v2u/tEd6IUJtzYSP5Uv2iMHyz9mRGTYXyPNlOMENwTQB7VUVrcwXkCzWk8U8LEgSROGUkEg8j0II/CvLfEWq+LtM8XWFhpja5eWsd1bJPLLao8NxE7jzGBjtcLtDEEmVCNudp5J7D4bW09n4OtIbuGWCZZbgmOVCrAGeQjg+oIP40AdPWT4p1ldD0eS6EZmuGYQ20A6zTMcIg+p/TJrWrkbUnxD41muT82maGTBEO0l2w+dv8AgCnb9Waom2lZbsuCTd3sjU8J6O2j6XtupBPqNwxnvJ/+ekrdcew6AdgBW1RRVRSirIltyd2UtW0qw1i0Ntqtnb3kGc7JkDAHsRnofcc1gjw/q+j8+GtYd7dRxYaqWuIvokufMT8S4HZa6uimI5VPGKWDCLxVp8+iPnH2iQ+baMfadRhR/wBdAh46V08Esc8SSwSJJE43K6EFWHqCOtOZQylWAIIwQe9cxN4MtLeZ7jw5c3Gg3LEswsiPIdj3eBgUPuQA3J5oA6iiuU/tjxBo5269pQ1C1H/L9pCliB6vbsS4/wCAGT6Vet/Fmi3dg91Y38NyqHY0cZ/eK391kPzKfYgUAbbusaF5GCqOSScAV5t8SdatrxIrO0kLsgaQkD5T0HBq7eXN7rM375jHDnKwqe3qay/FOhOdLW4skV7m3O8J08wd1/KqhLlkmJx5lY4bRraO31eLULSZracsPtCqMpcL6Mv94dmHI9xxXqljfWE8YLSAN3zXksa+ehmsSSAfmjP3oz6EU9bm8TgBga7nTjPWLOTmlB2aPZPP00DJlSq82o6bH911JryT7Rft03UmzUJT/HU+w7sftvI9Qk1uxBOCtUp/EVmnRhXnD2s45muI0/3pAKgeSwi/4+NUthjsJAT+lPkgt2Cc5bI7q78WW6nC4zWRd+L1ydtcfc6loqc/a3l/3EJrOm1vT1/1NpNIf+mjBB/WpdShHdmkcPiKnwxOpuvE0k2QgOTWFquoSRxlnJ+0SDEa9/r9BWNJrdzIcRfZ7Vf9hdzfmat+GrJdU1RIUdnkb5pJHySFHU1y18xpwi1A9LCZRJzU8RJJLodT4C0Y3hEsqEQxYVQf4j/hXqllYKqjA6d6zdE09ba3jjiXZEowBXQopSA4PSvkatR15tvY9avVcnoIXEQ24qnNOodQ55Y4FZ+p6mILVnz8wOAK8/8AEXjJoL9LewjW6vcZYuSEiHpx1NZWlU0REY2PTJgPLJWuR8VWn2qxlhAG51JXPZhyKt+GNVuby0xfIiykZGzpUurRN5YcDJU5FKF4SNItxdzw4TzHOdhpj3EgBJUfnWl4y0ufS9SkuIY2ayuCXRgM7SeqmsGxS41O8itbONpJZGC8Dp7mvejOMo8x7EasWrm74f0G/wDEEm6MeTabtplIzk+ijua9E0zwFpunQefc2huJAOtywOT7KOPzzWtZ3+keGNPhW8njgEMYjijHLH1IUc5J70mh+JP+ElvH+z2zxWULDDSH5pG+g6CvNq1qk05LRHn1atWd5LSJu6JYpZW21I44887UUAD6AVduH8uFm9KljXOBVPWnEdo9efbm1ZyX1POvGWttCxjiOZn6f7I9a4Ha0shdyzuTksTWpq8n2nU55W5+bAz2AqBVr3KFNU4K2569CmqcPM9O8HawuqaWtvKw+2W64P8AtD1rq9NvgD5UvHavDLO9ksblZraQrKvQrXoGi+JrXUVVLoi2u/U/dY/0rir4eVOXPDY4sRhmneOx6JJEHG5DVdlKnms+zvpYMB/mT1Fa0V1BcDBIBrlcYz20Zw6x3KdxOsC5bknoPWs2a5klyCcL6CrV5bmWVnQ5Hb6VReJ0PIr6DB4CFGKlJXkebXxEpuy2KU1sScxSMnspIFQTQXTRMhkV1P8AeX/CtGiuudCnP4ooyjVnHZkvhHW7nQIJbWe3Nxbs+9SjYKHvwe35V06eMtKuEaK7huYo2BDeZGGUj04J/lXJUhRW6gVcYKEeVbEyk5Pme5W8Q6HZS7bjQ9USWGSTb9nI+aPOTz3xx3FN0nw6kTiSQGV/7z9voKjvoVtp4bmMAFHAJHoa6nT5BLbg9+9fPZjS9lU91WTPVw1Zzhq9UOt7ZIh0yfWrGQo4pmTSV5tzfcCcmigClxUjEpaBSnpTSFcjZiO9QvIfWllbFVnenYaHmQnvSbjmoAxzQZKdhlyNqsA1nxSc1cjbNS0BZRQUJNYPiCAS+XHGo82Rwi/UnAroI/8AVNWbKm/WtKB6faUP5HNbUo3nFdzNuybPRAMACiiivsDwwooooAKKKKACiiigAooooAydf1uLR5dNjlA3Xt0lspZZNoLHH3kRgD6BtoPqKx3+IGhS20z2F2sjoqyL58M0McqGVYy8b+WfMXcwGUDDJGSAc1b8W6VqGsXejQ26Wi2FvexXlxLLK3mfuzkIqBSDnjJLDHoayYvhrpi26W8uo6rPbQQC2tIpJY9tpEJUk2JhASMxRjLljhQM0AWNT+ImhWkOpCCW4uLqzW5Ai+yTqkssAbzI1k2bSw2nOCcAZ6VuaDrltrGk2V6glt/tKgrFcxPC+cDIAdVJHPUDB6isiXwJpU0SxyS3jILm9uiN68tdCQSA/L0AlbHccZJq9b+FtPbRLbS9ZRdcgtxtjbUoIZGAxgDCoq8DjOM+pNAE/i3Vjovh+7vI08y4CiO3j7ySsdqL+LEU7wvpQ0XQrSxLb5UXdNJnPmSsdzt+LEmuI1HwfpF3410/TNNF1YQ2UR1CcWl3Kih87YsJu2gg7mzjtjoa6UaDrtrj+z/Fd1IB0TUbSGdR+MYjYj6tn3rOOsm+2hb0il8zp6K5gzeMbQfPZ6HqagcmK4ltGP0VlkH4Fh9aP+EovLfP9p+F9btwOskCx3SH6CNy/wCaitCDp6K5pPHXhrzBHc6rFYyE4Cagj2bE+mJQpz7Vv2t1b3cIltJ4p4jwHicMp/EUATUUUjsEQsxAUDJJ7UAVNV1CLTrUyy8seEQdWPpXmWt6XZ69qAvL+H/iYdI7iFjFLEPQOpBx7ZxWnq+pNqF885JCKSkSnsPX61Sik2Bm/ib9BUuSW7KSbLmgwzaVBMt7qT38eR5RljVZAO4ZlwG7dgfXNWJ9Q8wlpCQnZR1NZXm7nyx4XoPU0pkSCCW7uG+RBx7n0HvUqpBq6Y+SSdrGVrWh2t1K96rnT5sZMkR2n8awoNN1q5k2WF7LcJ/faFQPzI5rQt5RqmoLPesREp+SEHgfh3NdvZwPKitar5cY/jfgVwPG1akuXDr5nX7CNON6rOFHg/xC65n1KSMHsoA/kKrzeBn63WqXDH03mvSZrm1h+W5vJbhh/Ah2j9Kqtq0MKlrfTkVR/E4x+taOhiJ6yqkKvCPwwPMJ/BNmvOJpT7ms+bwrBE2Vs5CB7GvVG8UR8/Ppqf70yD+tRnxVb5+efST7faE/xqfqketRmqxU/wCQ8ui0y1hkAktAB/tLXcaLoGi+JbY2FzBFbXoX/R7mNQDx/Cw71vR6ta3Y5s7ScH/nlIrfyojGmx3CSpBLaSqdwZR0NKOClGXMpXQSxnMrNWZ5vrXh248PXxtdRtIxn/VzBfkkHsau+DYEjlvZdgV8onTovJ/w/Ku31uzOrQSGW9a7H3hHIcgH2HQVwMMU2h6ubhCZNOmGyZD96L0YeoH8s1wYui6cmjqoVfaRuesWRTYvpim6pMLePfu+XvXN2WuRxKEkYbR91geCPUVk+I/EBnTyrb5zXAk7cppya3Mbxlq32e1vLlGykIyvux6Vxfg+2a4fz5fmeVtzk1H4z1ZbuKLSbdt5Vt87r3b0qnYXVxYxbYGYfj/9au+nh5OOh1ww056nsWmMlsgIYdOlSX/ibTYEK3FxHkdVByfyFeNTXl9ccPNKy+nP9TTUt5W+9u/E4/lVLAq95M6Fgl9pneaj40tBlbO1aUf9NMKp/mf0rnLrxJfz7lgaK1Q/w2yBT+fWs1LPuQv481YWEgfeA+greFCnDZHRCjCGyKeySVy7B3Y9Wc8n+tet/Da18nTIiQNz5c/nXmgjHcsfxxXrXgkCOxt17eUuK58dL92kc+NfuJHXwD5qyvEWTYykdgTWtbctiqeqQGW3lj9QRXmLSKZ5a+I8DlZzIx4GSfemYz94k1PfRtBdzRMpyjkfrVfLf3fzNe+tj31qh44HAxSjOafbW1zdNttonlPoiFq2bXwhq9xy8XlL/wBNHA/lzQ5JbsmVSEPidhmleIr7TAFWUSQ/885OR+Fdbp3i2wu0Il32s2P4vuk/Ws218BSBd095HH6hUz+pIq+ng3TUH7y4uJG9AQB/KuWpGjJ36nBWqYefXXyNm21VlQMjCWP+8pzV+DU4JuHIB96xbXRLC0B+zRyI3r5jfyzimy28qEkKsg/I16NPHUno9D5+phZJ+5qjpvLgmGVYVC9m3VTmuaFy8PeWM+4yP0q3batOo++r/Q11xnGesXc5pQlHdGm0Ei/w0wgjqKamsj/louKWTUYJV7A1RJXv0ElrIpHatHw3IXtkLdSoJ/Ksi7vIhCwVskirXhe8iMCLuGSOK8jNkuSL8zuwV7tHRnqaSlX5jT2jIFeBZvU9C4wU6minU0DEpHPFOxTJOlNCKN02BVIyZqzedKoE81VikT7uOKZkk0gPFOQZNAyaHtV+GqkS1ciGKiQFlGwhFUb1xbzW102dsEqSHHoCM/pVvOBzWXq97FHbujEEkU4SakmuhNr6HpakMoKkEHkEUVj+D1nTw3Yi63eZsOA3ULk7f/HcUV9lCXNFS7nhyXLJopaz4uSx1mbStP0fVdav4IFuLiOwWLECMSF3NLIi7m2thQS2BnGKtw+KdGMcH2u/t7C5liEptL2VYZ4wUL4eMnKkKrEj0UnoKwfFPgWbVdU1K8sL3Tkh1SCKC/stU00X1vMYiTHIF8xCHXPqRwOMgGs60+FFpB4a1bRn1KV477S7TTFmWILJGLdCobIPOTgkDHTGe4ok6o+NfCq6YupN4l0Qac0vkC6N/F5RkxnZv3Y3Y5xnOKrWvj7w3ceJLvRF1azW7t7WK8DPcxBJo3V3zGd2W2om9uMBWU5wa5OP4XapFZyJB4nMFzPcCW6ki+3/AOlKI9irIzXplyvBG2RRwAVIqKx+EM1poE+jL4gVrG70i30u7P2MiRjAZTHJGwl+TmX5lIbIGAVzkAHexeMPDU1gL6HxFoz2RZ0Fwt7EYyyoXYbt2MhQWI7AE9Ki1/xpoWgajotnqt/b251cuLaWSaNI/lXdklmHByAMZyWA71y+gfDE6fq+m6jfajBd3Npfm+kbyrlzORbPAgZri5mIK7wwIP8ACBjuOo8T6Bd6pqmh6jpt/BZ3elzSSDz7YzpIrxlGUgOhBwcg54PY0AQeK/Gmm6J4Svtbs7iz1Ew2Mt/BBFdKPtMceNxRhnKgsoLAEDcPWro8X+GjpkupDxDo506KTyZLr7bF5SP/AHS+7Ab2zmvP3+EN5LpT6XP4jhNhFpF5o9mq6cVeKOd0be7ead7L5YHAUH272dW+Fd5q11Lqd54gjj1trqG4SWztprW3RY4WiCbI7gSZw7HcJQeg6cUAd4vibQWkhjXW9MMk6o0Si7jzIHDFCozyGCORjqFbHQ1kp490W617TbDSdQ07Ube5S4ae6tr1JFtvKVWw23I5DdyMY71i6L8LLSw03XbOa7Qpq2krpTm3jkVoVzOXZWlkkf5jPnDMeUHJHANY+HeoeIdPt7PxDrlpJHb2VzYodP09rY7Jo0TJzM4yNmeAAc4wKAO30XW9K122a40TU7HUrdW2NLZ3CTKG9CVJGfatCuO+H/g2TwsNQe7vo766vPLV51+1biqAhQTPcTHjJxtKj26Yr+KPDWjaL4c1PUbd9TtHtreSRPI1W6jG4Kdo2rIAeccEYpN2V2NK7si94F/02XWtbbJ+33jJESP+WMX7tce2Qx/GurrifD/gltP0Oxt7fXtetWSFQypcq6hiAWwHVsc5NaP9g65H/qfF+oSf9fNpav8A+gRpUwVooqbvJnS0VzH2HxfEB5evaNOBjIn0qQE/8CWcAf8AfJpd/jKL/lh4eusf9NprfP8A44+M/jj3qyDpJEWRCkihlPUMMg1gXPgrw1cSmY6JYxTn/ltbxCGT/vtMN+tRf2p4oi/1/hqzkP8A066pv/8AQ4k/z+dH/CR6nGf9I8Ia2o/vRS2ki/pNu/SgBP8AhEjB/wAgvxBr9jjov2v7UPyuBJx/kYrH8UjxTpGkPt1rTr6OUiELc2JjkOep3o+3oD/BWz/wmFsn/HzpHiGAf9gqaX/0WrVzPjrxjotxZWqfaZ4CswZhc2c0GPlP99B/9ascRKUKcpR3NaMVKaUtjnILjXgA1zoa3CDj/QrtGJHriQJ/Or8WuWMAH9oWOrWR6ZmsZGUfV0DKPxNTaT4o8PSKqJrmllxwV+1IGH1Gciuusrq0uo/9GuYJuP8AlnIG/lXztpVW/aL8/wBbnpuShpFnKW+r6Df5Wx1SxmkHBRJ1Lg+hXOQaxdetdTvQI9PtZpowe3C5/Hiut8QabY6hEUvrO2uVI24miVxj8RVXTPBWjxoq2Ud5YsB96xu5YB/3yrBT+IrbBYaNaTV3ZE1q7pxTsZGiaVNpcavd2Vy8uMsfKJGfw7VJqfiEmRLeMtNM/wByCI4wP9o9q3rnQ9Ws0JsPE+obR0S8ginUfiFRj+LGuev4PEMT/antdDv5idvnRmS1cj6ESA/nXs1f3FJ+z6HBB+1qe/1LWm6fd3DZvLgpn/llbfKB7F+p/CugttBsBgvaxMR/FKS5/WuRtPEV/bfLd6BqKY5LwGOZf/HW3f8Ajta9j4z0X5f7Q1FdPdsfJfQvbEe2ZQoq6bhOKktSZ80XZ6HR/YrKIfLFCPZUqnd29j/zwz/2yJH8q0bO/tbyESWl7FPF/eicMPzFPkKMP9dWvKjO7PHfHFpDbarcP9mjMAUMMRhcDFUNOkniKtZ311ApHAWQlfyORXUfEy236jCVO5ZIMMe3euJ0OTdZxeq/KfwrysfF05KUND0sE+eLjLU6fTfEd7b+KbPTLxbeeG6iLpNt2NuB5HHHT2qj40uTDqAhRikLb2facE4xxn8TWdrLbNe8MzjqLhkz9Vq941gL6hCWAwZByw4GVP8AXFc0asqjip6nbQpwhU0W5wdnqmoafLMkN0lxBvI2SjIPPUelO1DWtQvUMStDaxEc+VwT+NOuTIbuR2VUL4YAHPUA0q7yOdldXs4XvY9eNKGjsZ9naQw5O7c55JBFXVVfRz+IqQxA9UQ01oV/55D8AKs2VkSJtHZ/zqQFfST9arCJQfusPoTUiKB/Gw+ppATfL3V/1pD5fdH/AO+SaApxxK36GnYf/noPxX/69ACAx/3T/wB8GvUvCUoGlafKvQrsP4GvLdsn96M/XIrv/BEzTaDNCSPNt5NwAPY1yYyN4XOTGK8LnpML4KtVi7QFQw71kaVcie3HPIrVikDJsf8ACvLg9HBnkyWt0ec+LfChudTW6hkWKGQ4kJGcH1qxp3hfS7NVaRPtEnrJz+nSu4mh4KuoZDwc1jXVi8GXgBeLuvdfp6it4YiSXJI2dacoqKehFC6wLthjVV7ADpSPO7feaqUtyTxEu6sy8v4YCftd5FER/CGy35DmtVd6IyUHJm086jq361A97GOhzXMz+ItPjyIxPOR0IG0H8+f0qhN4pk/5d7OFP98lv8KtUZvobxwtR9Ds/toP3VJpPtUhHCGuAm8Q6lJkCcRg9kQD9etZ0+oXcmfNu53Ho0hNaLDS6s2WBl1Z6Pc3kaqfNeNfqax59R00sQbuEH2cVwUki92A/Gup8KeFFuZYb7U54IrL7wUyDL/4VrHC+Y6mGp0o3nI6FLG8e3SeBpRC/wB1jgg/nSfZdROQGibHqors5YVurVTalWjjGFVWyMVlSjY6n86xrVatGVk3bzPNhCnUvdIwdP8AD+qeIGmjtnVhDjzEDBOufXr0q/beAvEWnzCSzgDLnLJ5y8/rW14Kl+xeMvK/guomX8fvf0r1GuvD0I4qHPUbuc9avKhLlglY830i6cgwXClJ4ztZW6gjtW6mHSq/jbTjbzx6tbDAyEnA/Rv6flTNPuRIisDwa8utReHquD2N4zVWHMh0i7WoFWJ1yuarjrXPOPKzSLuhDUcvSpajl6UhmZeGs9utaF5WeetNFokTmrEa1BEOauxCkwJ4E5FWmAQZNMtlwM1R126NvbsQeam1xbspapqbeYILYM8jHaFXkk+grqPDnhNIVS61gCa64YRk5SP/ABNUvh3omVOsXq5kkyLdW/hX+99T29vrXd17+AwUYxVSa1PPxWId+SAUUUV6pwGHYeIEude1/TpYlgj0lYWa4aThxIhckjA2gY9T+FZkXxH8MSW7zLe3QAETIjafcrJMJWKxtEhj3ShiCAUDA0/UPBSXet6lqEWt6raR6kscd7Zwi3aGdUXbtO+JnAKkg7WB54xWFpfwf0PS9LvLCxuZY4LqNImP9m6czbFOdpJtf3gPGTJvPGc55oA6WHxpo02pW1hF/abXs6RyeSNLut0KuzKhm/d/uQSrcybeAT05qpH8SPCrxTzf2m6QQxiczSWkyRyRmRY/MjZkAkTe6gshYDcMnBrNh+Fekxy6EzahqMiaPtNurx224kSGQ5lEPmqpJwUR1THy7QMiq2lfBrw3pUFzb2TzRW8yLGFS2tEkjVZUlAEywiVuYwPndsjrzggA3/FfjS20HwimvpZ3tzA9zBbrEbaaOT95OsRYoULjGSQCvzYAH3hVqz8ZaHeRCSG7lH+mppxWW2lidbh0WRY2VlBU7XUnIAGcHBBFW/FWhW/iTQ5tMu5riCOR4pRLblRJG8ciyIy7gRkMinkEeornIvhxaJq8d++tazJi+i1OW3ZoBFNdJGsfmsFiBywQZCkLnkAUAVfB3xQ0jUvDsF1rlyLK/Fq91MhtJ44mVXCExMy4lwWQEIWOWA68VsL8QfDhRD9quxK8z24tm0+5W48xUEhTyTH5gOwhgNvIIxmsIfCHRJtO+wanqGq6naR2r2drFdNDttEeRZGKBIlyd0acvu+7jpkHS8M/DjSPD9zYT2kshls55bhClraWwYvF5ZDLBDGGAGSDjOT1I4oAg1v4iWYjtR4f826dtVtLGWaWxuBblZLpIZNkxVY2cbzgBjyDwQDW7ovjHQ9a1M2GnXcslxseRC9tLHHMqMFdopGUJIASAShOMismH4eWkMUVqus6wdKgvY7+309mgMUEiXCzqFbyvMK7lxhnPDEcHBDfBvwz0LwjrMmoaQNpZXRImtLUGMM2TiVYRM3p80jcdc4GADo9Y8SaHok0cWs6zpunyyLuRLu6SJmHTIDEZFch4+8WeHb/AMPwWlrrukXCXt7bQuY7yNgI/NUuxwemFOa9Erj/ABhBbzeJPCds1vCTNfyTMxQZPlwSHn8x+VZ1PhsXT+JPsa8Xirw9K4SLXtJdz0VbyMk/rU/9v6P/ANBbT/8AwJT/ABqaXS7CVCktjauh6q0KkfyqH+wNH/6BOn/+Ayf4VoQTRapp8yb4r61dfVZlI/nUiXtq7BUuYGYnAAkBJrOl8K+HpXLy6DpLuerNZxk/yqOTwd4YkQpJ4c0ZlPBDWMRB/wDHaAN2iua/4QHwd/0Kfh//AMFsP/xNH/CBeEwf3fhzSYh6RWqRg/goAoA6WsLxpD5ugyvjJidZB+eD+hNVz4D8LY/5AVgPcR4I/GquqeA9Ak0+5SLT8SNEwU+dJ1xx/FWdaHPTlHui6cuWaZk2awXICTxRyqB0dQw/WrSaDoiXEdyNH00XMbB0lFqm9WHQg4yD71xek+G9JkZSIZ48jny7qVM/98sK3R4U0n+7e/8AgwuP/i6+XhONPRN/d/wT16kHJ6o2NT5U1q6YdinnGAB0rjJvCmn7fluNa46f8Tm8P/tWtKy8J2OSUvNcjI7/ANsXJz/31If0r08q5W5tHJjL2imdNfbmgbB7egNYUykoi9smo7rwrAImI1HXP/BtN/8AFVnJ4d8p4ZBqusMEOdkl0WBweh4yRXdjf4TOfD/GI4IlIB2+5rQtFBj2tJLLkYIUACqE+PNbNX7Np41HlqgB/vNiuTLanxU/mdGMhtMqXPg/Q7uQzTaNa+cf+Wqpsk/76GD+tV28HQxnNhqGtWR6jZeGYD/gMwcY9q6JZrlhzLbD8SaRprkf8trc/ga9U4TzHx3p2tWc1nGdWhu18skC4tdrHnpuRgP/AB2uG0O71CJJlOnpOFlcEwTjOc+jAD9a9R+Ibs99abypcQkjb07157oAwbr/AK+H/ma4MwsorQ7sDdyeoajqBudT8PRvZ3lvIL1TiaPg8dmBI/Wuo+IKKyBScYCZwenzCsXWFMmu+GIR1N0z/kK1/HbgPcEjcA0eR/wIV5kGrq3c9Onf2iOE1UYvcMxICLgj096gjwT8shqS+wk0axrhhGocdDu5pquvHmLj/eHFeiezDYlAb++PxFOJcdlb6H/GkURnsV91NOKY+64YejDFBQ3zB/ErD6inKynoQaTOOoI9xzSbVfk4YfnSAlwCOVH5UbB2LD8aYFA6Fh9DU0EU00yRQgSO5CquMEmlsA61tp7qdIbdTJI5wqgcmvUNA8NtoNj9pmfdPIAJVzwF9BWj4O8O2+iWQuLhVa7YZZj/AA+wqa9na9lO4kRDoPWvOrVva+7HY8rEYnnfLHYrW8hs7ncpzC/INdBFIsiBlOQa5sEQsYpj+5P3T/dNXbOdrZwjHMZ6GuKcbHNub8cvZ+RSvCGGY+R6VXRg6gg5p6Oyng1Kn0kS49UYuvaBDqdtJGHkt5G/ijYrn6jvXlOueFrzSXJliZ4c8SITivdw6yDDjmop7VZFKlQ6nqCM100q06Xw6o3o4mVLQ+dRCP7zD8aPI5++/wCdeua14Isbxme3zbTHn5R8p/CuL1XwjqenkkRCeL+/Hz+lehTxdOel7M9GGJhPrY5f7OO7v+dRvaIepY/VjXSW3hzULjGI40B7tIP6ZrRh8EXb/wCuuYk/3QW/nitXViuo3iKcd5HBm1jByEGfelcuqbQzbR0Ga9Ih8AxdZ712H+yoX/GrMfgPSsfvJ7g/Vx/QUvbxM3jqS63OX+HOv3VrrkFq0rNbzNtKMcgV6dq8Qjl+XkZ4xWFZeEtFsZlmhRvNQ5DmRsj9cV0ErRSgebKzY9hWGJqRrRSW6PNr1ITq88Fp1KNlJ5fifRZAcEzKh/E4/rXrleV7bUOr8l0OVbHIPqKna+z96edvrIavC4n2EWmrnFXpe1aaPSLqGO5tpYZxmKRSjD2Neb2Aewv7iwlbc0L7QfUdj+IrPup42JJyfqc1gaRcfYvETR5+SfkfWssbXWIitLNGmHoOnfU9RRt0dVmGDSW8mUH0pWOTXnSlzI0SswzUMx4qQmoZelRctGfdVQP3qvXNUsc1a2KRPCOavRL0qrbr0q/EvSokBaUbY65/UYm1PU7SwjJzPIFJHZe5/AZrcuH2wk+grM8Dxm88YSTtnbbQsw+pwv8AImujC0/aVYxM5y5IOR6VDEkEKRRKFjjUKqjoAOAKfRRX1h4YUUUUAFFfO9j4jvIviQ4/th5ZU8Uy2j2UevTS3D27EoqfYW/drEpYOZAcgKcAV0fw/wDH99qX/COWN7qeiaKk2n2U6w6h500+otLncsDyTg5BG3J81tx59CAey0V4BpHxV1iDSNOVJ9ESYaTpt3Dp1x5013qMk7urxwu8xYkBVO4hyM/NxyLlj4t1OD4gW0t1rVrpuk+ZrFt9nuRPOt08N+ihIw04zMyD5AAQvzhUwwCgHudFfOsXxGvfGM1tp929jcW8OqaJeQXFrEkRIe/VSrolxOAflBwWVhyCo4z6F8QdY1LSPiN4R8jV7Wx0+4trxHguVYpdShoNsQ/eoplYEiPIJB38NnAAPSKK8F0b4u+JdS0a9uVttEW5UWgSNmjLWsk13FC0csUd08pwshO5liwVwV5xWjrHxD1m3F1pGqX2gadIl1e2Umq3FtILeQxRQukaRGYESOJjgGQ/6s4BzgAHtNFeDeEPH2paT4f8J6XC+lxrDpujQw6fPG7XepLNFGHkgYOAAmTn5H+42Sowa63wZ4y1/Utb0SPVhpbWOsR37RJbQSRyQG2lVBuZpGD7gegVcH1oA9Mrl9eUP458Kg/wLeSD/vhV/wDZqs3uualBdSw2/hXV7lVbas6zWixuPUbpgwH1XPtXMarrOsN420Bz4XvlkS2vNsRurfL58nJB34GOOvrxUVNvmvzLp7/J/kejUVzX9seIv+hX/wDKhH/hR/afihuV8N2SjsH1TDfjiIj9asg6Wiua+3+LmP7vw/oqj/prrEin/wAdtm/nR9q8Yucf2P4fi9/7Vmkz7Y+zL/OgDpaK5oy+MW4Fn4fTP8X2qZsfh5Yz+Yo/4rD/AKl//wAjUAdLQRXNCHxjjm+8P5/68pv/AI7QLTxi3J1rw+mf4f7ImfH4/ahn8hQBx0ijT9avbXp5cp2j/ZPI/QitiCYMK5b4gaZ4jstWhvbjVtNY3C7S1vprxrlfUNM3OMd+1ZsP9tsqn+3IFH/TOyAP6ua+XxOHUKjV/wA/8j2qc+eCdj0KTBTNSPfW9hEJbh8BhhEX7zn0AriUj1l48HxCwH+zZx5/DOf5Vma3pmp/uLxtevJTCf8AnhDkDvj5PStsDVVCbu1r6/5GVek6q22O+vNckVYi1ioSYZU+blv5U3T72K/slng3BCejDBFcrbw3UEcd1Pqer6hEiEJDcW8KKDxzlY1P6nrW5oWDpUG3gFcn616OY1XCmo9zlwsOaV+xHdcXDCnWssUbZnPy+5pl4NshJqpLqSWSF5N20f3ULfyrzMDV5K127JnbiafPTslqdDFe2n/LONm+impTcREcwyD/AIDXKJ4306L5ZrqSL/fgcf0qrqnxDsIjDBpt7a3V9O21UkkMSRju7sRwB+ZPAHp9AqsHs0eU6c1umQ+P5Q2rxeWCBHCAc9sk1xXhpPMgL/35Gb9a2vGuqxXOo3M8FxFMDGEQxsGBOMY496TQrH7HYRCTChEyxNedmM01FI78DFrmbIoo/tXxC0qIcraWzzN7FjipPFkhnmcRkEyTqoz04Of6UvhvK3Wqa1N8n2jEcOeojUYH59ayr2bz5IlbdzI0nBx0GP61w0l7yR6VJXqI5rUHaS7Ejv8AMyKeBwOOlCNIvbcP9n/Cn6l5cWpTxr9xSB7A7RkUxU4zG2P1FeievHYkQxuePlb/AGeKUhh6MPbg1EWB/wBauD/eH+NDMyDI+df1p2LJQ+fr6UZUnJHPrUayJKPX+YpQCOnNKwEoz/C2R716N8MdEDg6lcpznbED29TXnthAbq7igTO52C8V75odslpp0cUYAVFAFcWNqcseRdTixlTljyrqRazcAMsC9OprNdwq0X8mdQlz24FZurXqWlk8snRRwPX2rkgtDzFFt2RU17V47SAlxuY8KnrVLw14oEhFrqpVcn5JQMAexrjr2+e8uWlnJDHoD2HoKhzXb9Wi42luepDCRULS3PaY7hrbBB3xHkEVpQXMcygqea8n8Ma1qMEy20MT3kR6xdSB6g9q7+MhmXbuhlP8DH/Oa86tQdN6nDVpOm7M6EGpElK1jw3UkfEo/GrsdwjjgisE3EyauaIkR+GFI1srcoaqBgehqRXZehq1UT+JEcrWzK15pEUuS0W1v76cGsO8t57RisMvnAfwsMEfjXSXF+YYwDyW4FVPPgl++gzXrYHBxqr2jbsclfEyg+VbnM/2g6HE0Mi/hmnDUoT3wffiuia3tZPaozpNtIeCv4iuyWXQezMljJLdHPNqSA8c03+0VIrefw/Ax4WM/hTD4diB/wBXH+VZ/wBm/wB4v66v5Tnn1DPTFV2uWb+MD8a6keHYe6Rj8KeNAt17R/lR/Zv94f11fynImb1cH8aoXwb7Vb3Eat8jAk4PSvQRpVrEOdn5VWubWA5UAEfSqWXR6yF9efRF3SbhZ7ON0YMMdquiuQ0e4Gl6rJbO+IJBuUHse9dTHcwyDKSKfxrwcRRdGo4M7ac1UipImqKQdaGmjBwXXP1pchuhBrEsz7lDUCxkmtKSPdTPLVeSQBVKQxkMeKtIMVXjurcttEi5HvU5mjUZLr+dS7gVtWmEVq2e4rX+GtgYNKnvXGHu5Mj/AHFyB+u6uS1CX+0r6CzhcbpXEY9snFer2lulraw28QxHEgRR7AYr2cqo6uo+hxY2paCh3JaKKK908wKKKKACiiigClb6XZW+r3mqQw7b68iihnl3Md6RlygxnAx5j9BznnOBS6tqun6NZNeavf2lhaKQGnupliQE9AWYgVcrn/G+gSeI9IjtIJra3mjnWdJpo5nMZXPKGKaJ1bnhg478c0AZ+nfELQbzxLc6SdT0uNdlu1lN9ujP27zQ3EQ/ixtA+UnOe1a7+KfD6Xl7aPrulLdWKNLdQm8jD26KMs0i5yoHcnGK5AfDOaTTdSgvtde8u75dPD3c1tl82svmZPz5O7pycjqSxrOT4R3NtfXs+n+I5bffJdTWcpF001o85YsV/wBJ8n+IjiJWI7hvmoA6nVPiT4S0+30y5fXdNnsr+8Nkl1BeQtDG4jZyXffgKAoBPPLpxzUvgjxxpXiqJ44buxi1SOa5jfT1u0kmVIp3iDleGAbaG6cbgMnqeV0z4Wahpxe6h8RxPqf9rRatHLPaTzxhktmtyjCS5aRwVcnJlyDgdBit7w/4CXSLjQ5vt6yyabc6hcsRb7PON1Iz4+8cbdwGec7R0oA7eiiigArmtX/5H/w5/wBel7/OCulrmdZ48eeGj6294v6RH+lRU2+a/Munv8n+R01FFFWQFFFFABRRRQAUUUUAYni/Sf7Y0OeBRmZP3kX+8P8AHp+NeMQXBTg5GDgg9q+gq8e8d6ONN8QvJGuLe6/eAejdx/n1rysyo3SqI9DA1NXBlK1uO2eDV7cJbaSJhng1n2VvnBXpWp5BChh9K8Vs9A1ghm8Or64Yfmuar+H+bNl/uufyPI/nWhpa79C2nqCv/oIFZug/LcXEZ9j/AE/pXt5guegpHmYV8tRoXU1w1Y1wR3rd1XjBrhPE2qTLMbDSgkmoMu5mb7lun99/6L1P0yR4dOLk7Hp3SRleLNYMcgsNOjjlv3XPzD5Yl/vN7eg6n8yMC10yONWEn76aQ7pZWHLn+g9B2q/ZWaW+8b2lmkbdLK/3pG9T/h0A4rrvCXh6TWr5IYxtQfNI+OFWutX0hD/hxaRXPMwvD3g661W6A061XcDku3Cr7k17LovgS1gjT+1XW8IGDHtxGfqO9dTpmm22m2aW1pGEjX8yfU1cFevRwUYpOerPMrYuU3aOiMGXwhoMq7W02HbjGFJUfkDXBeO/hoFhW98ORs5iyXtGc5K99hPOeOhr1uiuiVCnLoZUsTUpSUkz40vjLHf3AmtzAS/+rx0A4/pTUKkZibB9O1fSfxC8CWniCB7q2iVL8DJxx5n/ANf3r558Q6FdaTI0nlvJCDgsi/Mh9CK5Je5Lll/w59Rg8dTxEbbMped/DIMGk6fcb8Kz4r4z3BjRVkgT/WSe/ZR7+vpVxQCMqcj0ptWO+Mk9hSAW/uPUiysnEgyP7wqHJx/eX0p6vxx8y+negZ1PgaFbjXomOCI1Lg/p/WvbrQYtuPSvFfhyEGszFD/yxPH4ivarBt1sMeleRjdaljyMa/fOb1JdupSj15rifG10xlgtl6Ab2H8v616D4hhKyRzgcfdavLdeSe78QzRQRmVyQqovXpVYXV37BhEnO76GRuB4I69jXU+HPB818VnvC1ta9cfxMPp2Fb3hvwtBYKt1qO2W46hOqp/ia6GWYvwOF9BXTUrW0RdfG/ZpfeRWttaadB5NjCqKOpHU/U96HAf7wzSMwUcmqV5fxW8Zd3VFH8THArkbcmcCTk+7LvnNEuCQ6f3W6/nQs8L8rJ5TejnH61w+p+Kc7lsl3t/ffp+Armru/u7p91xKz88AHAH4Vawjnq9Dtp4SctZaHsYluIjnkirEOo84cYrx+x8QahZACK6kCj+F+R+tb9n42mGPtlpFL/tIdprOeCmttRywk1tqd5fXCyTDB4AqEH0rmH8T6fcsGRpIHxyHGR+YqeHWUf8A1c8T/Rq93B6Uox7HgYqjOFRuSZ0Qdh0NOWdx0NYg1Nv7oP0NOGpn+7XWchvLdyDuacb6Q96wRqXqtIdT/wBmgDdN5Ie5pDdOe9YX9pE/wmkfUiO2PqaANppmbqajL46msGTVQOsqD8apXWr4jJDFgOpCnFZyqwjuzSNKctkbdkkd5rpDIskax/MGGRya3/7CsJTxEUP+w7L/ACNZvhO2VLfzydzy4Ymt55RHzXzGLr+1rOS2PWowdOCiUH8K2rcq9wPpKaVPD5iGEurkD/eH+FXlvyvenf2hms7xZd5oz/7Ek5xe3PPuP8Kjk0DeD5t7dMPTcB/StQXwNBuN44qW0tmNORjf8I3Z5yzzkjv5hqzBo1nF0Rn/AN9yav7s0oPNZ8z7lXZi3KJp+oW8qIFRJFfIHoQa9SUhgCDkHkGuB1CGOaEiQcV1nhqdrjQrR3OWClCfXaSuf0r2soqayh8zgx0bpSNOiiivbPOCiiigAor54+I/iK80/wCIHifytYaGWxl0+W2tV16aCd02o0kdvZD93OXGQd2MFs810Vt8QL6HUHsZtT0Tw/avf6mBqGs+bNHIYbto1hTfOgVtvzEb8AYCoAMAA9lorw29+JepaXc3VsuoaFpkYl1mVZNU86YzPbXYjjhj3TA7nDH5VyBj5VAG2q+peMdbk8V6fcyaja+G7VNWijuzqDTSQIZdIWUJKpmRAA7FQo2gvsblgdwB71RXzd46+J13rum+L9BDWdxp0uk6kyMkCwzwtCVUK6i4kbox+/HETgEAg8enfGDU7/SB4TurLWrTRrX+2BHdXN2jGAIbebHm4kjBTcAMEgFihzxggHodFeFN8XfEAvPEi/Y9JT+zrbUZUtpZIVmiNvG7RuyC5MsivsGQIUwGBDEcnVv/AIh6/pVzNYatc6Bbt59iG1WS2kjtbSO4imfMqGbJw0IQNvQEyDOMcgHsFFfPHhvx/qHh7wXbJbX2iRJt1O/jnvIJCupzf2hOPs9uFkBViMED94fnXg8mu2sfG/iGXXrc3EOmx6VNrp0U2vkSC4T/AEcyhzJ5m3IIwV2c+ooA9RrlPEzGPxt4Pf8AhaW6iJ+sBP8A7LWnq9/q9tciPTdGW+iKA+a12sQDZPBBBPpyM9a4/wAXX/iMX3hy4l0GwjeLUlWP/iZkhi8Ui7T+64Bz156dKzqfD935l0/i+/8AI9IormjeeMe2heH/APwdTf8AyJR53jH/AJ8PD/8A4Gzf/Gq0IOlormv+Kx7/APCP/wDkagQ+Mcc33h8H0+xTH/2rQB0tFc19j8Ynk634fXPb+xpjj8ftQz+QoGneKzy3iLTQe4XSWA/DMxP6mgDpaK5r+yPEh5bxQgPcJpyAfhlif1NH9h66eX8W3gbuI7O3C/gChP60AdLXJfEiyFxoa3AHzW8gb8Dwf6VY/wCEd1ZuX8Za4Ce0dvZBf1tyf1qnq3hO8udMuo5fFOvTs0bcN9mUE444WECsq8PaU3E0pS5JqRyWkoGRa3PswMXSuJ0PQ2lHz6xq2fVZwv6BQK6ePwvC8ZMmqa27Y/5/5F/RSBXzChFu1z2Jya6Gpo+RYOvYf0P/ANasyzHk6wR2fcv5HP8AU1X0vwvZsGL3esuwzj/ia3Kjq3ZXAPTvWT4h1G6fXjpmhSIt9uHnXLLuS0VhwSO7nqq/ieOvv1Y82Gt5I8yDtW+8u+LNQuJrg6ToYR9T2hpZXGY7RD0Z/Vj/AAp36nA5rAfSotL06SOMvJI5LyzSHLyuerMfX9AOBgCu10/SbbSdP+z229izGSWWQ7pJnPV3Pdj/APWGAAKw9di3QsK+f5knyx2PVgurOIsk3zbfevdvh7pa6foKSEfvbk7yfbsP6/jXjWjWhfU0jUZZmAFfRNvEsEEcSDCooUfQDFerl0Oabn2OXHTtFR7klFFFeweWFFFFABXj/wAXYFm1Q2mjf8fcsYbUXVMraxMdqyHtvbBCj2yeAc+g+Ktbm05bew0qJLnXL7ctpA2digY3SyY5Ea5GT3JAHJFP0Tw3a6bo9xZSu93NdlpL25k+/cyMMM59OwAHCgADpWVakqseVmlKo6cro+WvEvhkaIUksNwtmHyt1P8AwL1rDinw4SQBHzwf4W/wr3S/0YSwXmlXfMsUhRSe/ofxFeN65pL2F7JbTL0JxnuPSvMw9ZzvCe6PsMJXU48r/pDFAbkcN3o25P8AdaqCO9vgHc8fY/xL/j9KvRyLKoOQc8gjvXS0dZ0vw/lEfiJVYYLxMo9+/wDSvatFlzHtPavAdCu/sOsWkz/dSQZPseDXuenOI5MA8HkV5OOVpqR5eOj71+5rXtuk0bRyDKsK5m306HTb+eQxKZpOkncj0rrFYSLg9aqXtss0ZR+COh9DXLGfI7rY4U3axiOxY5JqCadYx15pmpStYo5uPkVRneehFee6zrsl8zRwEpb/AKt9a6qcHU2NaOHlUZtaz4mjhZorbE03rn5R/jXI3l1Ney+ZcyM7dueB9BULAHrTcMv3TkehruhTjDY9alRjSWgfMPQ0oYd+D70gfsQQfepoIpJ5FjhjaR24CqMk1oajRRsXtx9K63SvBE8qrLqEn2ZDzsU5b/AV1en6Tp2ngfZrZS4/jfk/maxlXjE46mMhHSOp5xY6Fqd7g21tIVP8TjaPzNb1p4GumGby7hhPogLn+lduZWPfA9qZ9awliJPY5J42pLbQxbTwnptvgyXF1Me437R+mKtnR7NRiISKPdyf51eLAd6Y0yL1YVDrTfU5ZXnrLUzzo8RP+tlH0amto0X/AD1mP/AquPexKPvCq8mop2I/Ol7WfdiVNdiJdGg7tIfq5obSLYDlc/ViaFvHlOI1Zz6KM1YitNUuOYbC8dfUQtj+VL35eY7KPkUvsUEf3UUfhVPVol+yNtAroE8P65N93T5R/vEL/M0298H689rJutEQBSSTMnA/OqVGo/sv7g9rBbyRa8GNu0mDP90CtC+JzgVS8IxGGwhQ9QorSulyxrglvcvqZ43etPXPepNlO2cUrjGLkGrMTVEFqROKTAnBpy9aYhqeMcZqUhMoavJ5dsTXc6JbfY9ItID95YwW/wB48n9Sa4DXSfIIXrXo1jMLiyt5l6SRq4/EZr2snSvJ9ThxzfLFE9FFFe4ecFFFFABRRRQBSfSrN9ah1Zoc6hDbvapLubiJ2RmXGccmNDnGePc1doooAKKKKACiiigAooooAK5b4jJjQ7S6BwbPUbS4/KZAf0Y11Nc58RrZrrwLrkcZw62ryrj1Qbx/6DUVfgZdP40dHRUNlMLmzgnHSWNXH4jNTVZAUUUUAFFFFABRRRQAUEZGDRRQB4/po+z6jcQf885WT8jiuwtv9X9RXJ3I8rxVqaHjFy5/M5/rT9Q1K81O4l0fw/L5MsYxeX+3cLUEZ2KOjSkduig5PYH5ZQtWaPbqO8EyOfUby8vpNG8PSLHdhv8ASr0qGSzUk8Y6NIQeF6DqeMAxyaXbaNbLBZq2Avms7tueR85Z3bqWPOTW54X0630u0jtrRCsY2sWJyzsSSWYnksScknrVfXE/0lB2O9P519GoXpcvkeRzWqc3maO7zLZHHdQa53V1BRga2dIk87SIT3C7T+FZOsr8rV8q1aR7cDO8J24fxFZYH/LZT+Rr2yvIPACCTxFagj7rMfyBr1+veyxe5J+Z52PfvpeQUUUV6RwhWV4l1uHQtPE8kb3FxK4htrWLHmXEp+6ij16knoACTwDVnWNTtNH024v9RmENrAu52P6ADuScAAckkAVg+GtMu7/UT4j8QQmK+dSllZvg/YIT2/66t1Y9uFHAyQC14V0SaxNxqWryJca7fYNzKg+SNRnbDH6IuT7scseTXQUUUAcJ4/tGtL611aJf3bMI5seo+6fyyPwFcB8SNCS+tPt1oMnG4Eele46jZxahYzWtwMxSrtPt715fNaz6ZPNpV98ydY2PRlPQivFx1J0anto9T1sDXei6r8jwOQY3bx7OP61VKvBJlOQecdm/wNdZ400htN1FnQfun5/Cudtrd7i4S1jQuZDhAOufSumnUUo8y2Pp6dRTjzI0dBsp9auktrNN7HqT/CO+6vZtLDw2cUMjl5rcBGYjG4etN8F+G4PDWk75FU3soDSvjknsPwp12xhu/tIHytw4HpXk4it7aVo7I8vEV1UlZbI6G1m3oCDzVsMH4PWsK0m8qQEHMbcg1rIwYAg1xX5TkaC8sY7mBop41liYcqwzXmvibwJLCz3GkZdOphPUfT1r1OGbHDdKkeJJBleDXRSnKGtN/IqnXnSZ83yK8MhSZGRwcEEUV7dr/hiy1VT9ohCy9pF4NclZeC4dNvGlvt1xCDlAB8v/AAL/ADiu6GLg172jPRjjYON3uc54f8L3mr4lYeRad5WH3voO9d/pmm2WjxeXYxDeRhpG5Y/j/SrbTl4wqYEYHAFRkgDms6lZy2OCriJ1d9F2FZix5JNISB1qrPeJHwDk1g6pr8NuSrPuf+4vX8fSsknJ2RnCnKbskdFJcIg5NZ17q8UAy8iIP9o4rhr7Xr2cnymESHsvX86xpZixJctuPUt/jXRHDN/Eztp4FvWTOzvvFVtHnY0kp/2RgfrXM33jK9eTbBbxoP8AaYsf6VkTN8pOaqQRGa5RF5LEAV0ww8FurnZDC0o7o9r8OWEUnhgXt20NzO/IdTkL7Vu/DCwjudRvrmaJHjiUIoZQQCT/APWrP+zjSPClnZsQXWPk9M12fw1s/s3hxZSMNcSGT8Og/lRCEZYqyWiR87iJ2pyae70OqUBQAoAA6AUtFFeseUFYnjG7+y6BcBWxJN+5THXnr+ma15p4oRmaWOMersBXBa7ejWNcKJIrWtsdiBTkM3dv6VyY2t7Gk31ehvhqfPUXkM0eHyoQfbipplyTU6r5agAYFIRmvlWz2PMp+Wc04R1Z2ijaKVxlbZShDVjbRtouBEq1Yi9KZgU4cGhPUT1KepQeZGcdRXS+C5/N0OOInLwM0Z9hnI/Q1jOMjPY1Z8Kt5GrTxKf3cse4j/aB/wACa9DLavs66j30ObFR5qT8jrqKKK+mPJCiiigAooooAKKKKACiiigAooooAKKKKACoL+2S8sbi2k4SeNo2+hGP61PRQBzngW93+BdJubt1TyrULK7HAXYNrEn/AICan0LxVpOuXPkadLcmUw/aEE9nNAJI8gb0MiKHXkcrkcisnwfCw0XxDpMPkyS217dQok6lo8P86hgOq/PyPSubl8B+ILjTLu0SW00+2+zxrFYrqdzeQPMk0cit+9QGFQIyu1Aww/sMxT+BF1F7zPRb/V4LLVdM0+VJTNqDSJEygbVKIXO7n0HbNaNeT3vgXXL/AFOXUtT03w7ftLqcl6+n3F1I0BRrWOFQWMB3EFN33MdOnZtj8ONWs9Q0GVH02SWyghhnvZ3EzqEzkQxvAWQjOFZZV6AsDjFWQetUV5H/AMK+1aPwrFpMGjeFI7hZIvtV5kSSagqB8u/m2zhZCxDZYS/eYZHWsP8A4VzrZS30Oew0u8mi0V7ZNRuXfy7N2uZWR4SIuZERlwBsxjggUAe6XEqwQSSuCVjUsQOuAM1V0LU4da0TT9UtVkS3vreO5jWQAMFdQwBAJGcHsTXn83gjXvt/kRzadJpo1htW+0SzuJ23QGMoUEe3O4k53cjsO+Mfhn4h+2eGH8zRR/ZEenJ9oj2pNiAIJV3fZzI4O1tv7xBg4K9aAPYZrhIZoInWUtMxVSkTMoIUt8zAEKMA8sQCcDqQKmNeZ23w6lt7TRSsVgb22nvJLyRZHjedJYrhI0EgUsMGcdvl+YjJ66PgPwdeaJoOq6bdG109Lo7Yn0wxiaNdm0sZVhiDP6EpkdyTQBwvi+4uNS8earp2i3Hkqsii6vUw3k/KMonYyf8AoPfnArsNKs7bSdGW2soxHDGpwM5JJ5JJPJJPJJ5JNZWpaVaaP4mez06BYLWOJAiL9BkknkknJJPJJJNbEj/uUQfxsB+FfNVryxHIu57EdKSk+xb08YXHoyj8sVl+JMq6N6TH+da9iPkQ+rZ/8eFZXikZhkI7S5/lX0q0PHIPDrYtrmE/wSt+Wc1V1n7hp+ivtvrxf7wV/wBMf0pusD90xr5TER5arXme5Rd4pi/DkbvEieyuf0r0JvEuhLrP9kNrWmDVsgfYjdx+fk9P3ed36Vwfw1UHX3P92Jj+oH9aiXQtfi8UyR6XpWoWmny6w17ObuazuLFlJJaeP/l5SY8FVGFVvbmvcy5fuvmefjn+8+R6VrOqWei6ZcajqU3k2cC7pJNpbaM46AEnr2FXa8IuNB8f6p4VfSdR07U2eDw81jI82owuL28E0REi/vTyUVsO+08kHHe1qGg+MW069awt/FEVqb4S2Wmy6qJpgghCt50wvI3CM+SoSZsEZKkHFd5xnquo6Empa5Y317O0ttZDfBZ7R5fn54lb+8QMbR/Ccnk4xsV5Faab4tgOrSX+jazfau8DfYXi19k0+NTbhRCy+er7w24eYY2YsQ28feHLNbeMtKj0+311PEbWl94ggSC0ttTMVzLF9iuDJGJDeSFV3orYaftkYPAAPoaqWm6rZalNqEVlN5slhcfZbkbWXy5diPt5HPyyIcjI5+teO3Gk/Eex8PXcMMOrX93e6JPZ24j1SMPYzmeVomkd5RucRPGvmJuJMfJ/ipnifw342Vtcj0bTrzF/qk10t1a6g0Uij7JbRoxVLqDILpJyzNt2Z2EGgD2u+u7awtJru+uIba1hUvLNM4REUdSzHgD3NUfEGiwazahJD5cycxSgcqf6j2rzS88OeNb3w3rks9zqya1/YlrHYJDqflL9t+zssx+Rwud5HLfLnDDkAja0DTPENv8AEy/uriHVZdGlaZlnvL0iOPONqxRJcujL1xugjYDksTUyiprllsOMnF3RyHi/SZmSawv49l3GN0Z6hx6g9wazfhP4dH2u41K6TIhPlwg9j3Ne4+JNFt9b09op8JKmWimA5jb/AA9RXI6DbC10uNcAE/M2O5NeFi6csMnCL0Z7mHxjnSceo3UpN8gQdByaxtRlCQMD3rQuWzeSk9q4zxrqDWtjIIz+8b5V57muOlFysl1LhFzkoobpXii3W/NnKwNsTtWXPRv8K7a0uTGQCcoehr59hYwMZBkxt98eh9f8a73wv4n+yoltfEvb/wAL91rpxGE0vA762FsrwPWkYMMg1IkjL0rCtLsMiywOJIW6EGtOG4WQe9eY04vQ89o0knDcNQ0CSD5eDVQc09ZGXoa0VS+kkQ4W2Kd3pCElkBif1TofqKxb6xvUBGwSIO8fX8jXXJdcYYVJ+5kHIwa0j/cf3i52viR4Zr1/qSSPF9lntI/VlOW/HoPwrmy/rX0jLZxuD91h6EZrKvdA06ZWa4srd+OfkFdcMQ4e7yfcd1LGwgrWPAt4pjMDXrc3g3TpXLLZonsucU1PBNjn/j1T8a9dYeVtTJ51SW0WeN3W3B4/KtPwTbo/iKy+0IrwmQBvMOFHvmvXYfCNnFjbbwj/AICKux6HBFjhB9BVxo26mNXOuaLjGG/mZPie7F1OI4H81Rgbk+YY+orsrXxZa2GnW9rY2VxMYkCZYhFOB+J/SstLC3j6sKmUW0Y4GadLDxpyc73bPHqVnOKj0RPJ4q1edv3MFvAh9i7D8cgfpVWWbV7sf6RqFxj0Q7B/47inNeIn3EFQSXkjdOBW5iVpdOiDFnO9z1ZuSaztgstXgkj+VJflIHc9RWizseprOv2D3dpGpy3mbvwxXPi4qVGSfY2w7aqKx2jfNAje1Q1IhxZrn0qsZAK+UnuevEloqv5wpRKKixVieiohJTw+aQDqKM0UAOk4SrXgy2Ml3eXrE4U+Sg9+GY/+g/rVR/mWr3hGcRXd3ZMfv4nT36K38lr0Mu5frC5jnxN/ZOx1NFFFfTnkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByukZtPiDrtttAS8t4LxT6kZjb+S11VcvrhFl448O3m7at0k9g5PQ5USKPrmM/nXUVnDS68/wDglz1s/L/gBRRRWhAV5hqHjrWNE1rxSLyxhvbG21G3srNI5XMivLDEyqVSFmKnczEjcwJ2hWGDXp9Zd54d0S+ubi5vdH024uLiPyZpZbVHaSPIOxiRkrkDg8cCgDij8RNWeNEh8LlLoWd3ezR3lzLbARwOi5TfAHYMJARuRfQ461V1Txrfazc6adLthaabHrFjbzTteMk7s6pIUESoQU2uASXGcHgiu/svD2i2MQistI062iEbwhIbZEARyC64A6MQCR0OBmmnw1oRv4r46LphvYQqx3BtY/MQLjaA2MjGBjHTFAHEr8UJxpX9oS6JEIbjTn1OySO/DvJGsiJtlGweUx8xTxuHDDOQa6zwvrt1qt3q9lqNjFZX2mzJFIsNwZ42DxrIpDFFPRsEbeo6mrUPhrQoWvDDoumRm8/4+SlrGPP5z8/Hzc885rQitbeGeeaGCKOachppFQBpCAACx74AA57CgDzzxgAvix29Y0qpeapbWU0K3EgVip2j1NXPGox4oPvEp/nXlHiO+N/r8zK37uJhEnPYdT/OvAUb4ty7M9/DUPb0lF7WParaaPfHGrA42jg9+T/SszxK6/Zp2J4BJP5CvMNL1e9tJGkSVi0m5iSemBgU3WfE1/d2LRMwVW3bsd+a9f26tqc7ymfNaL0O70441FGHR4R+h/8Ar1Nq3MLVx3gjWZrq+S3mOfKjwp711+pnMLV4WN1qtm8aLo+5LoW/hiP+J1cH0hP/AKEK9PrzP4YD/ia3Z9Iv616ZXsZf/BR5mN/inmafF6ykgWeLwz4keJ7KbUY2CWw328LBZJBmfICkjg4JyMA5rcj+IOkStOI4b1li1G00wsEUBpLhI3jYZbO3Eq5zgjng1ei8F6BDbxQR2GIorCbTUXzpDi3lZWkT73cqvPUY4IqtN8PfDU2qQag9hKLmGSCZAt5OsZkhAWJ2jD7GdVUAMQTgYziu05DH0z4r6VqVi1zZ6ZqcjNcx2cFuslq008z7iE2CYmIgKWIm8vA/EVRvviUNA8Qa5J4kiubOxjt9OW1sJmtkkSeZroMDJ5nljIhU5aTaAvUEkV0jfDzw4/nNPbX1xPKYz9puNTupZ4/LYsnlytIXjwWY/Iw6mppPAnh+VJRLbXcksqwK1w9/cNP+5Z2jYTF96splk+YMDhsE4wKALfgzxPp/i/QYtW0kt9nd3iKsyMVdGKsMozKeRwVYgjBBNblVNK0+HS7GO0tnuniTOGubmS4kOTnmSRmY9e546dKt0AFFFFAFLW5fK0i9cdRC2PrjiuUtxttFFdN4kGdDvMf8881zVv8ANbgV4ebP34ryPRwfwN+Zi3w2XcnuM15V8QLlv7RgjP3ACT9Sa9b1qIhBKvUcGvHfHXOsgMOGjH865cFrJHsYRfvDAHDbh909a1fDuk3Wp6ilnaKTGfmL44iHfPt6VR0qzmvbuO0t0Mkshwo/qa9o8PaTB4e01YYvmuGGXc9WP+HpXoVaigjrxWIVGNluwtdNg0m1jt7UkMo5bruPfNTLcBf9YDGf7w5X/wCtQzFiSx5qhfXSxo2WCqoyzHoBXmTipu55Kcm9dTbiumUA/eX1FWobtH4PBryefxXcxXpOnkLAvG1hnf7mtzTfGlpLhb6Jrd/768r/APWqZ4SaV7HTLDTSvY9EDA9DTgfQ1z9rqMNwge1nSVf9k1aS8YHDA1zODRg0bCyMO9VtRumRFX+8cmoVuc1U1CUGVMn+Gu3L05V4pnNitKbsSC7YU77c2KzzKg/iFMa4iXq4r6c8gvteOe5pjXDms57+Bf4s1C+qRD7oJoA0y7HvTSfU1kHU3dsRrk+g5q9b6brN8oMFlOVPcrsH5nFJtIdmTPKi/eYCq0t/GvTmtGLwPrM+DK9tAD13OWI/IVbT4bu5BuNT/BYs/wBRWcqjXwxb/rzLjBP4nY5G41XLFYzk+i1H4dka61KR5j8ykKB6V6Db/DuwjA3XVw3+6FH+NYus+HLbw7qtq1nJMy3IJbzCDggjpgD1rzca68qbclZHdhvYqVo6s2JXxCqiqDk5q6RlAfaq0i14N7natCuSaBmpNtOC07jGqTUyMaaAKkVaQEimpF5NRDinxn5hSsIklG1aq+Hi934mgMZwIdzsf9nGP5kVPqTbYTj0p/w8jDXWozEfMoRAfqWJ/kK7sFT5sRFGFaVqTZ21FFFfUHjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvxIBh8PRaiqhn0y7gvQD/dVwH/APHGauqqjrtiuqaLf2D/AHbmB4T/AMCUj+tUvBF6dQ8IaPcsSZGtY1kz1DqNrD/voGs1pP1LesPQ26KKK0ICiiigAooooAKKKKAPK/ifdfYdSurnPzJbrt/3jkD9a8hskJG5uwJJ9zXofxznP9rW9uv/AC0VWP0H/wCv9K4W1TMJ/wBpto/lXlRhac5d2fV4CPLh4vuTKu1tv92IfqQf6VmXQP2cf8C/ma2mUM9w/wBF/nWTej/R1/3T/M1ozrg9S94Efb4hA9Y/8K9G1BvkIrzLwg4TxFCT3TH8q9Jv+VP0ry8Wv3hx4tfvDZ+GA/4mV5/1zH869Jrzf4Xc6je+0Y/nXpFexgP4KPn8Z/FYUUVk2Wpt/bV1pV4AtwiefAw6TQk4z9VPBH0PfA7G7HMlcvX10lnbNNJ90FR+bAf1qxWD45kEXhe7kJwEaJvykWt6kn7zQ7e7cKKKKokKKKKAIL+H7RY3EA6yRsn5jFcTp0mYUJ645rva4O4i+xaxd2x4Ut5if7rc/wCNePm0HyxqLod2ClvEluIg6srDKsMGvJfiXossTQ3EaswU7QwHr0r15CGGDVe8tUmjMcq5U8j2PYivIpVHSkprY9SjVdOSZxHgbQF0bTxd3aD7dMvIPWMf3f8AGtyRy7EmnXSSwOFm5Xorjof8DVeaTYPc10yqe01M5ylOTlLdkV1PtBVTzXnviHWPtsz21s2IYz83+2fX6elafi7V9gaytm+c/wCtYen92uQdd4Dx/fHT39q6aFL7TPQwlCy55DsZ5HBoBycHrRGwkXcowehU/wAquabp0+p3SW9qhZz1PZfc11PTc7m0ldjdPiupLlI7DzDMx4CHBr07SrO9tLNReXjSzHkggYHtT9F0a20S12x4kuWHzyEcn/61W2JJyTXDXmp6WPIxGJ9q7R2GC4uk/hicfQiqmoTTTgZhCkdw1S3N2kKkk8+lc/qmuJCD5smD2ReSaypXhNShuYezdVcrVyZy4Pb86rXNzFbpvuJ44l9WOK5q+124lyIAIl9erVzGotLISzSM7HqXOT+delGpXn8UrG9LKYfaO6stcsr/AFWCxtDLNJK4Tcq4UfnXXaxpUOnBVTMj4yWb/CuE+EelRXetC4kfbNbneE6hq9I8VMTISeCB0qcU3Cle7u33MK9GlTrqnTWy1Ow+HVvH/wAI1bztEnnOzkvtGfvEf0rqqxfBkPkeGLBT3Td+ZJ/rW1XoYdWpR9EeLWd6kvUKKKK2MwrivHrB9S0uIfeUOx+hK4/ka7WvOr24/tbxDPcIcwx/uoz6qvf8Tk/jXn5lUUaLj3OvBxvU5uxex+6X6VA65qwx4A9KYRXzL3PURXCUuypSKMUXGRbaeq08LTgMUgG7eKVB8wpaO+aEINQXdHgelL8Ppgl/qNsfvOqyL+BIP8xUk2GRay7eb+ydZgvDxEG2yf7p4P5dfwruwtVU66k9jGpDnpOJ6PRRRX1J4wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct4CLW8et6a+B9h1OcIvpHIRMv8A6M/SuprlLDbZ/ErVoADjULCC7z23Rs0bfo0dZz0kmaQ1i0dXRRRWhmFFFFABRRRQAUUUyaRYYnkkOERSzH0AoA+d/ivqAv8Ax1eCM5S1VYR7kDJ/UkfhWXbRhWhQdFIP5CqE9wdS1i6vHGDcXDSkemSWrTtf9b9EJ/OvPbu7n2UYezpxh2QqcwOf7zn9MCsi8/1I/wB2tocWie+T+ZNY95zCuP7g/lSZdPcZ4dbZrtp78V6feH5DXlOlNs1exb3H8q9TuTmP8K83GL3kc2MXvo3fhWc6lqHtGP516TXmvwp/5Cepf9c1/nXpVevgP4CPnMZ/FYVgeL9Kub62t73Siq6xp8nnWpY4D8YaJj/dYcfXB7Vv0V1yipKzOeMnF3Rw3ijWbfXPhnqV9bB0xGPNhcYeGRXG5GHYgiu5rzv4oeH549E1vVdElSF5rVxf27fcnQL98ekigcHuODXe2E4ubG3nHSWNX/MZrKDfO1Lsv1NZpcice7/QnooorYxCiiigArnPGNkzwR38AzJb/fA7xnr+XX866OkIDAggEHqDWdakqsHCXUunN05KSOGhkEiK6ng1YVg4w3WquqWb6Jf7QCbCZv3Tf3D/AHD/AE9vpUisCAVPFfJVKcqE3CR7MWpxUkOmgypVlDKeoNc5relXQtZn0sq0u07Ec9D7V08cuOG5FPeJXGUNOOnvQGpcr1PnO5iuLe6kivUdJwcsHHJ96YDtbPY/pXuutaJZarEUvYAWH3XHDL9DXnWteBr20kLWZFxbk9ejKPcV6VLGQnpLRnq0sVGektDm9O0y41LUI47IfvGOHz93b6n6V6rpOmW+i2YhhAaZuXfuTVfw7p9vpGnqkBEkzcvJ3Jq8xycmpq1ubRHDicQ6r5VsIzd2NZ99fLErAMBjqT0FR6lerGD8wUDqfSuC1fVjeSNFESsIP4t7/Ss6dNzYqFB1GWtW1xpZGW1Y47yev0rAbJYtk5PrzQ3twaYW7Hg13wgoKyPXp0401aI2RtvUflVOSRZDgEGrMp4qvFbvc3CpFE0rnoqruNaLQ0PUPg5YeULvUCSMDYBjj860/EVw01wwHVmAAq/4Y8y08L2lrJF5dyFwygYwO2fekNhF9pS4lcmRG3KOwIrkxc1O0I7I+enNyrSqP0R6tYQfZrG3g/55xqn5DFOluYIR+9miTH95wK81utWmcHz7mZ89i5x+VZFxqGDhABnpxzXT9f8AswicCwjesmervrOnJ968g/Bs1WfxLpCAlr1MDqdrH+leVAXVweFKqf73+FXrbSejTZcj+92/CuinOvPVpJGM40o6Jts6vxB4ys2sbiDTFnuHkjKiVF2hcjtnBrH8NzQz2+YRjtj0qo0SRgqoGKreF38nWbmEfdOGA+tcuaUeaCqdjbBzs3A6pwQxzTaluRhhVctXz8lZ2PQWqH0AYqPcKXdUjH0UzdS7qAHUUm4UZFADxnGKztSia6kt7RPvzyCMe2ep/Ac1pJ0NQaef+Kr00N0y+Prsat6EFOpGL6siUuWLa6HdqAqhR0AxS0UV9geGFFFFABRRRQAV4zoPi3xENUtLvU7vUm0u41G/si0sVp9nYo0ohSLYPODDy+WcbeD1yK9mrDTw54b025n1RNF0i1uAHeW7W0jR8EEuWcDPPOeaAOW0Dx5e32kC6h01Z7Ww0y2vr+e4vNs/7y3Ex2IkO2Q47/uwWyABjiCw+JWpXdnHIPDE0clxNaxWzTPPDDJ57EDMkluvK4BO1WGGGCa19IfwzrGp6Oq+G4YbxdPF3ZPcWUQaC3VgiBSMlPvAhRjAPODxVy/8AeGLu1+zJoun2sDXEVzMltaxItwYySqyDbhl5PB9TQBgyfEa8S3SWTQ4ooorie1vLp7qVraB4pAhxJHA5IOchnVF4IJzXS+KddvtLvtIsdK06C+u9RkkRRPdG3RNiFySwRz0B7VZfwp4dkWzWTQdJZbIYtg1nGRBzn5OPl554xzT9UvbC31zRba6tvNvLl5Ray+WreUVjLMcnlcqCOOtAHDWvxQum0mLULvQY4Yrmygv7YJfby0ck6RHf+7G0jzA3G4EDqK0dZ8fXVpcapHY6KLqHT702k9yZpfLjAhjlLv5UMjLzIV+6QNpJI6V1p0LSDbC2Ol2H2cQG1EX2dNohP8AyzxjGzgfL0qk3g3wu1ulu3hvRTAjmRYzYxbVYgAsBtwDhVGfQD0oA5PX/F2par4S8Xz6RbW0NjYWN1Gb+PUGE6yrbFw0aLH93cVwxdTj5sdBU+jeP7i88QxaTBol7cWsU62U16qTsUfywxdsRGMJkgZMu7nO2rerz+E49W1O41Dw9bTXNm8Nld3jWUTlY54woJY/MY9rhG9Aem3JrpH8O6K+qx6m+j6c2pRgBLs2qGVcDAw+MjA460AVtX8U6fpN6bW6t9ZklCht1ro93cpg/wC3FEy59s5rj9b8a6XH4v8ADt8lp4gWPFxaSltAv1JDqHUAGHLHMXQZPJPQGvTa5b4hhotN029Q4+xanazN/umQRt+khqKnw3Lp/FbuJ/wnmkf8+fiT/wAJzUf/AIxR/wAJ5pH/AD5+JP8AwnNR/wDjFdVRVkHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xWD45+IOlReEdVEdv4gSSSBolaXQb6Jct8v3mhAHXua9Irzf47XZh8KW1uv/AC8XShvoFY/zxUzdotnRhYe0rRj5ngOn63aowzDqXCnpp1weSf8Ac9q6TSLuK9iuJoVuFVSI8TQPCemejgHvUFioAb6gfkP/AK9aUfFs59WP6ACuHQ+qlzX1f9feEx2wIPRBWRdfcUf7I/lWpdf6s+y/0rLuevsFFJl0yhZttv7I/wC0BXqkp/cj6CvKIzi4tD6OP516oWzAp9VFefjN0YYxao6T4WLjUtRP/TNf516QOledfC7/AJCGojv5a/zNeiJytergP4CPmsZ/FYtFFFdhzGf4itxdeH9TtyMia1ljI+qEVX8GzC48I6JMDnfYwN/5DFa7qHRlYZBGDXMfDEMvgXSonOWgV4CfdJGT/wBlrN/GvQtfA/U6iiiitCAooooAKKKKAK99aQ31q9vcpviccj09x71wl3BcaJefZ7ol4GP7qbHDD0PvXodQX1pBfWzwXUYeJuoP8x6GuTF4SOIj5nRQruk/I4xHVxlTmpUcqaoatpV5oUhkjLT2OeHxyns3+PSnWt7HOowRmvmatGdCXLJHqxlGavHVGoGVxhhUbw915FQg+lSJIVpc6l8QuVrYpXOnwysWKlJP7ycH8fWsq+sLuND5WJl9uG/KuoWRWHzClMcb9ODVxTXwsObujw7xfNfRTbHt5o7ZT8xKEZ9/pXPNh1DKfcEV9GTWSyqQ6q6+jDNYV94R0q5yZLFFJ7x/Kf0rsp4rkVpRO6jjIRXLY8NEmDtfhv51JFFJcyrFBG0kjdFUZJr0/UPhzpcisVmuYgOeoOP0qPTtDbS4vKsgg7GRk+dvqc/pXZSqe3TdNF1sypUl5nO6P4KZ9suqy+WnXykPP4nt+FdbZQ6fpUfl2NvGnqQOT9T1NH2C5f78p/AVKmjNJje8jfjj+VU8JWn8TR5VXMVU3bGTakQPmYD0FVxc3E3EMbH3PArZg0SKPkqoq7Hb28I5wa0hl8V8bucksY/sqxgQ2FxP/rWPPZa1bTSY4VyyhfU9zVs3SJwiiq0tw7967adKFP4Ucs6kp/EywfJhGEAzVeWdm4B4qs8qqMs1UJ9Q+YJCCzE4AHc1oQW7qdY0OTzTPCEZn1Ce7I+U/Kv0FaOm+FLq5tJ77WQ0ECRs6wnh3wM8+g/X6VN4fRIbSMKMDbXk5rVcYxh3O7BQveRpXj/MKpPJjvUly+4k1SkPNeC3d3PRirIlM3vSedVViaaGNOwy6JqcJqog09SaVgLol96eslU1JqVOtKwGhC2QRVO/drae2vU+9byB+O47j8sipoiag1U/6I4PQinGTi010Fa+jPREZXRWQgqwyCO4pazfDbM2gacX6+Qn8q0q+yi+ZJngyVm0FFFFUIKKKKACsrxXpsmseF9Y0yBxHLe2c1sjn+EuhUH9a1aKAPM9X8Nal4ssbe+t0SwMmlpayWd2rxEutxHI8TgDiNhGyEjOQ2QGHWCw+GjTXsD6vYaINNW4upxpUO6W3txJFEiKgZAD80bOflUAtkCvU6KAPBNe8JarZnStOutOh1zUms9Nt0uzBcSmyaJwJDFKYjGA2CSWeNsckHgH1TxZ4Xh8R6voUl9b2l1p1lJM9xb3K7hJujKrhSCDgkHmunooA8Wi+FeuC40eS7vbe7+yW1tDuW6WN7ZomJPlO9tI+DwflaPPIORyFl+GXiSfWNTvRdaRZveW13DI9piLzzI6sm5Y4EbGFIYtJIfmJB5IPtFFAHk1z4QvtO8LeK7GHSNNs38QNFa21npIaSK3zGI2kY+WgAHLliB0xycZ9ZoooAK5r4lQPP4D1wRnDx2zTA+hT5//AGWulrL8VJ5vhfWIyM7rOZfzQ1M1eLRUHaSZoW0ontopR0kQN+YzUlZXhKY3PhXRpz1lsoX/ADjBrVpxd1cUlZ2CiiimIKKKKACvIPj5dAyaLZjrmSU/oB/WvX68M+OUofxfYRg58u0BI9Ms3+FZVn7jPQyuN8Sn2ucZY8oD6kn9a0IubVB6lv51Rsx8sfsorSt1/cQe4B/M1yI+imV7/wC7J9DWbcD5nHoorTvjlZPxrMuv9fIP9kf0pMumZLHa0Tf3X/rXqcRzZxH1QV5VccRk+jGvT7N92m25PdBXBjNkzHGLZnY/C4f6dqJ/2F/ma9Erzz4XD/TNRP8AsL/M16HXqYD+Aj5nF/xWFFFFdhzBXLfD8NDba1aMeLbVrlFHorMJB+kldTXMeHc2/i/xVa/wvJb3ij/fi2H9YjWcviiy4/DJHTk4ooorQgKKKKACiiigAooooAQgMCGGQeoNcprPhKOR2n0phby9TEfuH6en8q6yisqtGFVcs0XTqSpu8WeZefc2E3kX8TRuOm7v9D3q9FcxyDg13N1bQXcRjuYklQ9nXNcj4g8Ni0gkuNLLkqCfIY5B9geo/WvFxGVyjeVN3R6NLFxnpLRkQYHoaeGI71w+neMLCWbyJZzbTg4Mc428+meldDFqeQCMOvqpzXlypyg9UdsoOO6NtZ2FP+0HvWXHfxN14qdZkboRQqk0ZuCH310AqoQOeapGRT2FQ6k4My88BapmUD+Kvp8ArUIvueTiH+8Zo+cq9hTWu8fdrMe5jHVqge/iXvXYYGnJcu3eoXfuxrIl1I/wCn2dnqurNiytpZF6bgMKPqx4oAty3cUfVhmqUl+8rBIEZmPAAGSa6rSvh+7EPq11gf8APOHk/ix/wrstL0ew0tALK2jjPd8ZY/ieaAPP9I8HalqJWXUG+yQHnDcufw7fjXd6L4f0/SFH2WEGXHMr/M5/Ht+FatFAGV4qn8jw/enu8flD6t8v9a5CwQpbj2GK6PxupfTLcfwi4Ut9MN/XFYqAGEbegr5/Npt1VHsj1MGrU7+ZXlqq45q1J3qpIea8pHYMIphFOzRiqAaBTxSAUtAEi1NGOagXrViMUmBbgXNU9bz9jfHWtK1XEZY1navIBEQe9O1rEp3Z3WihRo1gE+75EePptFXKo6JG0Wj2UcgIZYVBB7cdKvV9jD4UeHP4mFFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUPEGP7B1Ld0+zS5/74NX6yvFb+X4W1lz/DZzN/44amWzKjuiv4Cz/wAIP4ez/wBA+3/9FrW7WX4Vh+z+GNHhP/LOzhT8kArUoh8KCesmFFFFUSFFFFABXz38X5RL4/uwDnyoET/x3P8AWvoSvmr4iMz+PdcJ/wCeoUf98qKwr/Cetk6vWb8v8itaLgN7YFaEA2x249EWqVvwsje/9KvRfdh9dq/yrmR7U9yjeniT8azZz+/b3T/CtG8/j/Gs2YYmX/rn/hSZrAyrkfunH+0a9H0lt+j2h/6ZivObj7sg/wBr+leg+H23aJa/7g/lXFjPhRnjPhR3/wALj/peoj/ZT+Zr0KuA+FyHz9Sf2Qfzrv69LAfwI/11Pl8X/FYUUUV2HMFcs262+JyHIEV9pJH1eGUH+Uxrqa5XxdttfEfhPUGJAW9ezP0miYD/AMeRKzqbJ+aNKe7XkzqqKKK0MwooooAKKKKACiiigAooooAKRlDKQwyKWigDxP4r+A1e8OoWICCY5bsA3rXIaf4Z8UWDx/Yi2G7xyAr+Ir6UvbWG9tZLe4QPFINpFeVavb3vhjUfKdna1Y/upezD0PuK8zExdHW14v8AA9vCY+coezdm13MzS7bxPsQ3sFqw6NuYqw/Ktxbe7jQNNEEPfbIDj+VUri/lkj3xMSp61nSalNjaznFebOVCS0hZ+pbdSTvoaGpGQhfLDl8cjbWQ/wBpLbdrZ9KkN/IwwtWLWN3+Zs5rWlj50YKEUtDGeEjOXM2QRadcyn5mVR7n/CpLjTBBCXklLNjOAMVc83y2CKck1HrMuLbk8kYqJY+vN729BxwlOPS5tfDDT7e8uL6e5gSYRbVTzFDAE56A/SvTAAoAAAA7CuW+G9g1l4cSRxiS5cyn6dB/L9a6qvbwqkqS5tzzMQ17R8uwUUUV0GIUUUUAQXttHeWktvMMxyDB9vQj3HWuIsVkiaa2nwZYmKN747/j1rvq4GGf7TqV5cr9yWQlT7dB+gFeRmsY8sZdTuwTfvLoRTcZqjL1rQnHJqjKvNeEj0kV8808NxTMUoqhjs81ItRipFpASKKsRdRUKVPD94UhM0GOy3HvUfh+zXUdadp13Q2yhtp6FieM/kTTrj/VqKu+CcFtRPfzFH4YP/1678HBTxEU+hy1pONJtHUUUUV9KeSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXN/Ei4+zeAtfkHU2ckf/fQ2/wBa6SuX+JW1/Cctu3/Lzc20AHrunQEflmoq/A/Qun8a9To7OLybSCL+5Gq/kMVLRRVkBRRRQAUUUUAFfM3jd9/jnWz1/wBKK/kQK+ma+X/Ep3+MdYOc5vn/APQzWGI2R7OTL95J+RJAT9nkPuf5VfiODH7AfyqhD/x6OfdqtqcFPoP5VzI9eRUu+Q1ZshzLGfWL+grRuT1rOk/1kP8A1z/pSNYGbP0k+v8ASu58KndocHsK4ebrJ+Fdv4RIOiRD0zXHi/gIxfwI9R+GK4i1BvVkH867euL+GYxaXx9XX+RrtK9LA/wI/wBdT5XFfxWFFFFdZzhXM/EdSvhS4u0Xc9hLDfLjqPKkV2x/wENXTVU1ezXUdJvbJyAtzA8JJ9GUj+tTNc0WioPlkmWkYOoZTlSMg+tLWB4CvW1DwbpE8hzL9nWOQ/7afI36qa36cXzJMUlytoKKKKYgooooAKKKKACiiigAooooAKq6lYW2pWj215GJIm7HqD6j0NWqKTSasxptO6PJNc8N3/h+RpYN1xYk8MByv+8KxL3VtOtrUz3qkMSFSNFLPIx6Kqjkk1654m16DRoIo/Je81C6JjtLGLl527+yqP4nPCjr2B47/hWgvJG1XUriNNdlJIWFf9HtlP8AyzjGM/Vzy3oBgDyq+Xa81P7j0KWNurT+85zRLK98ma61JI45JSDHaR4YQL6Fv4mPfsOg9TbYzPlY4yPwqxdaD4i0piFgNzGOjxfN+nWqJXX7pvKjsbkE9cRGvMlRnzaxO2M4taMHMdoN0rAyelTaFpV14k1BQAUs4z+8kI4A9B71teHfAk8sy3GuNtQc+SGyW+pHSvRLe3itoUit41jjThVUYAruw2XuXvVNEctfGKOkNWOgiSCGOKIbUjUKo9AKfRRXt7HlhRRRQAUUUUAI2SpA4OOK850V2AlglG2WFzG49wcV6PXn+ox/ZvF98qjCyhZB9SBn9c15WbQvTU+zO7BS95xH3C4Y1RlFaVwM4qjKK8DqeiioVpNpqUilAplEOMUqnmpGWmqvNAiWOrUC5YVDGvFXLcYyaXUTEupNsbE9hWv4FUvp9xcMMCWUhfcDv+ZP5Vz+qsVtJMdcV2PhaHyfD1go/iiD/wDfXzf1r08qhzVXN9Dkxj5adu5qUUUV9CeWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXLeO0E8nhu3P8Ay01iBseuxXk/9krqa5jxDmbxl4Vt/wCFGuboj/di2D/0bWdT4ben5l0/i+/8jp6KKK0ICiiigAooooAK+W9bOfFuqZ/5/ZP/AEJq+pK+WtbH/FWar/1+y/8AoTVz4jZHtZN8U/QmgJNm/wDwKrUh2+X/AMB/pVW05s2+rVLM3yRH3X+lc57DWoy56ms4/fhJ/uf0rQueprPcY8j6Y/nUmkdjOl+/J9B/Wuz8G86Oo9Cf5muNl/1z/wC7/Wuz8DLu0xh/tn+ZrlxWtMzxf8M9d+G64026Pcyj+VddXM+Ao/L0ybPeT+grpq9PCK1GKPk8Q71GFFFFdJiFFFFAHK+B82l14h0pgq/ZNReSNR0EcwEq/qzD8K6quW2iw+JG4LtTVdPxn+9JA/8A8TJ+ldTWdPRW7F1NXfuFFFFaEBRRRQAUUUyaTyoZJNrvsUttQZY4HQD1oAfRXAeHPiLFqME93qMWl2dhDbfaZWh1ITz23IAjnh2KyOc9Bu5GM9M7d5400iy04X94urQWnzlpJNIu1EYXG5nzFlF5+82AecHg4AOkornB420A6o2ni8kM6zC2LfZZfKEpQOE83bs3FSCBu5zxWfr/AI7sYfD8N7olxFc3FzBFeWyyxSBXgaaOMv2x/rBwSD7daAOzrA8R+IGsLiLTNKtxf67cruhtdxVI0zgyysAdiD16seFBPSaDxLps2uf2Pvuor87yiT2c0KyhMbjG7oFcDI+6Twc9Kl0LQ7PRVuTah5Lm6kMtzczHdLO3Ys3sOABgAcAAUAVfDfh5dLlmv7+c3+t3SgXF66hSQORHGv8ABGOyj6kkkmt6iigAoxRRQAUUUUAFFFFABRRRQAUUUUAFcn4w0+RbqLVIQWWNNkwHYA5Dfqa6ykdVdGVgCrDBB7isa9FVoOEjSlUdOXMjhgwljDDpiqswqbTwFEkY+6jsg+gJFVZry1OqSaekwa7SMTPGATtUnAJPQZ7A8nBx0NfJODTfke0miJutC1Iy80zFIoU8ilReaQCpkWgCRBVmMYXnvUMY5FTy8L+FJdxMoXYluZltLVDJNLwqj+Z9BXf2EH2Wxt7fOfKjWPPrgYrnvBsSvNe3J5YERD27n+Y/Kuor6LLKCp0vadWeZjKnNLk7BRRRXpnGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXLzlpviZZoVOy30mZwf9p5Yx/JDXUVELeIXTXGwecUEZbvtBJx+ZNTKN7FRlYloooqiQooooAKKKKACvmDxOnl+MtYCjj7bJ/M19P15Z4m8Em61m7u41/1spk/Osa0XJKx6eWV40Zy5uqPMrT/AI9T/vNTpG/0eI+yH+VdYfB9zDGVCn7xPSqUnhi8+zKvlnIUDp6Vz8jR7SxFNu9zn7k/M31rPf7sR9G/9mNdm/he8djiM8+1EXgm9lUDYepPT3zS5GUsTTS1ZwEw/fN/un+deh/DKwkuNHmlC5UTFf0B/rV+1+HE8km6QYH0r0Pwf4dTRNMe24O6QyfmAP6UnhnUVmceNx9N0+WDuzQ8N25t7BlIwS2f0Fa1MiQImBT67aceSKifPSlzO4UUUVZIUUUUAZGt6c91faTeQHE1lcFj7xspVh+oP4Vr0UUkrO427qwUUUUxBRRRQAUyePzoJIizoHUruRtrDI6g9j70+igDirr4e2eoAnWdX1jU3W3NvBJcPEr24LK+5SkaktujQ5fd933Oa/iX4Z2XiaKNdd1nVb2RIpIPMljtCdr46DyNqMMcOoVhnrXe0UAcDo/w/wDI1a9n1HUbiWw/tOO/tbFCnlEpBFGjynyw5cFCcBtvCnGc0tr8L9LgiWJtT1eaCK1Wygikki2wQrMkoVcRgnDRqMsSccE9Md7RQBxWi/DjSdJ8VjxBBc3kl6HmcCVYf+WudwZxGJHAzxvdtoGBxXa0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFclqmr3mu6hPovhiXy0iby7/VVwVtT3jj7NNj8EyCcnCkA5PxNfXNv4nu9G8OyQvdSt5k1w/wAyWO7khh/E/OVT3ycDrpaVo9rpNiYrXe7uxkmnlbdJM56u7dz/ACGAMAAV0s3hi1t/DyadpaeU0DecjuxZpJDkszseWZsnJPOTmubW9eGT7PeRPDMOocYr53MKLpSfKvdf5nq4aaqLV6okdKYUq0oEgypzQYz6V5Z1XKypUqpUgSpUjxyadmwbGxrt5NR3bkRnapZjwqjkknoBSzzJEpZyAKveH7WW7vorl4njt4SWBdcbzjAx+ec1tQoyrTUIrQipNU4uTNfwzp0mnabsuMefI3mOAchT6fkK1qKK+shBU4qMdkeLKTm3JhRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIVB6ilooAjMEZ6qPypptYT/yzX8qmooHdkItoh/yzX8qeIkHRQPwp9FAXYmBS4oooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGN4j8QQ6GbGNrW6vLu+m8i2trbYHkYKWPLsqjAUnlh7ZrOs/HWky6zaaRfebpep3MDTJbX7RxPxJs243HLEgkbcggEg1c8XaJca7Zw28M2nCJXLSQahp4vIZRjABQspBHYhh+Nc1ZfDma0iiii1hPKezubG6T7KQDFM+8iACT9yF6KDvAFAHWW3ifQLqCSa11zS5oY5BE8kd3Gyq56KSDwTg8U218VeHru7itbXXtJnupRujhjvI2dxtDZCg5PykH6HNcdpHwwNn5P2zUorp4ZrRxIY7h2aOBiwjbzbiRcHPG0KBk8HOBsy+CI5Ly6na8XM+tR6uR5PICQpH5Wd3+yTu7bulAG+de0cW6XB1WwEDwfaVkNym1osgeYDnG3JA3dORVax8XeG7+5gt7HxBpFzcTkiKKG9jdpCOoUBsn8K4u3+F10NO+wXWvRS2sWlHSbZVsNrJGZUcM58w72+TBwFB64HOd+48Exy6re3q3aobnVbXUwgg+55EaJ5ed3OdhOe27oe4BoeJLbWNUuItNsJW0/TpE3Xd/G484jOPKiH8LHu56Dpzyutpen2mlafBZadbx29pCu2ONBgAf1Pqepq1RQAVWvrK3voTFdRLIh9RyPoe1WaKTSasxptao87uY20XVWs3ffHjdGx6lTWlHNFKBng10Os6Pa6tCq3KkSJ9yVeGT/AD6VyF5oer6ecRILyIdHj4b8V/wzXg4rAzpycqavE9OlXjUSUnZmltjHORUFzMqqecAVkxNqUjbI7K5L/wDXMj+datj4Yvb1lfVJfIh6+VGcsfqegrlhhqtV8sY2NZThT1kyz4Xsk1CV764UNHG22JT0yOrV1tQ2ltDaW6QW0YjiQYVR2qavosNQVCmoI8utUdSTkFFFFbmQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Lateral view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 510px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH+AfwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKK8M+JGt3Vl418QLHq/wBmktbeymtYTrUtvITli6wWo+Sd3ChcNjkjrmttfHF7DfNbPeaXodtLe3wN/rAkljBjdAsIDTKFchicbgAFO1fQA9Yorx9viZrf9v6tZi10xYrMXoWGWSJJsQxu0coX7R5jq5QHAiA2tkMQMlq/ErVm067mgv8Aw1dxxR2khvoyscETS+Zvg/eXCq8qhFOPMThuQOhAPYqK878V65f3fwiGtaffrbXDrBM10Ld4QE81dx2iQlVxnPzkbc84OayNP+I2rXHjS30hX0a6tWuIoRLG8MX2qN0BM8O66LFcnhVjkztI3Z4AB63RXjtr8R/EUWhWd/qEekSfbtKj1FDFBJGloGniiZpMyMXRRLvONuApHuKeg+L7nTpNZki1nQVhvtcnMmtTQt9iGyztiqqol6v0B8w/dOM5AoA9uoryb/hPvEc1rPfR22m21vZ6fp97PbTwSmSQ3Ejqyq29dgwmQSpPPI9PWaACiiigAoorzH4i+NdQ0XxPawaa1x9g06JLzUxDZPOHjeQLsZ1RhFtjWWTJK52qM4zQB6dRXB33ju8i0rxFrFppNpPpGjGeNpGvys0zxLk4QREBSehL5xzjkUzWPHeoaVc6glzolsI9Ngiurz/iYYdYpXZU8tfLw74Q5GQAcAM1AHf0V56/jrWJNaSxsfD9nJHPqVxplvLLqbRlpIUZ2ZlELbVKo3Qk5GMd6pab8SJ72VXg052uLyOwSC1mulWGOWc3AOXEZYAeSfmO7PygKpzkA9PorgtN8dX+r3sGnaXo9o2p4uDcpcagY4U8mXym8uRYmMmW/wBlcDrg8Vzx+IVz4b0jVJHh/taaHUNUmeKSecyxwRXLqu3ZDIAgA25dkUYAzjoAevUVwFz8Qd13PpsOnuuogtIEE6gi18jzRc8qe5CbcH5u+KNH8a6hqFjczWWlwz2+nWkMt3Lc3vlzM72yzYREhIbhgN3yAnOBxQB39FeX+IPG0uof2FbWSvavcPo9+8kNwc7Li6VWhOAMjaOT3DdKa3xY2T6gn9kxzww2Ul7bTwTzeXcokqIQGkgQfxg5QuOCM0AepUVW0+S6ltVe/git5yTmOKUygDPHzFV5xjIxwcjJ6mzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr4k8WtpMmtLbWIu10jS31K6YzeXg7XMcY+U5LeW+T/CADg5rUg8R6RJdx2L6nYR6k0QmNmblPOVSu7OzOcY5zjpzWDrvh28v9T8S2iZXT/EGlfZWugFb7LKFdMlSwLBlkBGO6HJGRVUfD+YXhUatF/Zhvf7RMP2P9953leX/rd+NnfG3OON2KAN6XX/DGs6TqKHWtKutPWEreNHeoVjjcEZdlb5QRnnIq1pWqaVPoZuNBu7S+sbZCitazrKnyL93cCecY964fVvh29voWmizuHubrStOtLOGOK2jPnSQSpIHKvIqkEqcoWHU4bNbvgLSdVg0LV/7fVYb7U72a5KhFXYrqqjKq7gH5c4Dt9TQBc8K+NNG1/wAOwaomoafE32SK6u4Rdo5s96Btsh4245GSB0qzJ4u8NxWEN9L4h0dLKZikVw17EI5GHUK27BI7gVyt38MIbnQ7TTm1No/s2k22miSKIoWeGVJBL8rggFk5UHPJwwPNV7j4Z6jJpbWcHiM23nyzS3flrebbkuiIGYm7MhZQmOXKEHlOKAOn8TeM9L0SbTbYXVlcX99d21vHa/alWUpNKqeYq8lgA27gc46jrWh4d1n+1hqEUsAtrywumtbiEPvAIAZWBwMhkZGHA647Vxtp8Nruz+ywwa5D9iS4066nR7EtLLJaLEo2v5nyqwhHBDYJOD2rqPCen3dvd67qOoxGCfUr0zLAWVjHEkaRJkqSMkR7jgnG7HagDoaKxtO16G5vNXtLmM2tzpr/ALxHbO6IjKSg/wB1gD9CrDtWtDIssSSJna6hhn0NFwH0UUUAFUPJsPt11b/Y1867j8y4f7MdkygbMO+3axxxtJzjtir9eXeLfD8viXxhqqaVaNA/9mxwXFxcW0kMN063EcnktJtBkVkRlJXcAGxz0oA7K48OeG/t6eb4f057m4haHzf7OVsxhQpRn24C7cAKSMjgZxUmv2ugfbtMutbsbGa8adbezmntRK6SHLAK20lfuk54HFefzfDfVptP1CKFdI09bqHUY4rG2kcwWv2i3jiRUOwcbkZ2wowWOAafqXwu/wBJd7DTNBmtFnsrhLC4BSKR40lSbdiNgC+9Du2sW289qAPTU0ywSVJUsbVZY5XuEcRKCsjAhnBxwxBIJ6kE1Wfw7oj2s1s+j6c1tMiRyRG1Qo6qSVVhjBALMQD0yfWtG3XZBGnlpHtUDYn3V46DgcfgKfQBj3Xhfw/d2VrZ3Wh6VPaWuRbwSWkbJDnrsUjC/hSX3hbw/fgC+0LSrna7yDzrON8M5y7cjqxJJPc9a2aKAKn9mWBnMxsbXzjB9lL+Uu7yc58vOPuf7PSqreHNEa9trxtG003dsgjgnNqm+JQMBVbGVAHQCtWigDHs/C3h+xJNloWlW5LI58qzjT5lbcp4HUNyD2PNNh8J+HYJZ5INA0iOS4DLM6WcYMgJBIYheckAnPcCtqigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimyOscbPIwVFBLMTgADvQB5n8YYGlvNHGmRTzaiwkN3DbkBptPTDzIfUkhAvuSB1NejadeW2oWFveWEqTWk8ayRSJ91kIyCPwrmfBKtq15f+KLhSBf4hsVYcpaITtPtvJL/AEK03Sv+KX8TtpD/AC6PqrvPp5J4hn5aWD2DcyKP98dhWcNfe7/kaT093t+Z2FFFFaGYUUUUAFYngnUbjVPC9hdXzK95taK4ZV2gyoxRzjt8ymtuuY8DYhPiCwHH2PV7jj087bcf+16AOnooooAKKKRm2jJoAWiozKopPOHtU88R8rJaKiWUFwD36VLTUlLYGrBRRRTEFFFFABRWJ4d1SS9utXsbkbbnT7oxH/ajYB42/ENj/gJrbpRfMrobTTswooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA88+IHxDTwt4n0rTRNpyQsqz332mULIInlWJfKG4ZYZdzwfljPqK1L/x1a2lvrV4NK1SbTNJ85bi9jEPll4hl0UNIHJB+XO3Ge9bkug6ZM2rNNaiQ6rGIrzczHzUClAvXgYJ4GOpPU5rLfwJ4feG7hNtdC2u42iuLdb+4WKUMoUlow+0sQBlsbu+c80AVL7x9a2U9ylxo+sKlpGs93JsixbROzBJHHmbsNtZsAFgB8yr0qKb4hwLqv2C30DW7mRryawikiWAJNNECzqu6UEDapOWAHB5zxW1rPhPRdZvxeajaPJPsWN9s8kaSqrFlWRFYLIASSA4IGTU0XhzSorqC5jtcTQXct9G3mP8ALNKrK7YzjkOwx0GeAKAOZsviPY3TmSC3vZ1nisza2aW6pM8k5m+Tc0u0keS2c7Qu0/M2eJJ/iPYoqCLR9ZuLjybmee3jSEPbrbuqSh90gGQWH3S2e2eK018C+HUt2hjsGjVlhUMlzKrp5TO0ZVw25SDI/wAykH5utT2ng/QrRFSCx24tp7QkzSMzRzMHl3MWyzMygljlvegDZsrqK9sre6tyTDPGsqEjBKsMjj6GpqitLaKztIba2TZBCixxrknCgYAyeegrnNQtte0i/mv9IlfVbCVjJNplw4EiE9TbyHgf9c349GXpQB1FFZeg69p+uwyPYSnzYW2T28qmOaB/7roeVP8APqMitSgArkPGkr6xfW3hWzdgbxfO1CRTzFag8jPYufkHtuPat7xDq9voWkXGoXe4xxLwi8tIx4VFHckkAfWs7wZpNxZWtxf6ttbWdScT3ZByI+MJEp/uovH1ye9Zz958i+fp/wAE0h7q538vX/gG/DGkMSRRIEjRQqqowFA4AFZ/iXR4td0iaylkaFyRJDcIBvglU7kkX3VgD+nQ1p0VoZmH4R1iXVtOkjv41h1aykNtfQqeFlAB3L/ssCHU+jDvmtyuR8WI+g6nF4qtVYwxoINViQcvbAkiX6xElv8AcLjriusjdJY1kiZXRgGVlOQQehBoAdRRRQAVzGk/6N8QPENuT8tza2l4vuf3kTfkI4/zFdPXJazd2+m/EHRrieeOKO5sLq2cu4UblaJ0/QS/nSbsNK51tFZy65pTHC6jaE/9dV/xq9DNHMm+GRJF9VYEUlJPZg4tbofSMAQQehpaKoRg3dy1vctFKTxyD6iljuQ4+U0zxjbO2mtdwAmW3+Ygd17/AJda53SdSWQKwPBrxcXOVGduh6FGCqQujoZbltp2nDDkVqaVfJf23mLw6na6+hrnrhsEMv3TVK3vn0nUhdDJtZPlnUen976j/Gs8NjfZ1OWezKqYfnjeO53dFNjdZEV0YMrDIIPBFOr3jzQooooA5K9/4lXxEsbnpb6xbNaSennRZeMn3KmQfgK62ub+IFlNd+GpprJc39g6X1t6mSI7sfiAV/4FW1pd9Dqem2t9atuguYllQ/7LDI/nWcdJOPzNJaxUvkWqKKK0MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorN1zW7DRIoH1CWUGeTyoo4YJJ5JGwThY41ZmwAScDgCpdH1S01iwS90+RpLdyygvG0bAqSCCrAMCCCCCAaALtFFFABRRUN1cJbIjSLKwd1jHlxNIcsQBkKDgZPLHgDkkDmgCaiiqeoalaafLYxXcvlvez/ZrcbSd8mxn28Dj5UY5OBx9KALlFFFABRRRQBheIPDVrq08d7FLLYavCu2HULYhZUH91s8OnqjAj6Hms+HxJdaLKlr4yjhtgzBItVhyLSYngB88wsfRjtJ6MeldbXHeLp5Nfvj4T09iFljDapcL/AMsLc/8ALMf7cnIHoMn0qZS5UVGPM7Eem/8AFX+Il1Rvm0HS5CtiO1zcDhp/dV5VffJ9K7WuMj0LUvCiq3hP/S9JX72jXEv+rH/TvI33f9xsr6FK3tA1+w1xJfscjJcwELcWsymOaBvR0PI9j0PUEjmiEeXfcJS5ttjVoooqiRGUOpVwGUjBBGQRXI+Fmbw9q8vhe4J+ybWuNJkboYMjdBn1jJGP9gr/AHTW3qmuWGmnZPNvm7Qxjc/5dvxxXF+LLnUfEVnF/Z8Uen3VrKLmzuZPmeOVc4PpgglWHOVYiuari6VHSUtTaFCpNXSPR2ZUUs5CqOpJwBWXceIdJt22yX8O70Q7z+ma4LQZl8RadHd30k7zhjHPBM+TDKpw6EdOD+YwRwa2VsbOJcBFFcM8zle0I/edEcJFK8n9xJ4q8U27WMMelXyq00mx2GVcDBPGeefWuH1+wtVl0S+/1hTUI1kZmySJFaLB/wCBSL+OK3tYsLS5iaKWNHjPY/z9q4PxZbX2maNcfZmluraMpMik5kjaN1def4hlR7iuCrXlXqLmdvyO2nSjCFonop0y3YYEaj6UyPTGtpRJZzSW8g7ocVn2HiFVK+Zgg85HeultNVtbhBu2k1ywTT+KzLm2ulyW217U7ZQLqCK7UfxKdjfl0/lVyLxbZdLmG6gPfKbh+lVZHtWHymqjqm75RxXYswr0tHJM5vq9OfSx0MXiDSJxt+2xDPBEmV/nXn2sQ2+kaoRaXEMlpLl4yjhtvqpx6VvGND1RfyqM2luTkwxn6rUV8f7ePLOJdGgqUrxZXs9Xt5IQrzR/99VO00EqFfMQgj1prWFo33raE/8AABUD6PYNnEAQ+qMV/lXE2mdGhreFNRNlcnTbl827nNu5P3T/AHP8K7KvMJdFIH+j3kyeivhh/jXS6fr91bQJFqFsZyowZoCMn3KnH869vA4+Cj7Oq9tjgxOGbfPA6qisC98UafBp008co85F+SGQFGZuwwff0ri21TV7smR9VlRjztiwqj6Cu2tjqVK3W/Y56WFnUv09T1M1x/gxxouqaj4XnO1YXa70/P8AHbOclR/uOSp9itYVvrOu2jArfC4UfwzIDn8ev61sE2fjO3jimaTTtasz5tvPC3zwt03If4lPQqeCOvY1FPGU67XJv+ZcsNKknzbHa0VzHh7XLxdSOh+I444tWVDJDNFxFexjq6Z6MONyduoyK6eu2MlJXRyyi4uzCiiiqJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5rxto93q8NiLOzsbpoJTJie8ms5EO0gNHNECyHk545B7Vx134J8VNZTFbzT7y7u9KutLl+13Up+zpLJuTbJ5ZaXap25YKTwfau18V69eaTeaLZ6Zp8N7d6ncvboJrkwIm2J5CxYI56Ie1cfF8UrtNK+333h+KFJdOfUYFS/3llSaOJ1f92NvMgII3ZA5x0oAzrLwTqV142v520+ytxaajYTLq0hcTlIrWAPHAPLwyMVZSd4HUFTipdS+GN8/hPStMtLbQ5LpA4v5Z40Z5TgiNkkkgl+7lhjaDg4BWui1zx3dWV9qttYaL9sTTrlLeafzpCiBoRIXcRRSOoBO3hSO5Kiqt54w1DWtD8RyaPaWiWNjZyCS+XUGEokNsJQ0SCL5l+dcMWQnkgccgzHsvh9rFnd6ReTRaXPcWdhDb3NzJILiSQxw7D5Svb70JPQrKAepUk4qh4O+HmrNpPh27NlpujGK30xpraN38y4aGaOV5JwY12y7VKhfmwSQWxjHRaD8Qbm41az0iHRb67hia3tbm9VJ3ZXeJGLnERj2DcMlpAepxjGe91fU7XSLT7TfNKsG4KWjheTGe5CgkD3PAoEecW/w4v9PtoJdKGjQ6k1pqEF3LJGXS5MzhohINv7xVAIIbpngGsix+FWpww7rqy8P3ix6nFex6fO6+QyCB4pEJjtUVclkbiLkoM5PNer6P4h0bWsjSdVsrxh1WCdWZfqoOR+NalAHlTeBNdN0Ldxpj6XFd6ldKy3ksc8v2pJQE4iIj2mTG4FuOQARg9L8NPDd54Z0q6tLyHTYFeffFHZImQu1R87pFEHbIPOwHGAS3WuwooAKKKz9d1a10PS57+/crDEOijLOx4VVHdicAD1NJtJXY0m3ZFHxbrj6TbQ29hELnWL1jDZW5PDNjl29EUck/h3qXwtoaaFppiaU3F5M5mu7p/vTyn7zH0HYDsABVDwnpN01zNr+vIBrF4u1Yc5FnBnKwr792Pc+wFdOSB1qIrmfO/kXJqK5F8xaxPEHhuz1iWK63y2eqQAiC/tiFmi9s9GX1RgVPpTtR8R6fZMYxIZ5x/yyh+Y/iegrn73WdW1AFYSljCf7p3P+fb8KwrY2jR+J6l08NUn0shZfGMvhiQWnjbyUGMQ6lbD9zN/vpkmFvrlD2btS3mtX+sDbaBrOzP8QP7xx9ew+n51Ss9IibzDcYnMgIcyfNuB65z1qTSNIsfD0U6WUksdo5DJbM+6OH1EYPKg/wB3OB2Ary62PnWi1H3UdkMPGm+7Ft7KK2GFQbjyWPUmpWbFZuoayociLn3rEub67nY7XIHtXluDbO1JvcNXnHh/XBq0RA0+9Kw36joj9I5/bsje20/w1sS3q85cfnWCukzaxFLblZLpJFKOiqWBB4IPasvS7KTS3vdI1a7tku7GMSQfaLtUNxCc7cHoXGCrD1AP8QrpjQnUjdLYi8Yys3udPLexn/lov51XluIHRld1ORXLx6j9pbbbwWZc9FNzuP5AVZQaiR8sFknvhm/rWfJbc25bEESrb3b2anEbAyQZ9P4lH06/Q0ou7m3JAzx6VFeaDc6hcpc3ly5kj/1flDYE+la2gWMYvBa6vfOkcmBHMyAhW9G6cH1q4rmdkEmkrlaLX7tAMZNaEHiS543jNdgvw+Unm6j2+ojP+NTj4fQAY+2n/v0P8a6f7PrP7P5HM8XR7nLx+KE/5aLirKeJbU9Titeb4bwv92/wfeH/AOvVR/hk4OU1CM/WMj+tS8tq/wAv4oPrVF9SBNftm78Vai1m0Yjn9arP8OL5B+7urdvqWH9KwfEmh33hy2jmvIJHgZtvmQHeFPv3FZSwdSmruJcatKbsmdxFeWci9f1qcJBIP3cmPrXkSavCpG26aM+kgK/zra07W7hQCrrKnqpzWLj5FOn2Z31xYiVCskaSp6EZrIm0GzY/IskJ/wCmbEfpUen+JBwHJU+9bceoW10uW25PcVNl0dibzjuY9voywybvtEzj0YikvIZLSaK7tG2zwncp/ofY1veQrjMcgP1rn9SfxAlxLHbaZpM1uDhHl1GRGYepUQMB+ZpxU0+ZBzp6M6PxDAfEvhSLUNMwmqWh+12bd0mTqh9jyp9Qa3tC1KLWNFsdRt+I7qFZQP7uRnB9x0rgfBt94qglvLSDSNEcZEoD6tKoXPBxi2Oe3pTvAN14qt9LvdPttG0R0sL+4g/eatKm3LlwoxbHIAcAHjI7CvpqFTnUZ91r6o8qrDlvHs/wZ6XRXNfbPGP/AEAvD/8A4Opv/kSj7Z4x/wCgF4f/APB1N/8AIldRznS0VyPxDvL208JxTGWayVp4Fv5rIl3t4C4ErI2AcAZ+bbkDJwO3F32oaDa+I9AuvD+uXeq21tdzyybruTUEiIsLk/u3ZiWJwcqHPIA4oA9iorxvw/8AFLVL6DV7qRdOurDSzaXNxPBEATays6ysFjnmAZNofls4DAqDirl7421q1ii1Kezt4pZ9MN2iOZglvE93GiPKm/B2RPvchQeCAVGaAPWKK8X1fxdd6Zq99rdhfaTr0yaVBH9qsEC2yK12ylmBmIwoOTmRR6lRk16B8Otfu/Efh972/FmZFuHiWS0lidJFGCGxHLKqnnBXeTx70AdRRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQzWtvPNBNNBFJLbsXhd0BaNipUlSehKkjI7Eiqv9iaV5Sxf2ZY+UsL2wT7OmBExBaPGPukgEr0OBWhRQBgN4M8Ltai2bw3optg28RGxiKBsYzjbjOOM+lWbjw1oVzereXGi6ZLdrH5Ine1jZwm0rtDEZ27SRjpgkVrUUAZT+HNDk1GDUH0bTWv4AqxXJtUMsYX7oVsZGO2OlatFFAGXq/h7RtZx/a2lWN4wxhp4Fdlx0wSMj8Kyz4Oht+dG1fWtLI6LFeGeMfSObeoHsAK6iigDl/s3i+y/wBRf6Rq0fZLqB7WT8ZELr+UYo/4STU7TjV/C+pRqOsti6Xcf5KRIf8AviuoooA5uDxx4blk8uTV7e0nwW8m+zayYHX5JQrfpWdoccni7VofEF4jLo9qxOlW7DHmHoblh79EHYc9TTNYRfG+sSaMqh/D1hKP7QkxkXMw5EC/7I4Ln6L61onwNoUTFtMt59JcnOdMuJLVc+6IQh+hBrL+I/JGv8NebNzVL6HTbGW6uDiOMdupPYD3ripLjUteJNw7W1oekEZwSP8AaPf+VZHjXT9btb2xsLbxFLdw4M/l6lbo/Q4A3RiMnv1z+NMtNc13T1/0vRIbpB/Hp92pY/8AAJQmPoGNeXjq8nP2cXZdTsw1NRhz21Z0cOlxW0WEUL9BUMoWPqcViXHxA0qMEX/2rT3HUXlu8aj/AIHjYfwas298XWFxEXtpo50P8Ubhh+YryqlPXRHZTbe5vXerrbIdrDNc9ea09020sSM9BVTSrHUPFVyU06ErCD88z8Kv4/0rprtdJ8DKtvZxrqWvsu4tL9yAH+I+nsOp9hzXTQwkpq70Q3NKXLFXkU49LmSyN5qs0OlaeOs10dpP+6vUms+91uytcLoemveNnBu78Hb9UhGCf+BY+hrHu7m51Vhd6pJLf3eWBZlyFGTwi9FGPT8ar6PbSXDi3torqe7clhbxnOwe+eg9yQK7oUYQ+FG6o6c1R/5f1/Vie7v73XoJEuL+4lt1+QjeYYVPoqJgE/gfrXP67auhtWtEs4ry3DSRyJ8nmYGGQg9Nw474OD2r03SvBcdpZ/aPE2ox28CtvaGF9gG45w0h5J/3QPrUp8VeFdDLpoumLPKPuzRptP4yN8xrrjRk9Wc1XHUYJwgr+miOBtLWHXNMW50vSLu4SRSVkS2dn3DtvxwwPHXgiujsrfX47eJW8P6k7hQGYooycc9TWO/j/UdH1q6ewtobfT9VmDtG5aTy7kjBYcjG/Az/ALQz/Ea9F8GXeqa1Z3N1qepTLslCNDAsa7QQMEkgnv8ApU1cDCp8TOWWZTkrWOezqsSk3Gh6lGo6n7OWA/75zWbd39tM5hlBjl/uSKVb8jzXout/bNJ0i7voNRdhAhk2XCrIr47ZAUgnt15pdDv4vFuhRS6pYWrsz+VJA6hgCOcjPTINc8sqj9mRMce/tROd8IeMW0wpY6q7PY9I5urRex9V/lXp8MqTRJJE6yRuMqynII9jXm2ufDyJ0mm8P3BtmTk21wS0Z+h+8v6j2rldG8Xah4I1M2GrwSwxH5mt5T8pH96Nuh/Dj1rSnVqYb3K2q7hOlTxHvUt+x7tRXP6T4w0HVLRbi21K3CnqjuFZT6EGry67pTNgaja595QK71Vg9mjidOa3RpVDd28N3byQXMayQyDayMOCKfHIkqB43V0PRlOQafVbojY8g8WeHpPD9yJVTz9MkOFcjJT/AGW/oe9U7Xw5p2phXt0EMhHDRHYf0r2W7toby2kt7mNZIZF2ujDgivKNb0u68JagrJvk02Rv3cvdf9lvf3714mNwfs/fp7HrYbE+0XJLcybrw5q1ju+zTpdIP+Wc64b8GH9az01SSxcC/t7qzYdW270/Mf4V6Vpt5FqduvzKJAOvrTLy0RkdJY1Jx3Fea9Gr7PqdKqdHucpY6+ZlH2a5hnH+wwJrSTULlsbkODWJq3h+yuYndLWJbheQwGCfbiptH8PW91pouLee8RV4aMXD8H863xOEdBq+qZFKvCqrrQ7bwYsj6tLKVIUQkN9SRj+Rqz4W/ceLfF1r2NxBdAf78Kg/rGayPAUiaZqstgNwiuRuUsxJ3j3PqP5VrP8A6D8TY2PEeqaaUHvJC+f/AEGU/lXq4G3sYtdGcOJT9pJPsdZRRRXpHCFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcz4y1K6U2uiaNJs1bUiVWUc/ZoR/rJj9AcD1YiujnljghkmmcJFGpd2Y4CgDJJrlfA0MmoPeeJ7xGWfU8C2RhzFaL/q19i2S5929qzm7+6uppBW959Df0TS7XRdLt9PsI/Lt4F2rk5JPdie5JySe5NXqKbLIsUbSSMFRQWZj0A9atJJWIbbdzy/4tXLWes6fMO8LLwf8Aa/8Ar1xM3iKXZhSc1v8Aihn8UahcXZVhAo8u3XoQo7/UnmuRbw/KHO53Civm8ROFSrKSPdoRcKai9yG41mWTO45/Guk8EfDC38RSpquuWiQ2Z5RUHlyze+4YIX+dVvAnh6LVPFENvIm+3izLNnuo7ficCvYvF3iKDw3pqMsYlupf3dtbg43EDqfRR3P07kV2YKgmvaS2Rjiasm1SgrtnP67ocvhHw7dXfh/XdUtI7dP3VpMyXMTMSAoPmKX6kdH/ADrye1XWf7RkjvJ7S6EqmeS9wyOSTjLJzls8YBFb+ta1rWt2siXupMIpHBEUcarGCrAjjGcAgdTnin+CfD11rcbanrpFho+3kqxzMqk5wf4V9W/L1rtlJ1HaKNKNKOEg51Zav+rDvCfh7UNZ3os3kaXEDuu8YMmPvKingn1boPc8Vr6h4r0rw3BLpvhOBJpc4kuc5Un1Y9ZG9849KwvF/i6bVoxpek/6No0Q2KiKFMgHTp0X2/Oudt7bAGBXRTpKHqebicVOu+y7E+oXl7q90Z9SuZLiQ9Nx4H0HQVXkCoD2A/Wr4g2oeOaZYwrJdeZKQIoj37t/9atDlCPSIbmwl/tFCRMhUIDgqPUHse+fWp9LuNR06COR7x0vEXa80LFd4HQn3I5I9c1akuYnc/OuB0GarIhupyT/AKmM8/7R9PoKALL3up6wU/tG9uJ4VO5I5G4z/eI9a6Pw7qb6LO+6My2c2BNGOvB4Ye9YkJCtmn38kktnIltOYJiPlkChtp+h60AesWOqadqGTBcRMW+6WcbkHoQec57UzXdFs/ElgbbUYUnUtlHAw0LDoynnB/T618+3uvTWL+VrkCRt/Dcxcwt7nPMf48e5rU0rUr+1kE1pfTw5GR5chCkfToaTSkrMabi7o7eIf2DcjT9Qgj37d0M0cYVZ09QOzDoR2+hFXI73T7q4Ft8pmZd4Ur1A61X06+/4TLSpdKvTHHrEQ820uB8oLL3x69iB1BrlNHuXl8XWiXEZiuIkmSaNuqMuAw/OvnMbg/YyvHZnsYat7WOu6OzFrPYS+fps0kHchDwfqOhrqdA183TpbX4VLhvuSLwsnt7H2rPt5EGnuwQyHaSFXGW9hnA/OuGutZ1CCbcfDesRjOVPm2mQex/19LDYipRas7rsKpTjVumte57XUF5awXttJb3USywyDayMOCK5XSvF2pXtlHKvhDXZGHyuUmssbh1xm4Bq5/wkeqf9CX4g/wC/1h/8k19GmpxutmeQ04u3VHHa5oF94XuGurIyXGmZzkctF7N7e9aulazDfwqJiM461tnxFqZBB8F6+Qe3nWH/AMk1yWuade3ErXOk+ENfsrk8lBLY+Wx+guePwrzK+AablS+476eKUlarv3Ll3YMpeWJ1ePOeD0qj4Tl+z69d2T/6q4Xco9//ANdYyQeNIQVfwrqTZ9Li1P8AKao4pdf0rWLK61HwxqqbyVTbNaksfT/XcfjW2Khegm91YxoP940up0upxSW1yk8PEsLh1+oNbXjaYP4f07xJaAl9LmS9IHUxH5Zl/wC+Gb/vmuav9Y1CXeT4V1oZ9ZbP/wCP1Z8LeIb2Sxu9In8J61cxsG+RZbP7jcMDuuB69vWuDL5OMpUm99tVudWI1ip9vyPTY3WSNZI2DIwDKR0INOrzfwH4l1WHQV0ubwtrlzdaU5spWSazGNv3M7rgHOwpyMj0Jro/+Ej1T/oS/EH/AH+sP/kmvci+ZJnmyjyux0tFYmmazf3l4sNx4a1ewjIJM9zJasi8dCI5mbnpwK4DSdX07dJc6xruq/8ACWxX0o/slL6RC5V28uFbYEqYmUL8+05zndVEnrVFeQ2PxI1i4gt/s02halLO1gGe1ikVLV7idY2gl+dvnAJIPBGDlOmZtR+Iup6b42tdDMljqDfaY7S4ijtBbybmj3bkDXLOVztwfKK8435HIB6xRXk1t8Q7+XQbG9bWvDKzXc8MVyvkvt0YOrsftIM2ScqIxkRDcefSoX+IOppZx6mYLQv9gkbzwZhblRfJALjy93+r2Hzem7bxuAzQB6/RXAfCO7N8vi25N9Z6h5mtsftVmmyGX/RbflBvfj/gRrv6ACiiigAooooAKKKKACiiigAoorzz4h2Jn8RafNqunS6loa2U8ccYsXvoYLsldkktunzSLtBAwODnlc5AB3xuYBdi1M8X2koZRDvG8oDjdt64yQM1LXhllF4m03TlvdD0RrW7i02eGFIrSWJFQ368rHJ5jIxiy4jO4joFONtbeiXPjXUxp9vcanqFrDJNdmS6jsMShFjjMSv59rGM7y/IjAI45IJAB6xUN5dW9lay3N5PFb20Sl5JZXCIijqSTwBXlFnrvjWY6ZJdx6rBfSRWDJZx6YDbz7wv2kzyFCYmUl+N6Y2jhs4rD8Ut4mufBl9pM1rrFtDNptx5FvpukBhczm4mBjlxEfLGwRkY2FtxO4mgD2/U9SsdJs3u9UvLaytUIDTXMqxoCTgZZiB1qyjK6hkIZWGQQcgiuN+IumXup3vhNbGe9gWLVg80lrEj+UvkTYkbejAANgZIx8/rgjmLPWPGMiXIkn1SK6NncNdCfSCYLKcOBELcpFumBBbp5vAB46EA9aorxu417xcNIsZo38R+YJZklhWwzPcAbNrI5sdir94BZI4iSc78Ctbw9rnii6+Iwtp7bVo9DdrpZEvLf5Ytp/dlXW3RQDg4xLLkEZweoB6dRRXNSeL7a1kddU0vWrAKSN8li8sf13w71A9yRQB0tFY+l+KNC1aQR6brFhcTZwYknUyA+hXOQfYitigDkfHjNqUmneGoGIbVJCboqeVtUwZPpu+VP+BGusRFjRURQqKAAAMAD0rkvB3/ABN9b1nxE/zRSSfYLI/9MIiQzD/ek3H6AV19Z09bz7/kaT0tHt+YVx3jLUGu3OlWrYTg3Lj07J/jXQ65fGw095EwZm+SMHux/wAOv4V5rqd2thasN5aV8lmPUk9TXn5jiXBeyju/yOnB0eZ876EU2oW9pMlujKDnAq5qluraYbhB1HNebX900l4su7ndXpVrMLjwycnnbmvIjBLc9Od1Zk/wktkiTV7+UhVDLHuPAAALE/qK4zWtXm8Sa1c6mZ1S1Y+XbKELMkQPHfAJ+8frjtV1NYS28JXekwPi5v7plcA8rCFXefx4X8T6VgMbj7VI1vbiVXZI1RWwzyHAAUfitevSl+5jFDoUbTlVl10RteFNAm1zVDYB2awgHmTznglSSRH7MTnnsOfSrPxC8SjUHXR9KPl6ZbYRtp4cjjaP9lcY9/yrc8QSJ4O8FxadDg6ndsweYd3P33HfAHyj8K84tYhgDHSu+lT5F5nk4zEe2npstv8AMLaDoSKv/JBEZJSFQdSaQlIIjJIcKKt6bpxu2W6vwRGDmOI9vc+9anIQW8V3qH/HrF5MPeSQcn6Crtt4btUX/SpXmPpnirc10xGy2ACjjdj+VV1gaQ5kYsT6nNAFg6JpJGBbp+FUbjQ5rXMulzEqOTC5yD9Kne0xyowfarVhLJHKscjFlbgE9jQBkQTCZM4KupwynqpqDUL4WkeAN0zfdX+pqfXR9h1fzEXIuF+6O7CuYuGkF9IZjls8mgCVA0jM8p3M/XPeqn9mS2bF9HlWAHk20mTC30HVD/u8exq5G+Oe1Tq64B3CgBui681tqdsZVex1GNw0cch4cj+4w4b6Dn1Ars/GS29v4j0TxVajZYagPIuP9lyuNx/LB/3K4m5jjv4jbywC4RuqEZGf8a6XVdI1jw98Oxa3k8N7ZyS74tOuCTcxPwwEb87+Oqt0B+8Olc+KpKrScWdGGm41Fbqdtpd6kEnk3Bxjp7iptZe1khbaQeK8g8NeNreZzYyRXLxRcLvX99B/ssOpA/zmusbVbKS33G+hKezfN+XXNfNShKPutHscqb5kd14E1OCK7msJpkSSVRJEjHBYjIOP0rua8M0TT5tTuJr2ZHjjICQK3BCjnJ9CTXZaV4kv9JKwakr3lqOBIP8AWIP/AGb+depg8dCCVKfTqcWJwrlJzgeg1R1qO8k0ycaZIsd6q7oS4ypYchW9j0P1p2manZ6nD5tlOkq9wPvL7EdRVyvXupLRnm2cXqZfhrWItd0aC+hRombKSwv96GRTh0b3BBFR+K7B9Q0WZIE33MZEsQ77lPQfUZH41jgf8I947wPl03X8nHaO8Rf03oPzT3rsKi3tIuEvRlv3JKUfU4W0nW+sVmUYdfkkU8FSPWqUM/8AZutW110QNtf/AHTwf8fwrW1O2+w+JpWQYgvo959N44P5jBqnqVoHhO4ZNfNzpyoVtOh6sJqcNdmaB/4lHxHB6W2uWuPb7RD/AIxt/wCOV1tcR4nE114Jt9TtlL32kOl7GB1YxffX/gSbh+NdjZ3MV5aQ3NuweGZFkRh3UjIP5Gvo6Uk9uuv3nl1Fon8vuJqzNW8QaNo8scer6tp9hJKMot1cpEX5xwGIzWnXBeM/C+ra74nZrGe2s7CfR5rC4uJrcTn55FyqL5i7WwCdxDDjpWxkdRc+ItEtZJo7nWNNhkhDGVZLpFKbQpbcCeMB0Jz0DD1FRz+KvD1vp8F/Pr2kxWM5Kw3D3kaxyEdQrE4J+lc9/wAK9ii0vU7W1vgk1zqFvqEE0kAfyzAkIjSQbh5i5hyeV++cYPNRWfgXUbDVhrVlrVmNake4ed5tOL27Cby8hIhKGQjyl53nOTnOaAOrXxDorX8tiur6cb2JDLJbi5TzEQDJYrnIGOc1V/4TLwv9i+2f8JJov2TzPK8/7dFs34zt3bsZwQcVyafDALq97cvfwXVtcS3c6293HcyBJLhHV/lFysZX94wI8sEqcbs/NT3+HuqtpscH/CRp9pild4Lgw3Ra1VkVdsLfavMAypJDu6nIG0AYoA9FjkSWNJInV43AZWU5DA9CDTqitY2htoopJWmdECtI+MuQOpx3NS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGfqui6VrCbNW02yvkxjFzAsg/8AHga4rxp4c0/QvD88vh9r/TtQndLa1jtL6VIzLIwVf3W7ZxnP3egNei1yWp/8Tb4g6ZZfettJga/mHbzXzHED7geY35VFRtKy6l01rd9CLSfDOu6DptrZaN4iiltreMRpFqNgknA7BojGfxOT65q3/aHiu0H+l6FYXyj+Kwvtrn/gEqqB/wB9munoqkraIlu+rPLPE/jSB79I9Q07V9OECcrcWhcBz6vFvQcY/irh9R12w1WQiyvrecn+GOQEj6jqK7/XJ993ev8A3pWH5HH9K4HW9Os792+12sE//XSMN/Ovmq1SNStKTPboQcIJIw7tdq5967uxvo7bw0ZJ32xqmWPtXm+paNa2wH2Z7m3PpFMwUf8AASSv6VW1i61H7JHZW+pmeCIBnWeFTluy5Tb061Uaam0kzojCVR2sbel/ablb7VIxGHkPyxuDkRr6H8Sce1d98NtMN7ryTPmSHT08wn1lckA/gNx/KvN9P1DU7FEtJdMSZ4VAxaz5c++1gB/49XeaD4ks/D3w/vbiez1Sxu7wu8TyWcnlHdhU/eKCgwBnBPrXq0KeqXREY6vy0ml10/r5Gb4z1Qaz4muZI2JtYD5MAzn5QeT+JyaqWyYHNZGk3tldti2uoJj3CSBj+Val2ziJYYf9dKdi+3qa7z54s6dB/aN75r/8e0Bwo/vN61p3s5kbyYzhR97H8qURrp1hHDFjdjA+tMs4ueeaAJreE4GRV2KMCoxgCnq+KALAjUjpUM0ABjYcYdf51LGc0twDsT/rov8AMUAYPi8HdYsgHmeZgE9Kwr3TLi5YMzwq3qAea6Pxan73TVPVpf6GoJVwaAMGDQZW4e4AH+ytaln4fjXG7dIf9qrtsMsBW/bqqRFj2FAE3grQYjqH2mREENuwChh8pfrz9Ov5VyXiHVJNX1GTVf3jxq4t7aFef3ROAQP7xI3H647CvRZS2n+Ab24TCzfZJpMkd2Xg5/EV5YN9p9miaNpCw2RNDyCQPTscetcuIlsj1ssprWfXb/M56TTLS48S3PnJJFKVWRZUzHJGTwcH8OnQ9812OnLPpYSTVLQanZY/4/LWL99GP+mkQ+8P9pP++R1q34S8ML4h1LU1uZPIuoreJoWVtwX5nyG9e3TpU93bah4du1hvoyg6JIOUf6H+nWvJxNOaXNa8f6+46qkouo4p6nUaRd2V9Yx3OmTw3Fq4+WSJgwP5d/atL7LDdJhgA3rXDfYra7uWvtMuX0vVH5eaAApMf+msZ+V/rw3owq/b+JZ9MkSHxNAlnuIVL6ElrWQ9sseYz7Px6Ma4IxV9NfLqZyut9DTudGmtrgT2jvDMvSSM4Naml+J723kWHVoPNToJ4hhvxX/Cp4L0MoyQyEZBHOamWGC4cEAA100KsoP91L5MyqJSVqi+ZL4tsv8AhIPDFwumyA3kW25tHHVJozuT6cjB9ia0fD2qR61odjqUI2pcxLJt/unup9wcj8KbZW6xONnHHasXwd/xLdc8QaE3EcU4vrYf9MpskgfSQP8AnXu05ttSfXQ86UVytLodBqlgl/bhGO11O5HHVTWSbR5Itsi/OODXRngZPSuek8W+GltL+7TW9OnhsY2lufs86zNEqjLEqhJ49MZor4eNV36ip1XBWNDTbYQwPC4BR+x6e9Ynw9Y2dnf6DKT5mj3LQJnqYG+eI/8AfLBf+Amuksp4L2zt7q1bfBOiyxvgjcrDIODz0NYdzp91a+OrTU7OEvaXlq1re4IGwod0Tkd+rr+Iq1Dk5bdA5ua6Z0lFVdUv7bStMu9Qv5PKs7WJp5pNpbaigljgAk8A9BS6be2+pada39lJ5tpdRJPC+0ruRgCpweRkEcGtjIs0UUUAFFFFABRWdY63p99rGp6Va3HmX+m+V9qi2MPL8xdyckYOQM8E471V0zxVoepyCO01O3MpuZbNI5D5byTRf6xUVsFtvcjIoA26KKKACiiigAoqtqOoWemWrXWpXdvaWykKZbiQRoCTgAkkDkkCrNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAGuS+H/+mxatrrcnVLx2iJ/54R/u4/0Ut/wKr3j2/k03wjqU9v8A8fLR+RB6mWQhE/VhWlomnx6To9jp8H+rtYUhX32gDP6Vm9Zpdv6/zNFpBvv/AF/kXaKKK0MzynVj++ux/wBNn/8AQjXM3K/MxNdPrS7by9X0mf8AnXKarKI4nJOK+Ta99rzPoqfwo5TXJcyYB5JwBWdGiII3kDMhcDAGSeeTinuxvLouT8nb/d/+vWhYR/6faSHht+5fYAHFelRp8sT0qcPZw8zZNy1vYTzbgrTZbCnqSMKvvXcfEhRp/h7R9JjclUC7lzwNiBf5kmuJhij+3ruT5rm7ijQdl3MobaO2Tk12HxXbzNas4lJ2pATggDBLnPT6V6GGW7PCzR/CvX9Dg20yzvExeWkE/wD10jDfzo0fw9bT6jK9rPeWa24AXyJ2wGP+y2V9O1X1wqk+grR8NJs0tpj1lYua6jyDKuLXWFumEGrJdKnAF5bAk/8AAoyo/HBq5b3Ws2+1bjSoZ1zy9pdAn/vlwuPzNWrRSx3HqTmtJFyBQAnJqWKMselPihyRWnaW3QmgCK3tyccVPdW+22Lf3Cr/AJEGtCKIAU+WMNDIp6FSP0oA5HxtB5Z064/hSbB/Hj+tUJV5rd8YKJfC7SE8qiv+lZCLvjRsfeANAEcC7WBqaTXNPinNhPdRw3bL8iS/JvyP4SeG/DNOSOnXFpDdwNDdQRTwt95JEDKfqDQB1njCUf8ACuZyMYeCJBg9QWUdPxH5V5kVuWkSaGEmNN2QSAzZGPlHetfXNBFh4Cgk0fUby0824SE2jyedbtiTIOx8lQNv8BXvXFx6veWUzwX9k0xySJrLMg9eUPzD6DdXHX1ke3lz5aT9f8j1P4NyR3Gq6zJESQkMKE4I5JkOP0r029tLe9tngu4UmhcYZHGQa81+CF1Y3MOsGxuYpWEkSMgOHGEySVPI+Zj1Feo1vSj7iTPPxsk67cfL8jzbXPA1xZO1xoTmWIc/Z3PzL/unv+NYUGpuhe2vIyDgo8Uq9u4INezVm6volhq8e29t1Zx0kHDr9DXDiMtjPWnoy6WNa0nqeTW1jNYN5nhe5S3TOTp1wSbZv9zHMR/3cr/s11PhrxBbXV4thfxS6ZqpGVtbnA8wDqYmHyyD6HI7gVbHgx7ObfaTmaL+6/DD8e9as2g2Op2Js9VtYrmA4Plyr0I6EdwR2I5Fc9HByUv3iLq1ote4zatY9oyetc3rP+hfEHw/djhb2CewkPqQBKn/AKA/51GLTxB4aGdOkl1/Sl62lxIBeRD/AKZytxL/ALr4P+2elZ/iTX9O1ew0u9sJj5+natatcW8qmOa33t5ZEkbYZeHPUYPUZFerKPLD0OODvL1Oj8daRda94O1nSrC4FvdXlq8MchJABI6Ejseh9jXmN3pHjTUvDl1oTeFNOtLGPRJrSAnyfNScxhNsUgmIKucklkj44PTJ9rorYyPD7vw18QU1azEN5qMGnwW1ktsLB0YQGONRKkkbXMSNlgckrJkdNvQ27fw749j1lb2O51JX/wCEkunxLqXmQjTWX93mIybSoOcKBuHoOK9looA8Ig8LfEC50i+tLwai0k2jX1tfC81JZ4r65cMIjAvmERDkclYwBxjvTZ/B/j+z8P3lhok2pQBtD09IU/tT/V3kbp5yRkv+7+UMOMIeleq6Tf3UXjHV9IvpjIjxpfWRYDIjPyOnH91xn6OK6SpjLmKkuU8XvNG8f6healMi6vaW1zr1ncRQnU0VorIK3nKNkpCjJGVB57A03TfDfxAs7qykgu9SDRatepuutS8+MWLJ+4Z1ZzvwxzyC479q9qoqiTwOw8NfEuPRdYWe91s6pNp7wqv2pPKefzARJHKbpmRsZHEca44wD1teLPC3jy3063svD82t3s32PzjqMurt5y3JYExFRPFGEHOGKSdcY7j3KigDgfAGiazYeNPFmqazb+XHqUOneXJ5iN5jx25WXhSSMMcc4z2yK5bR/C/jPTbu2+wrLZRNreqXc5FynlmKVD5Duob5xuwduCR3Ar2eigD5s8Gal4jv9XFnpl3qGs30OhTteRnXjNbzXTSYVlkilZYsrwoBRhjov3q2LDw78Sj9ohnfVYrWTVNOnRf7TIZIAri5UMbiR9udvBc7uoHYe90UDueM6N4c8e2Wo6dKLrUysOsXiubnUjOn2Bl/cl1aQ78MT1y49uKxrTw18Tk0fU1nv9bbVZLKWIbLpPJllMmVdJGuiUbHA2xRjHB9T7/RQI8G8V+BfGOq6P4n08f2hdWsi6dcWENxqhfdMgH2hVLSEgZycMQucEdBjcfR/Fo8cafd6fba6dH8y2V7bUtS2x2sSrlyHiuyZWJ6iSNwTnnHX12igDm/AVrqNpo08erx38dwbuZ1F9fLdvsLfKQ6gALjovVRxXSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcn4w/0zX/AAvpfVZLxr2Qf7MCFh/4+yV1lcon+k/FCU9VsdJVR7NLKSf0iFdXWcNW35mk9El5BRRRWhmeW+Ivk1LUB/01Y15l4svfMdbWM8ty+PT0/GvQPHl9HZXupyydFc8ep9K8ngL3E73E3LE5P1/+t0r52lS5qsm9k2fU4KHNFSfQsWlv0Vun3n+nYVYgbzNTt+WVPMwSpwScHgVI48qIRjAkfqfQ/wD1qzJrtbe5gZcYjcYB7885rveh2/Fc7DSkVdYgLs0hF5bCPfj5FLqT09+9dT8TEA163dc7Gt8Lk56O1ck2bdoJ/tIDpNE2PK+XIcYGc5rv/ilatKtnfJtYI7QvtHTPKn8cGurDbM+ezTeLPPpuIJT/ALJ/lWxp5A0OLaMfuv6VlS7RCwY9Rir/AIelE2jxr3QFGH04rpPKLVon7tT7VoQpmqOm8x7D95DtP4Vs28fSgCa2i5HFakKYFQWycCrqDAoAUUy5by7eVz/CpP6VZhiLnpxVXU13NFbj+Nst/ujk/wBB+NAGD4z/AHHhKVT12qgHviszTmWW0jxwyqAR6cVc8fTedc6ZpSHLMwllA7Dr/hVS5tZIZPPtuo6j1oAsiLmrawqsRYjoM1WsbhLkYHyuOqmte1t/td1Dajo5y59EHJNAGV47RYfDnh/T5VB3ym4ZT/sqT/OQVxl4ZJZLWGAxRMrFgNuFVQDngeua6fx3ffbPFTpGcx2MKwYPI3t8z8fQoPwrlbwrHBNcwIisEMfyLgM3b9TXBWleTZ9HgoclGKf9XJPDulWuqBri6hC3RkZ454WKSx84G11ww49DXc6ZqniHSSI4tVjvYe0WqqfyE6Dcv1dZPqKxvBlp5YjXsigV101qkoxjBrx442pRneL07GNelCq25I0ovGtvaqv/AAkdjdaMD/y8ygS2je4nTKqP9/YfauotriG6gSe1ljmhcbkkjYMrD1BHBrz62e/0ly1nIfLPWJuUb8P8KfY6bod7cNLYfaPDerOctJp8nlJI3qyYMbn/AH1Jr2cPj6dbR6M8yrhZQ1WqPQ6CAe1cp5/ivSP9db2viG1H8dsRa3QH+4x8tz7hk+lW9M8X6RfXa2TzvY6i3Szv4zbzH/dVsbx7qSPeu45ToK4P4w6HYX/hC91CWAJqNkiyQXcfyyxgOpIDDtx0OR044rvK5z4jpv8AAPiAf9OMp/JSaip8D9C6fxr1JtMXWLPTb1dZv7a4WNC0F7FCVkK7TzJGMruH+zw391eleTaV4qn0a0u7nT9RGu39vprTyzw6vNfW7FXTc88DgG3YgsQqHHDDHHHt9g/mWNs/96NT+lT1aJPKtX+Jb/bJxpWpaDFpg1eDT01K5zJAsb2jys5YSKGIddoIIGOOvNZN/wDFTxBBb6aVstLjee2acS3DRwQ3hE8kYEbTXEewMiK4I80gSLxjBPr+oabaahLYy3cXmPZT/abc7iNkmxk3cHn5XYYORz9KuUCPFfE3iPU1udJ8UXa2qQaf4hudJEMCyJI8AkkQl334P+rQ7cYyueh2i3ZfErV5tKmuY20a+n+xw3LR28ciixleeOM205Ltl8O3OFOUOVxivU9Z0+HVtJvNPuRmG6iaF/owIzWV4C1CbUPC9r9sP+nWu60uh382IlGP44z+NRe0rdy9437Gzp63aWka6hLBNdDO94IjGh5OMKWYjjA689eOgsUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcb4g8TXuieJrxblrd9EtNHm1WWOO3Y3B8ogFVcyBec55X2z3rD8SePby5hgsdG03WrHUZL22hkGy1MyxSq7q0e+Ro8sI2A3dOcgcV2Oq+E9I1W/uby/gnlmubN7CUfa5lRoHGGTYGCjPqBnPOc1I/hjSH1Bb5rTN0rwuH81+DCHWM4zjgSP9c854oAwD8QrODQ21KTT9RNlFO9obm5mtLYPIkjxtgyTIp5TPHHzDHIYKad8StJ1K90a2srW8c6pDHPC8jwQgKzMvR5VMhUqdwjD449RnYuPB2iT2NraG1mjjtbiW6gaC6mikikkZ2kZZEYONxkfIzjBx0rPufDHhfSRosNwl1FBHcRwWVsb25eEyhmkTMW8oSCCdzA8gc8CgDNn+Jtm+ltcpY6jYedayXVpNdQRyLcLG6q+1UmByC44YrwcjNaUfj2ybVmsm07Uo4/tc9il3IIhC80SM7ID5m4fKjEMVC+4qHQPhvomnaQLS+WbUZmtzbSTTXE2PLLhyqKXIiBIXITGcCtm58JaHdRGK4sVkjNxNdlWkfBllR0kY891kcY6c8DpQBx03xWhvQI9A0ye6u4b+1triDzraX5JiwyrxzlN3yEYLcEjIxzXRjxxp4hDyWl+jf2k2ltGURmWZYzIfuscjAI4yc9u9EXw+8ORQzRra3ZMohBkfUblpF8kkxbZDIWTaWONpHWpT4G0A6it8ba5+0rL54b7dPgS7Nnmbd+N5XgtjJ6k5oAl8G+K7TxZZzXNjbzQxRkD97NA5OfURSOUI7q+0j0610NZOh+HtO0SS6lsEuDNdFfOmubqW5kfaCFBeRmbAycDOOTWtQBynhj9/4w8XXXVVmt7VT/uRBj+shrq65T4efvbHWLztd6rdSA+yv5Y/RK6us6Xw3NKvxWCiisPxrr0fhvw3eai+DIi7YUP8ch4Ufnz9AatuyuyYQc5KMd2eE/FO+a78X31lEcxwzkvg9Wx0/AVlafb5K4+5Hz9T/nms+3Mk88txcOZJpXLu56sxOSfzroEi8m2WMnDN94/zrzIxSu0fYxiqUFTXQy76TarSE9eB9P8A69c3LIZpyc/KPX+daWvXO5/LTjPHHYVkhCzJAg5blvp6UpM6IKyOo062N7aWX2y6nKTKzRIrY2Y6H3P1r3Tw7cL4p8GraXp3SxqbecqOQ69H9uNrfjXieg3ttbaRJHMsJeNirCQZJHVceg57V3XgHVI9K15YpiVstR2xSfMSFk/gbnsc7f8Avmt6E+V2PGzGh7SDaWqMu50qax1CW3vR+9Q8Hsw7EexqnYyf2dqjRPxBcHKn0buK9j8SaLHq9oScR3Kk+VK3HPv7HvXlep6eZklt50aKeNsEHqjCu4+dLwHk3AmH+rb73sfWugtFDICOhrj9D1Ly3+w6oAkw4Vj92Qe3+FdfZQyQgfZyskJ6Kx6fQ0AakERPQVfgtWbBbpWfDdSx/etJj/ulT/WrP9oXBGIrXb7yOB+gzQBoTPHawMzsAAOTWNJcR2sVzqd9hUjXO09gOi/j1NPmwkRvNTnVYY+d7cKv+6O5964DW9Vl8W3i2tmrxaPC3J/56n1oAfozS6pqFzrF3ndMcRA9k/8Ar1vG6t7SCSW8lihgUfNJKwVV7ck8VHbwiGFY0XCqMACnSMFicsAwweCM5oAhisU1STzdFkSbHWSJwUH4jiuphhXwzo1zqOpss9wibm29D2RF9yxAoj8E+HzbRefoVn9sEeTcxxCOUnvl1wwGfevOfHemxf2sNI0LVtThjtQJZle8edDKclUAlLhcA5+rDioqS5Vc3w9H201Hp1Mm2KXk7veoXvZ3eW5w5VgxJLZx9cD8KhuQwu7SyjcPbIN4JGGCjoD26nr7VSQaqbYzLfW7xhfv3NttkAH+0jDA+oP0rstF8J6+2ii71HQVmvLgCRJLS+USKmOEaKQIoPU/f79ulefKnKcWobnvVq8aSvPQ1vDG2OLJxzXRg9xXnc+oXvh/jVdJ1eyjBxve1Mif99Rb1/WtbRvG2j3biIaja+bnGwyhX/75PNeJVw9SL1RgpxlqmdxDKjDbKBiobrSo5hujxVeKaOVQyMCDzxVy1dwwweKmE1L3ZIiUXHVFzR5ry1/dysZIh0DdR9DWtfWdhrFmbbUrOC7t3+9DcRh1P4HioIOVGRyavxICB7V9FhXJRSvc8ytZu9jmv+EUudN58Ma3d2CjpaXWby2+m1zvUeyOo9qxPHOta1Z+Ddbt9d0Nyr2UqC902Tz4clDyyHEifkwHdq9GrmviU+zwB4gPrZyL+a4/rXXU+BmVP40W/Ces6brOj276XfW92I40SQRSAmNsD5WHVT7HBrhZvjBbx6Re3H9kub631Q6etp9o/wBZGHZfP3beF+R+MdVxnkGvR7LT7WJ47pbaAXnkrE04jHmFRj5S3XHA4rl3+Gnh97KaFkuDPL5gN3vHnKj3P2goDjbt3+2ccZ71S2Je5LqnjvTrCyvS8ge+jkuYoYLaCe5ZjDwxZVjBUAldx+6M/ePWs26+IaJpmgJb7ZdWvZtOjuo0tZnhgFy0e4GQDajbXJUM2enB76F38P7Ca4nuLbUtUsridrnzZLd4sulwytJGdyMNuVGCAGHrUSfDnT4prcwanqsVtFNZ3LWqvF5c0tsEEbtmPdkiJAQpAOOmeaYhNI+IWnDRba416cQXcnmvItvbSyJFEszxrI5UN5anZ95yBkH04t6V/wASn4garYHi31WFdQhHbzFxHKB7keW34msu9+E/h+7e1kZpvOgjaLfLb2twXQyvJgiaFwMNI3KgHBwScCtTx8Bp8eka7GNv9lXamUjtBJ+7k/IMrf8AAazqaLm7GlPV8vc62igUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5x4z8O+INT1jWrmwutWhQQWK6eLXUmgTeJn+0HYHCk7Nv3hg9skcR2+meKNF1dJraLVdR0u21S4Mdq2oiSSS2e2jCEtLJ8yrNv4dtwzkA8V6XRQB5BpOj+NYbrw+9ymqzXCQRJdtc3/AO4hcbtz5juQZG5GQ8Tg4ABAzVjTtA1+XT9FS4sNYTV7W9gnvLvUNTW5gkZY5Q0kSec21dzA7QiHBAxxx6vRQB5r8LNK8WafqE7+KJ9QYG2CSCZxJFJNu/1iMbqUjjPAjiXBHAxivQr+CW5s5Yre6ltJWGFniVWZD6gMCD+IqxRQBy/k+MLIfurvRtWQdFuIpLNz9XUyL/44KU+JdQtDjVvDOqwjvNZ7LuP8Ah8z/wAcrp6KAOesvGnh27nEC6tbQXJ6W92TbTH/ALZyBW/St2aVYrd5iQURS5PsBmmXtnbX1u0F7bw3MDdY5kDqfwPFcN408J6HpPhTWb7TLebS5YbSV1Gn3ElshO04BjRgjDOOCDSk7JscVdpGz8Mo2j8B6Mz/AHpoftDfWRi//s1dPXF6NoHiPStHsodM8RRzJFAiLBqVkkgUBQNoaIxkD3O4+uaunVfE1lj7f4dhvUHWTS71WYj12TCPH0DNSgrRSHN80mzp68J+O2tm98QWmiwNmKzUTSgdDK33Qfov/oVemSeOtHtY3bVhf6SUBLfb7OSJPwkx5Z/BjXzjPqX9uaxfaq0iu1zK0vytnGTwPwHFY4iVo27nqZRSUqrm+n6l/S4g0yjHyrz/AIfrV/UJQkLNn/ZH9aj0xdkDSHq3I+naszxHc7Itinn7o+tcuyPetzTMK4lEs0krcon61PYxmKJppBmR+1V4YvMlig7AeY/9BWrGAW3dl4X6+tZo6Sxply2mXYlI3iQbJQADn0xn0roCYIJnilwkc8e1FJ4Q55APbt/SsG2gDqXYZ3DAB9PX8a09OnMUkaXbDYilInccN7Nn8qo5aqTd0eweCPErapZtY6hM/wDaVumN3Xz4843j36bh2PPQ0njfSzIo1S3BZV+SY4+8vQN+HQ+30ry5JTFfgwXMloYSHilRcsj+gY8fgexxXoOh+O0mC2fiPyojJhftC58mUdww/gJ7/wAPuK66VZPSR4GLwMk+ektOxz1zp8F7FsnQMKhthrmkEf2bcrcW4/5Yz8/rXWal4euLJzJYKbuzI3rsO50U9MgdR7is2ORSSucMOqngj8K6TyyovjPU4htutADsO8Z4P5GkbxbrVxxY6NBbE/xzHdj8K0CAe1WbeNOrYoA5t9J1LWJRLrt5Jc85EQOEX8K6PTdH2KFRAqj2rRikgjHOKnivxI2y0jaaT+7Gu4/pQAyaySGHnrVHTLJr7U40VCbeJw8rAccchfqcflWs9hNJG1xqk8dlaIfnLSAED3Y8KK4nxT8TbOytzpvgpVnnGR9rAzDF2yuf9Y3uePrUymoK7NqGHqV5ctNXN34o+Po/DUDWGnGKbXbhflVTuECno7+/oO/06+Labqdxo++S6zcSTv5zl3+cuepJ7571QMohmmuZ5DdXsjF5JpW3fMepJ7mtPQdHa+v4rvVoXlsgwZoSxRpx6Z6qv8/1rzq1e7vJ2Pp6GFp4SlZ6vr5ndfCTw9feI7i31bUk8jRbV90MeObqQHqc9UU/mR7GvdqwvDeuaXqFrFb2IW2aNQq2pAQoAOAo6EfSt2u2go8t4u585jK061S8lbshkkaSxtHKiujDBVhkGuK8R/DvTNTVmtkjifr5ciB4z+B6V3FFVUpQqK0kYQqSh8LPCZ/AjaPc4NhJaL2lsJngX84yP1rpNG0HUjHvsvEWpw8cJcJFcJ/48m//AMer1FlDKQwBB6g1W+xRKcxKE74HSuN4HllzJ39ToeK5lZqxy0MPjC25SXQdSUHgOktmce5BlGffH4VbXX9ZtQBqHhS/I7yWNxDcKPwZkc/gprpY02jnrT67KcOVHNKVzmP+E50SLjUJLzTG6n+0LKa3Uf8AA2UIfwJrN8ea1pmr+BNRXSdSsr0TGKIG2nWQfPKi/wAJPrXc1wPxN0DR7+LSEudLsZZ7rVbaIytApfbu3N82M8qpFFX4GVS+NHeSMUiZlRnKgkIuMt7DJA/M1zGm+OtEuNGt9S1O5i0OK4eRYk1S4hhd/LbaxGHIIDcdfT1GdXSdDtNGt549JEkPm8hZZpJkUgcYVm4HqFxmuW0nwDPaw6Yt7qsFw9jb39urR2ZjDfamRicGRsbSpHXkN2xzoZl2Px5pj+KNS0w3mkRWenQJLc3U2oojDcAfljxgoNygsWGCwGDW0viXQmggmXWtMMNwN0Mgu49sg3hMqc8jcyrx3IHU1x7/AAyDaFJYDV5FlzYvFMkbx7HtoljBOyQMQ23PyspGeDxmr/hXwGuh6zZ6lLdQzzwQ3UbBYpfnkmkjcybpZpHDYjIPzHO49OhANu08V6LPHpvnalY2tzqMay21tNdwmSQN027XIfnjKkj0Jp93caR4jsdQ0mG/s7ozQPHLHDMrsqktGSQDkYZWH1UjqK4yx+GE1jp0OnQa1EbN7azt7zfY7pJPs5ypibf+7z7h8dRg12fhHQk8O6Q1kkqzM9zcXLSCPZuMszyYIyc4DBc5529ulJq+jGnbVFfwDfy3/hOxN0f9MtwbS5HfzYiUbP1K5/Guhrk/D/8AxLfG3iHTDxFdiPVIR/vDy5f/AB5Af+BV1lTTfu2fQqoveuuoUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcp8Tvn8H3FsPvXc9vbD33zIp/QmurrlPHX7258M2o6zavE5HtGryf+yis6vwNGlL40zq6KKK0Mzh/jJqh03wLeIjYlvGW1Xns33v/HQ1fOkek2c+wvbR+ax4dRtbnpyOa9Z/aAvzLqGkaYh4jRrhx7sdq/yavPrFMzZ7KOP5CuGtK89D6fLqKjhk5LfU0o1WG3VFzsjXjJycDpyetclqUv2i+wT8ick10mozeVaSH14rjnzIu0fencJ+HU/pWM2ehSXUuWCkRNKRiSdt30Hb9K04Ig7Kn8CjLfT0/GoIlAG7HAGAPataxgOAMc5y3uaEi5ysi7Z23m9eB3PoKg1Zk2+Siqc/KAen41oTyLZ2xXI3EZY1zdxcEh5HOCfXsKp6GEE5O4RanLpKMsEgaEnJSTofcHqKuWXidfLYPaymWU4xGQeOyj/PNcrPK1zLn+AdP8a9S+H/AIYi0mFNX1lP9JI3QQsP9WP7x/2j+n1rnqVVTVx1+SnHmktTqNAm1LQfDFt58nkghm+zSNuVASSE/AHHFW4vGlhqJC6pppkP3d6orgD2BwR+tcrr+qvqcrtLIsNnCCzMxwqqOpJrzzV/FU2ohrPw+GtrL7rXeMSS/wC4P4R79fpWVGvWT9x6fgeX9UWId3HU9d1Txh8PbG5aC5vHhnHLRRrKWUY6EKCAapJ48+Hgx/pupt7CCfB/8drx220qC0j3TFEJ5JbljSTXlrEOAXx6nAr0FiZpa2NVk1Hu/wCvkexv8S/A9rhrTTdRvZPQwHB/F2rH1X4v6vNCYdD0e002HORLct5jD6KMAfrXJ6D4T8TeIQraXpEsVu3SeYeTHj1Bbk/gDXoeg/BIllk8RauznvDZrgf99tz+QFUp1amxnKhgMM/fd39/5fqeV63rWoa04fXNRuL45ysbHbGD7KMD8hS2ml312oAjFtB6vxkfTqf0r6Hf4Z+HY7IRadafZLhR8twCXcn/AGi3WuH1bwzfaLMftib4CflnTlT9fQ/WuXEqrT1tp3NaeY05rkpKxyej6BBC6FUM0w6O46H2HQV2+maI5w0vH1pmlvbQsCMZro7a7jkAAYV49WpJkTnKTuyNdJhKjaMMOQR1FaVnrGpaZhLlTeW47k4cfj3/ABpsb4IKmriSxSrtlABqsPWnTd4SsznqxUlaSujZ0zWrHUflgmAl7xSfK4/Dv+FaVcRfaPFcDcmNw5BHBFP06/1XTpBFOxuoOg3/AHh+P+NezRzHXlqq3mcM8Kmr02dpRVa1vI50B5Rj2arNenGSkro42mtwooopiCuU8Uf6R4w8JWnULNPdsP8AciKj9ZBXV1ykf+l/E+Zhymn6WqfR5pCf5RD86zqbJeaNKe7fkzq6KKK0MwooooAKKKKAOT8Vf6D4p8MaqOFad9OmPqsy5XP/AANF/Ousrl/iXC0ngrUZohmazC3kfqGicSf+ymukt5VngimjOUkUOp9QRms46Ta+f9fcaS1gn8v6+8kooorQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlPEH77x54Vg6+Ul3ckfRFQf+jDXV1yrfvviivcWukE/QyTD+kdZ1NkvNGlPdvyZ1VFFNkdY42dzhVBYn0FaGZ82fEy+/tH4haowOUgdbdf8AgC8/+PE1n2K7ULep/lWb9oa+1C6vJDlriV5iT/tMTWxCNkSg+g/WvNvdtn2kYezpxh2Rl+IptkAj7nisW1Tfd7e0aY+hPJ/TFXdYk86/UE8A5NQaUM27zsOZWLD6dqh6s3grI1bZN8g4+Vf59q37GMRRmQ9un1rN0+E4Ve/9at6hOIYdi9uB7mrWhhP3nYoapcebJszwOTXP6lMZH8pTwPvf4VcvZ/JiPOZG6fWr/gTw03iDVf3wYWMGHuG/veiZ9T/Ksqk1FXZrdU43fQ3Ph54YV401rU0H2ZDut42H32H8Z9h29etdDq2ovdymKI4XuT0A9TV3W7wMVtLUBY1AUKgwBjoBXlvjPWjPcy6Np8mLdPlvZ0PMjf8APJT6ev5V5sVKvO7/AOGPO97ETKmuao/iB/stqWj0aFuWPH2lgfvH/Z9B+NVVuo7dDHZouR1c0y2guLxlt7aP5VAwi8BR6k9q7DQvDUcBV5AJJuu4jhfoP612ynGkrI7XOFCPKcjpWnXV7qwt9TeSKOQeaj7fnePIDBQeMjPf1FfRnw88JeD7W1jutItlurtfvTXYDzIfoeF/AVxF54Vlv7APbFYr6BvOtpG6Bx2P+yRlT7E1paDJ9qsYdR08y2typKSJnDwyKcPG3uCCPQ/Sop41QfM1dfkeTiZVKy5Oa39dT2WiuP0jxcBiHWE8thx56D5T9R2/DiusgniuIllgkSSNujIcg17NKvCsrwZ4lSlOm7SRJTZESRGSRQyMMFWGQRTqK2Mzide8CQXBabSZBbS9TE3MZ+ncVxV5aanosoW+gkjGeH6qfow4r2umSxpNGySoro3BVhkGuCvl9OprHRnZSxk4aS1R5Lp+sjgOa3re5jmUFWFaOseBdPu90liTZzHsvKH8O34VyN5oGtaRJzE0sQ/5aRHcv+IryK+AqU9baHdTxFOps7M6iKVwRtY1q2mXA8xQa5rQ5Z3C+ah/KuutUJUcYq8JQmndmOIktkTwxgtkCryqFUAUyFNq5xzUle9Shyo86crsKKKK1ICuT8Ef6XqfibVDyLjUDBGfVIVEY/8AHg9b+t36aVo19fy48u1geY++1Sf6Vm+A7B9N8H6Vbz/8fBhEs2evmP8AO/8A48xrN6zS7Gi0g33N+iiitDMKKKKACiiigCtqdqL3Tbu1cZWeJ4j9GBH9axvh5dNd+BtDlc5cWiRt/vKNp/UGuirlPht+60G6tP8Anz1C7gA9AJmI/RhWb+Nej/Q0XwP1X6nV0UUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyuifvviF4nlP/LGC0tx/wB8u5/9DFdVXKeC/wB7rPi26/v6n5Q+kcMa/wA81nP4o+v6M0h8Mv66o6usLx3efYPBmtXIOGS0kCn3KkD9SK3a4b403HkfD+9QHBnkih/NwT+gNVN2i2Vho89WMe7R8/6bHgIvuFrWnkCoTnpk1naeMbSewJp9/JiB+e2K85aI+ykrswLuUt9ocddu0fU8f1rVs4goiiHRFH/1qx8bzCv/AD0mBP0HNdFYpkFsck1CLlojTtD5cZf8B/Ws68n8yQkn5V4FW72Ty4giHn7orA1KbCiJDyeKtuxnBXdyGOObU9RjgtkMksjiOJB3Jr20WUHhPw5Bp9uwNw43SOOruerf0HtXO/B7w6saya5eKMYKW4Pp0Z/x6D6H1q9rV8l3qFxdXMgS0gBd2PRUXkmvOrz5tDixVXnn7NbI5PxxrMuj6Wkdo23U78lIW7xoPvSfrge59qzfh98OdW8S2MlzaKILCIELLJwZ2HVU/qx4z+m98OvBV38RNal8S+IFkg0Qtst4T8rSxqflRfRf7zdySB6j6LtoIbW3jgtokigiUIkaDCqB0AFejhcJ7t5HJiMcsNH2dL4ur7eR8/2elLpkhtGt2gkQ4ZGHOfU+v1rrNHtoAAWxmvRNc0Kz1mLFym2YD5Jk4Zf8R7V5zrWlal4fk3yoZrXPE8Y4/Edq4cXgqlPVaoyo4qNbR6M6JAoGFxiuY1Qf2Bro1QcaXfssN8M8RS8LHN9Dwjf8APY1Y0/WFcAE1qyrbajZy21yiywTIY5I25DKRgg15sbweuxrKIXFjHKOmDVKGG90ybzbCZ4j3Cng/UdDVXwtczW0s+g6hI0l3ZKGhmfrcW5OEf3Yfdb3Gf4hXTRlc4YcVScqctGK/MtUP07xgVIj1WAqf+esQyPxXr+Wa6myvba9i8y0njlT1U5x9R2rkp9NhuFyuM1kTaVcWk3m2zvHIOjIcGvUpZjVh/EV0ck8LTn8Lsz0yiuFsPE+oWmEv4RdRj+Jflf/AAP6V0+ma3Y6jhYJgsv/ADyk+Vvy7/hXqUcZSrfC9TjqYepT1a0NOiiiukwKz2UDPuEYVvVRinxw7TzgipqKnkje9h8zCiiiqEFFFFAHJ/ET/TLPTdEU5bVb2OFwOvkqfMkP/fKEf8CrrB0rkrf/AImnxIuZTzBo1osC+nnTHcx+oRUH/Aq62s4aty/rT/g3NJ6JR/rX/gWCiiitDMKKKKACiiigArlPBH7vUvFdv/c1Vn/B4o2/mTXV1yvhn5fGfjCMdDNbSfnAo/8AZazn8Uf66GkPhl/XVHVUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHB3v9qwePzaHxLqw077DJqLW6QWpxtlUeWD5O7ZtJHXd/tZrJ034qXd7Z290PDF2sF1JbLbSEzIjiaZIwC8kKJvG8NhC6nB+bjNemm2gN2LowRfaQhiE2wbwhOdu7rjIBxWXbeFvD9rcST2uhaVDPI6yvJHZxqzOrb1YkDJIYBgexGaAOVk+IOoR+J20b/hG57iW2mgt7x7QzzLE8qq25WEAQoocZLtGepAOBnZ8EeKLrxC95FqOnR6Zd26xs1o0kpmQNu++rwxjGVIDIXUkNhuOda+8PaLqGoRX99pGnXN9Fjy7ia2R5ExyMMRkYqlZxaF4Z1ay0nStJtrCTUxJIPsVtHEh8oDO/bjnDccHv0oA5eL4g61czQC08N2TxXT3yW7yaoyEi1kKOXAhO3ODjG7nrgc0lv8Qrm5eCXTtOa4fUBp32e3uLpYo4/tMMkmSyxFhjZzndnsB0Pex6Vp8Xl+VYWieUZCm2FRs8w5kxxxuJJb1PWmQ6LpUPleTptjH5Xl+XsgQbPLUrHjjjaCQPQEgUAcK3xLuWs55YdEgM1jbXF1fpLf+WsaQzvCwibyz5hzGxGQgxjJGa6Tw14kude1TU4oNOSHT7G4+ztcSXHzuxiikXEe30kwcsMYGM5IXQuvDWhXYhF1oumTiGRpovMtY22SM25nXI4YtySOSea0Le1t7d53t4IomnfzZSiBTI+Au5sdThVGT2A9KAJq5X4d/Pp2q3H/AD8ateP+UpX/ANlrqq5X4Yc+C7STvLNcSf8AfU7n+tZv418/0NF8D+X6nVV5f8frjZ4c0637y3e78FRv6kV6hXjX7Qk2ZtCg9BNIf/HAP60qztBnVlsebEw/roeY2nA+iiq+qsRAfck1Yg4RvqBVDWG+SNfb+dcD2PrFuUrZd13br/djLH8Tj+ldPZkJyf4R+tc9pq5vJn7Iqp+mf61ru5jtxj7x5/PpSiE1fQS8nBZ3J4XgVV8N6XLr+uw2seQJDl3H8EY+835dPciq2oSYRYgeT1r1j4T6F9h0j7dMuLi+xtyOViHT8+v5VhiKvJHTczrVPZQbOl1V4tL0EQWyiNAgjjUdlAwBXnswtL7UrLS9REj6YzibUFiPzOg5WP6E4Ld8D3rpfH2pRwGQnlYRhV/vN2Fc/wCF9OeUmSY7ppTvdveuGL5HfseTC9r9z33TntXsYDp5i+ybAIhEAFCjoAB0x6VZry/SL288Pz7ocyWznLwk8H3Hoa9D0rUrbVLYT2km4dGU8Mh9CO1e/hcXCutNH2PHr4eVJ33RdpHVXUqwBUjBBGc0tFdZznG694Gtbpmn0pxZ3HXZ1jY/Tt+H5Vxt5FqmhyhNQt3Rc4Eg5Rvoa9kpksaSoySoro3BVhkGuGvgKdXVaM66WMnDSWqPEtZuJLuK2v8ATwv9q2DGSAE4EqkfPET6MPyIU9q6jRdWtdX063vbR8xTLuAIwR6gjsQcgjsRW5q3gjT7otJZFrOU9l5Q/h2/CvNdS0fVfBOt75U36RqMuPMjOViuD6+gf/0If7VeVWwFSMbWvY7YYinN6O1z0BJGX7pq3FdgjEigiuPs9b5Akrat72KYDDDNcEZTp7G0qae5ry2ttcDIwDVCTRRvyACB0pVbn5TWlZu/AJyK2pyjUeqszKXNBaMt6Y9xBEqvIXUcYfn9a145Q3BBBqlHzgYq5EvOTX0GHcrJXPMqWbuS0UUV2GIUUUUAFNldYo3kkYKiAsxPYDvTq5j4j3EkXhK7trZsXN+yWEOOu6Vgn6Ak/hUzlyxbKjHmkkR/DeNpPDz6pMCJtWuJL9s9Qrn92PwQJXV1FZ28dpaQW0C7YoUWNB6KBgCpaIR5YpBOXNJsKKKKokKKKKACiiigArlfD/HjzxYP9mzP/kNv8K6quV8N/N428XuOgktY/wARCD/7NWc94+v6M0htL0/VHVUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmmofDSDUdcutRvrTS7iSfXEvi8qlna0FusZhOV5ywJKfdIxk9qz2+HuvWWly2ultpLmbTb/AEsrNPJGkEU1w8kRTEZztRgpXgDAwSBz63RQB5Jc/DjV5dS1CS0bTLIXVnJA15vE9xvMIjBQ+QskS5HIErDGcAE5q1deAdQu7CGCwsND8MultdwH+ypWYM8saKsn+qTnKkHOTjHJ7eo0UAcP8LvCd34Vt9QS8WGI3DRkRW88bxAqpBYKltAFJ4zwxOBzXR6xpd3fyxtaa7qWmKowUtEt2Dn1PmxOc/QitWigDmv+Ec1T/odPEH/fmw/+RqP+Ec1T/odPEH/fmw/+Rq6WigDmj4d1QDJ8aeIP+/Nh/wDI1c38ONA1KbwRpMsfizW7dJIi4ijisyq5Ynjdbk/ma9FuDtgkPopP6VzvwyGPh/oPvaIfzFZv416P9C18D9V+ov8Awjmqf9Dp4g/782H/AMjV478b9LvbbXNKin8QapekwMwaeO2BX5xwNkKjt3zX0PXhvx8/5GfSP+vVv/Q6mu7QO3K1zYlJ+f5Hl8dhcFCf7Uvep/hh9v8ApnWfqlpOLoIdRu36DlYv6JXQRf6pfcn+dZOpuPtjN/dy35VxNux9Oqav1+9lfTLKeSJmGo3a+ZIeixcjPX7ntWoqNGNstxJPtO7fIFB9h8oA/So9MGy1hB7R5/E0y9lKwHH3nP6Ur6FKCTuvzZb8MaU3iHxHBa4Pklt0rD+GNfvfn0/GvoCMpBEWUBUjXCgdB6CuF+E2jfYdEbUJVxPe/cz1EY6fmcn8q6LxFqJsjYwqCwu5fIwB/GQdv5kY/GvJrVPaVbLoebi6nPPlWyPP9embU/ERiBzDbHc3vIf8B/Ou18NWmyIMRWbrvg688PyfaGb7RbytveZR91j1DDt7GtDRb9Y1CtxSr05U/da1MIyU43jsdBNCsiYIrKEd1pt2LmxlaOQdx0YehHcVrxSrIoKnNK6BhyK5oTcHdC30ZraL4ptrsrDfAWtyeBk/I59j2+hrpK8zvLAMDtA57VLpes6hpJEYJnth/wAspD0/3T2/lXtYbNPs1fvOGrgr60/uPR6KytJ12y1LCRyeXP3ik4b8PX8K1a9iE4zXNF3RwSi4u0kFUtb0y21nSrrTr5C1tcIUbBww9GU9mBwQexANXaKok4TQtPtdaiutM1+FBr+mMIp54l8szoc+XOOxDgc+jBx2qvf+C760JfTZ1uEH8D/K3+B/StrxlZ3FrLbeI9JhaXUNOVhNAn3rq1PMkfuwwHX/AGlx/Eav6z4ksdL0GHVm824trgxLbrABumaUgIBuIAzuHLEAdyK5quEpVfiRvTxFSnszibT7fazbLyCWMjswrq9NfegOKuaXrcOo4gv7K40y7aRoktNQ8sSSlVDEptZlcYPVScc5xisQ+LtAi8TDS3vdOtoJbOG7trtrxAly0kkqbEB4Yjy88E53dOOeWOXKm7xZrLFc61R1ECdKuDpWKviLQoru6tH1vSxd2il7iH7VGHhUYyXXOVAyOT61H/wmXhjy7eT/AISPRdlwSsLfbosSkHBCndzgkDiu+nDlRyyd2b1FZX/CR6J/aT6d/bOm/wBoJu3Wv2pPNXaMnKZyMDk8VU8QeKbLS9FN/ay218xSGaOKO4X95FJIqCQEZyvz5yBg1oSdBRWRF4n0Gaa9hi1vS5JrJXe6RbuMtbqn3i4z8oHcnGKiPivRBNchtTsRbW0fmTXRu4fLj+baVb58gg9yAOcZzxQBuVyfiL/TvG3hrTusdv52pSj/AHF2J/49Jn8K6PTr+z1OyjvNNu7e8tJM7J7eQSI+CQcMCQeQR+Fc7o3+mfELxDdHlbO3t7FD6Egyv/6Gn5VnU1su7/4JpT0u+y/4B1dFFFaGYUUUUAFFFFABRRRQAVyngP8AfzeI78crc6rKqN6rGFiH6oa3dcv00rRr6/lxstYHmOe+1Sf6Vn+A7B9N8H6TbzZ8/wAgSS5/56P87/8AjzGs3rNLsaLSDZvUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDenFnOR/zzb+VYPw2GPAHh/H/AD5RH/x0VvX3/Hlcf9c2/lWF8N/+RA8Pf9eMX/oIrN/GvR/oaL4H6r9To68N+Pox4n0Y+tq4/wDHq9yrxf8AaAhI1PQJscFJk/VDU1/gZ25U7YmPz/I81i/1cX1/rWHqpzJPjuu38zitqI/LEP8APesO7+a4x/elUfkc/wBK4JH1UdzSHyxbV7/KP5UunWLa1r9pp8WdruFYjsv8R/LNRyNsjB/ujd+Ndz8GdJMs13qsq/8ATGMn82P8hWNefJBtEVp+zg5HpQWO1tkSNQscahVUdgBwK5XXFnv7S/v4Sf8AiUKl+uO7RuGx+QatfxHeCBGjQ810XhHRlfwfcRTj59Sjffn+6wKgfl/OuPA0HVqeh4Ner7OPN3OqHlXdqCQskEqZwRkMpFcB4l8GSW5a60UF4urW/wDEv+76j2rovh3dNeeB9Fkk/wBYtssT5/vJ8h/VTXRV79SjDEQXMjzIVJUJvlPFrLUpIH2vng4IPBFdFZ6hHMo55rqPEPhex1gGQjyLvtMg6/7w7/zrzvVtH1LQZc3MZMOflmj5Q/4fjXhYnATpa7ruenSxEKumzOqBDDjmhbdJeGwK5iw1kqQHORXRW1ykyhkNefbleps0yC80ggbkGR1GKlsde1LTcJL/AKVCP4ZD8wHs3+Oa0YboqMMMirBt7W7XBwGNdlCcou9KVmYTaatUV0aGl+ILDUMKsnkzH/lnLwfw7GteuGvdCwCVAZar2t5qel/LBMzxj/lnL8y/h3H516VPMnH3a8beZyywkZa02eg1leJdNuNW0p7S1uLaBmZS32m1FzFIoPKPGSMg+xB96zrDxZC5CX8D27/31+ZP8R+VJ4016507Q7W40N7OS5ub61s0adWkjXzpljJIVlPG7PWvSpV6dVXg7nJOlOm/eRg6f8O7rTZLW707VrK1vre7kuESHTitnGskXlMkcAl+ToGzvPzZOOcVTPwsuRp6WCa5B9kl0mHSLotYEySRpJI5aNvNxGT5mOQ2MA02Dxj4piu0juhpF0Hvb/TkS3tZY3aS3hlkSTmVuGMeCnvnd2qrN8Uri5s/M0q60FtmmWd1PJLKqrFPI7CSPLyopZQBhGdTngtWpmbGofDm6vLnUiutpa2dzKblLWC3lMZmEyTK8qSTOjHcnzbFj3bmz2wnjPwFrvi2ya31DxRFDHJbtbyxW1pPFCSSSHCLcjLYOCHLqcDgVW0Xx9danqemwS6toum289vFMkt9aNG2oM0royQL5+FxsAyGkyXUgYIzymi+PtW0DStA0uytbFYPsccqm8khi+1FpXDIjyTx7cAdlkOSMgcZBnX2PgXUL3Vb86vcwwaUNYkv4oY4B5058kRqxl3kBeT8uwHjrg0tr8Nr0WEdpe69DNHBp9vptv5diYysUMqSKW/eHcx2YJ4HOcdj6VRQI8wufhhfXt7f3GoeJpbprixvrFDJDKzItwAASGmKDZgcIiBsc881ta54GGoSF4Lm1j22EFlGkts7LGYpfMWRTHLGysOMbWBUgHPau1ooAy/DOnXWk6Jb2V9qEuo3Ee7dcSAgtliQPmZmwAQBuZjgcknmsj4e/vrXWr7r9s1W5cH1VG8sfpHXUyuI42duigk/hXM/DBCvgPR3b700RnP1di//ALNWb1mvn+hovgfyOoooorQzCiiigAooooAKKKKAOT+Ix+06XY6Ov3tVvobZgOvlg75P/HEYfjXWAYGB0rk7j/iY/Eu1j6xaTYNMfaWZtq/+OI/511lZw1k5Gk9IpBRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEV4M2k49Ub+VYHw2OfAHh//AK8oh/46K6GZd0Tr6qRXNfDA5+H+he1qo/Lis38a9H+hovgfqv1Ooryn4/WzPpui3QHyxXLRsfTcv/2NerVw/wAX7Y3nhQW6f6xp1dfcqCf6Uq3wM3wM+TEQfmeAxn5Y/of61irG9xqUEMYLO8hwB34rYj+UKCMEAgj862PhZp0d94ne4n27LaNnAPckgCvPdup9bUqezg59jHfSdRvI3+y2sjjJycccf/Xr3PwlpiaH4at4MDMUfzH1Y8k/nU8ccEVusCIo3EZwPxP60viO5FppewHBIrjxU4OVou9vzPIq4qeISi1bU5G436pq6wpkl5Ag/E4r2e3iWCCOGMYSNQo+gFeW+A7eJ9ctWndBI2+VVY4LYGOPXrn8K9WrtyyFoOXc83HS95R7HKfDv9zp+rWXaz1W6iUeil94/R66uuV8J/ufFPi+2HT7ZDOP+BwJn9VNdVXoUvhsclX4rhTZEWRCjqGUjBBGQadRWhmcXr3gS1ui02lP9km6+WeYz/8AE/h+VcZcxanoUwjv4HjGeG6q30PSvZ6jnhiuIminjSSNhgqwyD+FcFfAU6usdGddLGThpLVHl1jrcb4DnBrYguUfBRqn1nwFazlpdKlNrL18tssh/qP1rkryw1fQnzeQOIh/y1T5kP4jp+OK8avgalLWx6FOvTq7M7eC+dOG5FWC9vcrhwAa4qx1kMAHIrZt7tJcbW5rGNacdJaoJUVutDTfSI3bchBFX7Oz+yjKgq3qOKg0/dwc8VqRksea9HCwj8SVmclacvhbuWoXfgE7qnpkS4XPc0+vagnbU4ZbhRRRVkhRRRQAUUUUAUPEEnkaDqUo/gtpW/JSap+CIhD4M0GMfw2EA/8AIYp/jJtnhDXG6YsZz/5DapvDK7fDelL0xaRD/wAcFZ/b+Rp9j5mlRRRWhmFFFFABRRRQAUUUjHAJ9KAOU8D/AOl3/iXVW5+06i0CH/pnCBGP/Hg5/GusrlfheP8AihNKkP3pVeZj6s8jMf1NdVWdL4EzSr8bQUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvwu/5EPSl/uLIn5SMP6V1Vcr8M/l8KrF3hu7uP8riSs38a9H+hovgfqv1OqrjviNJtTSkH8VwT+Sn/Guxrh/iE2/U9HiHYSv/AOgiscbLloSZphVeqjyLxxpbWN4lxGv7iVTyB0PNP+EiYuNRkP8AcQfqTXe3Vrb6laNY3YGOSv1x1rB0TRv+EZtXQsGmnAJHp1wP1ryq0/aUOZHvxxKdN0pbnVWbm51BQn3I+v1qj4ulLyxxE9T0rW0aEW1n5h++3Nc/qji41XLH5E5Jrzlpoc61lc5fU5y3iWOKFiosoQAVOCHbnj36V6b4c8XSxRxw61l0IAW5A5H+8P6ivKNBDXt1cXrdbmZpB/u5wP0r0q2s45LRVZe1dEMRPDtOIqtKNRWkbnh+RH8feJGidXjmtrKZWU5BGJVz+ldbXj2jS3ei+NtTNgVKGzgZ42HDDc/5d69K0fXrTU8Rg+Tc94XPP4etezhMZTqrl2Z5mIw8oPmWqNeiiiu85AooooAKQgMCCAQeoNLRQBzmreD9LvyzxxG0mP8AHBwD9V6VgDwlqNhNujkS5iHQrw34g16FRXLUwdKo7tam8MTUgrX0Oa02OUKFcFSOoNbcEfQVYdFb7yg0IgXpThh1B6ClV5h1FFFdJiFFFFABRRRQAUUUUAYvjUE+DtdA6/YJ/wD0W1WvDhz4e0sjobWL/wBAFJ4ki87w9qkQ6vayr+aEVX8Fyed4P0OQc7rGA/8AkNaz+38jT7HzNmiiitDMKKKKACiiigApr/cb6U6kYZUj1oA5f4X/APJP9E/64f1NdTXLfC7/AJEHRh6QkfkxFdTWdL4I+iNKvxy9QooorQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfh78lprcH/PHWLtR+L7v/AGauqrlPBv7rW/F1t/d1ISj6PDGf55rOXxRNI/DI6uuC8Xt5vi23QdIbXJ+rMf8ACu9rzzxDIE8azhv4oY8fka5MydqDN8Ev3nyMW6kKXeRwRUErtdX0W87iTWpqGnmeTchIp+maSIZfMf5m/lXzqlpY9XTcuXk3kWYHTArhvEly0Gk3DRn9/c/uI/8AgXU/lmt/xJd5lWBD35pYPB0+v6Yt5FMEeBmEMbj5X45Oe3pWtGlOrK0VdkucaavLQ57wzaqpiiQcKAK9AiXbGB7VxtnaXWj3pjvImilX+Fh19x6iuotb+OVQMgGsqyadmVvqjNth/wAV1qQPfT4P/Q5K0buwWQ7l4YcgjqKzo2A8eS4PEmmKf++ZT/8AFVv1m3bYBuneIb7TiIr5Wu4B0b/loPx7/j+ddbpuqWmpR77SZXI+8h4ZfqK5XyFmGDjNZ9zpkkUglt2eKReVdDgj8a9PD5jUpq09UclXDU6m2jPR6K4fTvFN3ZkRapEZ4xx5qDDj6jof0rrNO1K01GLfZzrJjqvRl+o6ivao4qnWXuPU4KtCdL4kXKKKK6DEKKKKACiiigAooooAKKKKACiiigAooooAjuYxLbyxno6FfzFc78M5PM8AaCT1W1RD/wAB+X+ldNXK/DD5fB9vD3gnuYT/AMBncVm/jXo/0NF8D9V+p1VFFFaGYUUUUAFFFFABRRRQByvwv48E2MZ6xyTxn/gMzj+ldVXK/Dr93pep23/Pvqt5Hj2MrMP0YV1VZ0vgRpV+NhRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFZXiu4u7Xw3qM2mTWsF8kLeRJdMFiV8fLuJ46461wll4u1HR7yTTr59TvtWnltobez1UWsIQylxvM9sCvlnYcArvyOh3DAB6hRXnviH4hXWgahbWt7pdpM4a3S9Fpczym2M0mxct9nEeMEEb3QnkAdM1Lr4nXVpp819caFF9lZNRa28u+LSSGzL7t6+WNit5Z+YFsEgEcjIB6bRXm+veL2udf0+xgZrWO1v7GSeVLjiRJoZ3KMABwNgPJOcg4FaHgjx23iTW7jTpbBINtol7DcQvM0c0bMVBUywxEjgEMoZSDwaAO4orBvtc1C2u5YYfCutXcaHCzwy2YR/cB51bH1AqD/hI9U/6EvxB/3+sP8A5JoA6WuU0X9z8Q/E0R/5b29pcD34dD/6AKm/4SPVP+hL8Qf9/rD/AOSa5qXXtRg+I0E7eE9bVrrTHiEPm2e9zHKG3D/SNuAHPU556dazn0fn/wAA0h1XkelVwHj2A2/iLTb0cJMhhY+4OR+h/Str/hI9U/6EvxB/3+sP/kmsHxtqmp32gy/8Ufrsb27CdXeWyIXb16XBPTPQVli6ftKTiXh58lRMuiJiqkDIPemahcx6dZM8hAbFYegeIrq6hi8zRdRtoSpJuJpLcoMD0SVm/Suc1rUJ9WvWjVj5SmvmowSfmesk5PXYlsfO1nVgIgS0jbU+te16fapY2UNtF9yJQo9/euQ+G+iC1tPt8q4eQbYgey92/H+VdvXvYCh7OHO93+R52Mrc8uVbIqalp1rqVuYbyFZF7HoVPqD2rgta8MXmmFprMtdWw54HzoPcd/qK9Ioror4WnXXvLXuY0q86T02PC1vzH4usJSc77OaP8mQ12VteJMo+YZpPHmgW1z4q8NvCBbS3Mk8DyqvU+UWGR/wCsTVdK1PQ5N1xGWgzxNHyn4+n414OIwU6bfVLqerTrwqJdGzp1bHIq1DcA/LKMiuSsNYzgOc1uQ3McoBBFcScqbLlC5o3GnxXCkx4PtWJPpkttMJYGeKRejKcEfjWnHKyHKmriXiuNsyg+9aqUJar3WR78fNFKx8TXtphL6L7TGP4l+V/8DXS6drNjqGBBMBJ/wA83+Vvy7/hWHNZwzjMZGfSoodLCuCVFejQxleD5Ze8jmqUaU1daM7KisyyaSNAAxKjs3NaEbl1yRg17NOqpo8+UHEfRRRWhIUUUUAFFFFABRRRQAUUUUAFcr8Pvkttcg7Q6xdqPoX3/wDs1dVXK+Dv3Wv+Lrb+7qKzAf78EZ/oazl8UWaR+GSOqooorQzCiiigAooooAKKKKAOU8H/ALjxB4us+y36XA+kkKH+YNdXXKaR+5+I3iKP/ntaWk/5ean9BXV1nT2+b/M0qb/JfkFFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBFdW8N3byW91DHPBINrxyKGVh6EHgisuDwr4et9PuLC30LSorG4Iaa2SzjWOQjoWUDB/GtmigDD/AOEQ8Nb7d/8AhHdH3W4Cwn7FFmIA7gF+XgA88d6i8PeDdD0Fbg2en273Ny8zT3UkKGaUSyM7KzhQWUFsAHsAOcV0NFAGRYeGNB09dthoml2qh1kxBaRoNy52twOo3Ng9tx9TT9J8PaLo80k2kaRp1hLKMO9rbJEzjOeSoGa1KKACiiigArlPFn+jeKPCV6fui6ltGP8A11ibH/jyLXV1ynxMBi8MG/UfPp11Bej6JIpb/wAd3VnV+Fvtr9xpS+JLvp951dNkRZI2RwCjAqQe4NOBBAIOQe9FaGZ5BeRS6E1/pcudq5MLH+JD0Iqt4N0h9V1JYVQiBTumf0X0+pr1vU9KsdTVVv7aOYL90t1H0PWpLCwtdPg8mygSGPrhR1+vrXlxy1KpzX909B473LJak8aLFGscahUUAKB0Ap1FFeoeeFFFFAHKeO/3c3hq5HWLV4VJ9nV4/wD2YV1TAMpDAEHgg1yvxO+TwlLcjraXNtcj/gEyE/pmurrOPxtehpL4E/U5nVvBum3rNJbqbOc/xRfdJ916fliuVv8Aw9rGlEsqfaoB/HDyce69f516hRWFbBUqvSz8jWniqlPS90eS2urkHa55HUHtWrBfxyY55rsdV0LTtUBN1br5n/PRPlcfiP61yd74Lu7Zy+nXAni/uSfKw/Hof0ryK2WVIax1O6ni6c99GW7Z9xBU1tWzNtGa57TbS6il2TxtGw7MK6m1iIALdaeFoSi9TOvOL2J4k4AFW1G1cU2JcLnvT69ynDlR58pXCiiitSAooooAKKKKACiiigAooooAK5TQv3fxA8UxH/lpDZzj/vl0P/oArq65WL918Ubkdp9Ijb8Umcf+z1nPeL8zSG0l5HVUUUVoZhRRRQAUUUUAFFFFAHKr8nxSk/6a6Mp/74mP/wAXXVVyt9+7+Jukt/z10y5T/vmSI/1rqqzh1XmaT6PyCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqOu2K6pol/YPjbdQPCc/wC0pH9avUUmrqzGnZ3Rg+BL5tS8HaRcyf61rdFkz/fUbW/8eBrerlPAP+jf29ph4+xanNsX0STEq/8Aow11dTTd4q5VRWk7BRRRVkBRRRQAUUUUAYHj+2N34I12EDLNZSlfqFJH6itPRrn7ZpFjdA5E0Ecn/fSg/wBanu4VuLWaB/uyIyH6EYrn/hrMZ/AeiF/vx2ywt9U+Q/8AoNZ7T9V+X/Dmm8PR/n/wx0tFFFaGYUUUUAIyqwwwB+tMWFVbIz9KkopOKe47tBRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAVymo/ufiXor/8APfTrqL/vl4m/xrq65XxN+78aeEJuxluYP++oS3/slZ1NvmvzNKe/yf5HVUUUVoZhRRRQAUUUUAFFFFAHK658nxB8LP8A34LyP/x2M/0rqq5XxL8vjTwe/rLdJ+cBP9K6qs4by9f0RpPaPp+rCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlNN/0T4k61B/DfWNvdj/eRnjb9NldXXKa1/o3xC8N3A4Fzb3Vox9eEkX/0Bq6us6fVef8AwTSprZ+X/ACiiitDMKKKKACiiigArlPhz+60vUrLtZ6pdQgegMhcfo4rq65Twt/o/i3xdadFNxBdqP8ArpCAf1jNZy0lF/1/WhpHWMl/X9anV0UUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr45/d33hafumrxp+DxyL/WuqrlPiN8mkadcdPs+qWcmfT98q/wDs1Z1fhZpS+JHV0UUVoZhRRRQAUUUUAFFFFAHK+Lvl8S+D3/6f5V/O3k/wrqq5XxpxrHhFvTVMZ+sEtdVWcPil/XQ0l8Mf66hRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBynjz9zP4avBwYNWhUn0WRWjP/oYrq65X4njb4Mu7gfetZYLkH02TI38ga6oHIyOlZx0m16GktYJ+oUUUVoZhRRRQAUUUUAFcpH/o3xRlHRb3SVb6tFKR/KUV1dcp4l/0bxp4Tu+iySXFmx/3494H5x1nU2T80aU92vJnV0UUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8UOPA+oSDrC0Mw9tsqN/Suqrm/iTH5vgHXwOos5GH4Ln+lRV+B+hdL416nSUVDZSCaygkHR41b8xU1WQFFFFABRRRQAUUUUAcr43/5CXhP/ALCy/wDomWuqrlfGXz694Qi7nUmf/vmCU11VZx+KX9dDSXwx/rqFFFFaGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGF47t/tfgrXYRyWspsfXYSKv6Fcfa9E0+5znzreOTP1UH+tT30IuLK4hPIkjZPzGKwvhvMZ/AWgsx+YWcaH6qNv9Kz2n8v6/M03h8/6/I6SiiitDMKKKKACiiigArlPiP+50nT7/ALWGpWtwT6L5gRv0c11dYPjyzN/4L1q3Tl2tJGT/AHlXcv6gVFRXgy6btNG9RVLRLwaho1heqci4gjl/76UH+tXapO6uS1Z2CiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsnxfH53hPWosZ32Uy/nGa1qqatH5ulXkf9+F1/NTSkrpocXZplfwtL53hnSJf79nC35oDWnXP/D6TzfAvh9/WwhH/jgroKUHeKY5q0mgoooqiQooooAKKKKAOV8S/P418IR+kl1J+UJH/s1dVXK6z8/xE8NJ/wA87W8k/wDRS/1rqqzhvL1/RGk9o+n6sKKKK0MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuU+GXyeEo7c9ba6uYMem2dx/LFdXXK+Af3f8AwkVv/wA8dYuMD0DbX/8AZ6zl8a+ZovgfyOqooorQzCiiigAooooAKbIqyIyOMqwwR6inUUAcr8MmYeDbO1ckyWLy2TZ7GKRkH6AV1Vcp4P8A9F8QeK9O7JfLdp/uzRqT/wCPK9dXWdL4Uu36GlX4m+/6hRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJl3RSL6qRT6KAOY+GLZ+H+he1qq/lx/Sunrlfhb/yIOj+0bD/x9q6qs6XwR9C6vxy9QooorQgKKKKACiiigDlbr5/ihp4/556TO3/fUsQ/pXVVyo+b4pN/saMP/Hpz/wDE11VZw6+ppPp6BRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvhb914t8X246faYLgD/fgUfzQ11Vcrp4Nv8AEnWEIwt1p1tMD6lHkU/zFZz3j6/ozSG0vT9UdVRRRWhmFFFFABRRRQAUUUUAco/+hfE6M9I9S0wr9Xhkz/6DKfyrq65TxsDbal4Z1Nf+XfUVgc+iTKYz/wCPFK6us4aNo0nqkwooorQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4W/8iFpPurn/wAiNXVVQ0HTY9H0e10+E5SBNoPrzmr9RTXLFJlTfNJtBRRRVkhRRRQAUUUUAcrZ/N8TtTb+5pVuv5yyn+ldVXK6WCfiPr7EHAsbRQf+BTGuqrOns/V/maVN16L8gooorQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKrGziOpLfYPniIw+20kH+YqzRRa4XCiiigAooooAKKKKACiiigCrqdjDqNm9tcA7GKtkdQVYMCPoQKtUUUrdQv0CiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBVisootQuLxQfOnRI39MLux/6EatUUUkrA3cKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Posterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34954=[""].join("\n");
var outline_f34_8_34954=null;
var title_f34_8_34955="Revised diagnostic criteria CFS";
var content_f34_8_34955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised CDC criteria for chronic fatigue syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A case of chronic fatigue syndrome is defined by the presence of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Clinically evaluated, unexplained, persistent or relapsing",
"fatigue that is of new or definite onset; is not the result of ongoing",
"exertion; is not alleviated by rest; and results in substantial",
"reduction in previous levels of occupational, educational, social, or",
"personal activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Four or more of the following symptoms that persist or recur",
"during six or more consecutive months of illness and that do not",
"predate the fatigue:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Self-reported impairment in short term memory or concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sore throat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tender cervical or axillary nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Muscle pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multijoint pain without redness or swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Headaches of a new pattern or severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unrefreshing sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post-exertional malaise lasting &ge;24 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CDC: Centers for Disease Control and Prevention",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fukuda, K, Straus, SE, Hickie, I, et al, Ann Intern Med 1994; 121:953.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34955=[""].join("\n");
var outline_f34_8_34955=null;
var title_f34_8_34956="High-calorie food fortifiers";
var content_f34_8_34956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Increasing caloric density of beverages and foods for toddlers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fortifier",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Calories",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Add to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonfat dry milk",
"       </td>",
"       <td>",
"        25 kcal/tablespoon",
"       </td>",
"       <td>",
"        Potatoes, ground meats, cereals, pudding, yogurt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheese",
"       </td>",
"       <td>",
"        100 kcal/ounce",
"       </td>",
"       <td>",
"        Vegetables, casseroles, fish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sour cream",
"       </td>",
"       <td>",
"        30 kcal/tablespoon",
"       </td>",
"       <td>",
"        Beans, squash, potatoes, gravies, casseroles, salad dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipping cream (also called heavy cream)",
"       </td>",
"       <td>",
"        60 kcal/tablespoon",
"       </td>",
"       <td>",
"        Gravies, casseroles, salad dressings, hot chocolate, cereal, potatoes, eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Butter, margarine, oil",
"       </td>",
"       <td>",
"        40 kcal/teaspoon",
"       </td>",
"       <td>",
"        Gravies, mashed potatoes, cereal, rice, pasta, bread, muffins, tomato sauce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Instant breakfast preparation",
"       </td>",
"       <td>",
"        130 kcal/packet",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        Recipes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        One jar (4 ounces) strained fruit plus one scoop formula powder*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        8 ounces whole milk + 2 tablespoons nonfat dry milk powder = 24 kcal per ounce*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        8 ounces whole milk + 3 tablespoons nonfat dry milk powder = 28 kcal per ounce*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        4 cups whole milk + 1 cup nonfat dry milk powder = 28 kcal per ounce*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Mix 1 cup whole milk, 1 package instant breakfast and 1 cup ice cream in blender (430 kcal)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Mix one-half cup whole milk and one-half cup \"half-and-half\" to increase calories",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1 kcal = 1 calorie.",
"     <br>",
"      * If making any of these changes causes your child to have diarrhea, stop and call your pediatrician.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Can be used in cooking (eg, mashed potatoes), baking (eg, muffins, waffles), desserts (eg, pudding, custard), etc.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453.",
"       </li>",
"       <li>",
"        Frank DA. Failure to thrive. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.204.",
"       </li>",
"       <li>",
"        Texas Children's Hospital. High-calorie, high-protein diet.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34956=[""].join("\n");
var outline_f34_8_34956=null;
var title_f34_8_34957="TNM stage nasopharynx";
var content_f34_8_34957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the nasopharynx",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor confined to the nasopharynx, or tumor extends to oropharynx and/or nasal cavity without parapharyngeal extension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor with parapharyngeal extension*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor involves bony structures of skull base and/or paranasal sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less, in greatest dimension&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"3\">",
"       Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N3",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a lymph node(s)&Delta; &gt;6 cm and/or to supraclavicular fossa&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N3a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Greater than 6 cm in dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N3b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Extension to the supraclavicular fossa&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage II",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Stage III",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Parapharyngeal extension denotes posterolateral infiltration of tumor.",
"     <br>",
"      &bull; The distribution and the prognostic impact of regional lymph node spread from nasopharynx cancer, particularly of the undifferentiated type, are different from those of other head and neck mucosal cancers and justify the use of a different N classification scheme.",
"      <br>",
"       &Delta; Midline nodes are considered ipsilateral nodes.",
"       <br>",
"        &loz; Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho. It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder (Figure 4.2). Note that this would include caudal portions of levels IV and VB. All cases with lymph nodes (whole or part) in the fossa are considered N3b.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34957=[""].join("\n");
var outline_f34_8_34957=null;
var title_f34_8_34958="Pacemaker algorithm";
var content_f34_8_34958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Pacemaker algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for the use of the different types of pacemakers depending upon the need for atrioventricular (AV) sequential pacing, the presence of sinoatrial (SA) node chronotropic competence, the AV conduction rate, and the need for rate-responsiveness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of MD McGoon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34958=[""].join("\n");
var outline_f34_8_34958=null;
var title_f34_8_34959="Fibroid embolization 1 PI";
var content_f34_8_34959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_8_34959=[""].join("\n");
var outline_f34_8_34959=null;
